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Abstract 
 
This thesis reports a series of investigations to identify the disease loci of three distinct 
epilepsy syndromes, and also a pilot study to assess the feasibility of using saccadic eye 
movements  as  a  biomarker  of  potential  interest  in  genetic  studies.  The  fact  that  some 
epilepsy syndromes have a strong genetic tendency has been known for decades, but very 
few susceptibly genes have been found. I sought to identify disease loci in three distinct 
epilepsy syndromes: familial temporal lobe epilepsy (2 families), photosensitive epilepsy (1 
large  family),  and  Kohlschütter Tönz  syndrome  (5  families).  Medical  histories,  seizure 
patterns and investigations were gathered through interview and case record reviews. The 
DNA  samples  were  collected  and  underwent  an  eight cM  whole  genome  analysis. 
Parametric and non parametric linkage analyses were carried out to these pedigrees. One of 
the  families  with  mesial  temporal  lobe  epilepsy  was  considered  to  have  single  gene 
inheritance and three regions of interest were identified. Five genes were sequenced in 5 
individuals in this pedigree but no pathological mutations were found. The other family 
with mesial temporal lobe epilepsy had more complex inheritance pattern and no disease 
loci were identified. In the photosensitive epilepsy pedigree, our analysis showed polygenic 
inheritance  with  one  region  of  interest  on  chromosome  16,  but  with  no  specific  genes 
identified.  In  the  Kohlschütter Tönz  pedigree,  a  disease  locus  was  identified  on 
chromosome 16 in a region of 30 known genes but no causative gene was identified. These 
results, both positive and negative are discussed. In the pilot study to assess the feasibility 
of  the  methodology  of  using  saccadic  eye  movement  as  a  biomarker  (as  biomarker  in 
pharmocodynemic studies), a system for measurement was devised and a control group and 
patients with widely varied antiepileptic drug measurements were examined (including one 
patient with phenytoin  toxicity). The experiment showed the intra individual variability of 
saccadic  eye  movements  was  too  large  to  allow  small  changes  to  antiepileptic 
measurements to be easily identified. That seems that the measurement of main sequence 
will not be useful as a biomarker for pharmacogenomic or pharmacodynamic studies. It is 
possible that other measurements will be more reliable and these are discussed. 
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Aims 
      This thesis reports studies in two broad areas. The first is a series of investigations in 
families using advanced linkage analysis; and the second is a pilot investigation assessing 
the potential of saccadic eye movements to be a biomarker of the pharmacodynamic actions 
of antiepileptic drugs, for future use in genetic (pharmacogenomic) studies.  
 
1. Family Linkage Analyses (8 families) 
In  this  body  of  work,  I  studied  8  families  within  three  epilepsy  syndromes  (familial 
temporal lobe epilepsy, photosensitive epilepsy, Kohlschütter Tönz syndrome). I collected 
appropriate clinical phenotypic data (from clinical examination, note review and hospital 
inquiry), carried out the laboratory genetic analysis of the DNA from individuals in this 
family  (preparation,  genotyping  and  sequencing),  and  devised  and  conducted  the 
computerised analysis of this DNA using various linkage programmes. The aims of the 
study were: 
i.  Familial  temporal  lobe  epilepsy  (two  families).  To  identify  the  genetic  basis  of  the 
familial  epilepsy,  to  determine  whether  there  was  a  similar  genetic  cause  in  the  two 
families, to determine the mode of inheritance in the families, to identify linked regions, to 
sequence candidate genes within the linked regions and to determine the clinical phenotype 
associated with any linkage discovered. 
ii.    Photosensitive  epilepsy  (one  large  family):  To  identify  the  genetic  basis  of  the 
Photoparoxysmal  response  (PPR)  in  a  large  family  with  photosensitive  epilepsy,  to 
determine the mode of inheritance, and to identify linkage.  
iii.  Kohlschütter Tönz  Syndrome:  To  identify  the  genetic  basis  (linkage)  of  this  rare 
syndrome (in five families), to determine the mode of inheritance, to identify linkage, to 
define the clinical phenotype associated with the linked area, and to if possible identify the 
causative gene.  
 
2. To conduct a pilot study as part of a programme to investigate the potential of saccadic 
eye movements (main sequence, peak saccadic velocity) to act as a biomarker of value in 
pharmacogenomic studies of epilepsy.   
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The long term aim of this work is to determine whether saccadic eye movements were 
useful as a measure of the pharmacological effects of antiepileptic drugs – in other words to 
determine whether they would prove a useful pharmacogenomic biomarker. .  The 
hypothesis was that pharmacological effectiveness on epilepsy would be mirrored by 
pharmacological effects on eye movements.  The specific objective is to determine whether 
effects on saccadic velocity due to drugs correlated with drug effects on epilepsy in terms 
of side effects or efficacy. If the AED effects on saccades did indeed correlate with clinical 
AED effect, a second phase of the programme was planned to identify whether 
polymorphic variation in SCN1A (or other candidate genes) could be identified as 
underpinning the saccadic variation – thus potentially leading eventually to the use of 
saccadic eye movements as a biomarker, and identification of genotypes which correlate to 
clinical response. The first phase of the project reported in this thesis, the pilot (or scoping) 
phase, which had the following narrower aims: 
1. to devise a clinically applicable method for measuring saccadic main sequence and peak 
saccadic velocity.  
2. to carry out measurements in a suitable control group, to identify mean values and the 
range of normality. 
3. to carry out a pilot study in patients with epilepsy, to determine whether changes in 
blood levels were reflected by measurable changes in saccadic velocity in a reliable 
fashion, and to determine the extent of this effect 
4. In a preliminary manner, to whether the there is an association between the magnitude of 
the effect of saccadic variation and clinical effects (side effects/efficacy).  
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Personal contribution to the work 
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and South Wales (Swansea); taking consents; and interviewing every subject in person to 
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blood samples; and the phenotyping. I also personally carried out all the laboratory based 
molecular genetics studies including polymerase chin reactions (PCR), genotyping (for fine 
mapping part) and gene sequencing. I selected the linkage analysis software in carrying out 
the linkage analysis, based on the study design of Professor Newton Morton, the sequential 
tests of linkage analysis. I carried out the computation linkage analysis, including software 
installation, files formatting, and the linkage analysis of the 8 families involved in this 
project. I searched the bio informatics database online including several websites to retrieve 
information of the genes within the disease loci identified, and performed the literature 
reviews to identify possible candidate genes. I formulated the findings and results to write 
up the experiments. In the work I was assisted by discussions with my supervisors and also 
Dr Mary Davies (chief technician in the genetics laboratory). 
 
b. The saccadic eye movement pilot study 
     I  was  responsible  for  the  overall  design  of  the  study  (in  collaboration  with  my 
supervisors  and  also  Prof  Linda  Luxon  and  Dr  Doris  Bamou,  who  advised  my  on  the 
technical  side)  and  the  literature  review,  the  design  of  the  testing  schedules  and 
methodology including computerized electro nystagmography and the video based tracking 
eye movement recording facilities, and later on the infra red limbal trackers for this pilot  
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study. I devised the methodology and the experiments in the eye movement recording. I 
recruited subjects from the Epilepsy out patient clinic as well as organized the appointment 
for the eye movement experiments and conducted the measurements on the patient and 
control group. I reviewed medical notes of the subjects, carried out the data conversion to 
re construct the saccadic main sequence. I did the statistical analysis, and formulated the 
findings and results to write up the experiments. 
 
B. Skills Training 
      I  sat  in  the  epilepsy  out  patient  clinic  with  Professor  Simon  Shorvon,  assisted  in 
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laboratory in the Institute of Child Health, Great Ormond Street Hospital in operating the 
IRIS  6500  infrared  limbal  tracker  (Skalar  Medical,  Delft,  The  Netherlands)  with  Dr. 
Richard Clement, as well as learning to use the software Mathematica in carrying out the 
conversion and analysis of saccadic eye movement measurements.  I learned the laboratory 
skills in carrying out the laboratory works on molecular genetics with the help from Dr 
Mary Davis, Dr Vaneesha Gibbons, Dr Andrea Haworth, and Dr Richa Sud. I learned more 
skills  in  primer  designs  and  PCR  with  Professor  Sheau  Yu  Teddy  Hsu  in  Stanford 
University, California, USA where I spent several weeks during 2008.  
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Introduction 
 
Section 1: Familial Mesial Temporal Lobe Epilepsy 
and Its Genetics 
 
1.0 Background 
      Epilepsy is one of the oldest recorded diseases. The description of epilepsy  can be 
traced back as early as 1067 B.C on two tablets known as part of the medical textbook in 
Assyrian Babylonian, the Sakkiku,.  
      One of the characteristics of epilepsy is the heterogeneity of its clinical presentations as 
well as of aetiology (Berg, 2007). Some epilepsies are mild and some are severe, some 
(especially in childhood) conform to syndromic categories, but others do not, and clinical 
seizure  type  varies.  The  aetiology  of  epilepsy  is    commonly  divided  into  three  main 
categories, idiopathic, cryptogenic and symptomatic (Commission on Epidemiology and 
Prognosis and International League Against Epilepsy, 1993). Idiopathic epilepsies often 
refer  to  epilepsies  that  their  causes  are  primarily  genetic  in  origin,  and  symptomatic 
epilepsy refers to the epilepsies that occur in the presence of a causative insult or condition. 
Almost  any  grey  matter  disease  can  result  in  the  development  of  epilepsy,  common 
examples being stroke, head injuries, and cerebral palsy. One important consideration is the 
fact that epilepsy is often multi factorial and can be the result of both external and internal 
(usually polygenic) influences. 
      The  term  “cryptogenic  epilepsy”  is  used  to  describe  seizures  that  are  “probably 
symptomatic”  but  their  aetiologies  cannot  be  identified  through  available  medical 
investigation (Commission on Classification and Terminology of the International League 
Against Epilepsy., 1989; Commission on Epidemiology and Prognosis and International 
League Against Epilepsy, 1993). Some of the epilepsies that were classified as cryptogenic 
have been found to be genetic in origin through rigorous twin studies (Johnson et al.  2001; 
Johnson et al.  2003), and appeared to have its influences on epilepsy outcome. Other 
studies revealed that a frontal lobe epilepsy syndromes [Autosomal Dominant Nocturnal  
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Frontal Lobe Epilepsy (ADNFLE)] is also genetic in origin, that the gene mutations on 
acetylcholine  receptor  subunits  (CHRNA4,  CHRNB2,  and  CHRNA2)  appear  to  be  the 
susceptibility gene and have been identified in several different families. (Aridon et al.  
2006;  Beck, 1994;  Fusco  et al.   2000).  These  mutations  cause  gain  of  function  of  the 
acetylcholine receptors and reduce the 2 mM Ca
2+ induced increases in the peak 30 uM 
acetylcholine response (Rodrigues Pinguet et al.  2003; Steinlein and Bertrand, In press). 
These findings show that epilepsies which tend to cluster in families and failed to have a 
clear pathogenesis identified may be genetic in origin. 
      Familial  epilepsies  can  be  inherited  in  an  autosomal  dominant  (AD),  AD  with  an 
incomplete penetrance, or autosomal recessive (AR) pattern (Baulac et al.  2001a; Berkovic 
et al.  2004; Cossette et al.  2002; Phillips, 1995; Tournev et al.  2007). The majority are 
autosomal  dominant  (Shahwan  et  al.    2005).    Epilepsy  can  also  be  the  result  of 
mitochondrial inheritance in such case it usually is part of a wider syndrome, such as in 
“Mitochondrial  Encephalopathy,  Lactic  Acidosis  and  Stroke like  Episode  Syndrome” 
(MELAS),  and  “Myoclonus  Epilepsy  with  Ragged Red  Fiber  Syndrome”  (MERRF) 
(Hirano et al.  2007). Alpers Huttenlocher syndrome is another mitochondria disease in 
which intractable seizures are a part of the clinical presentation, and is caused by mutations 
in the nuclear POLG gene (encoding mitochondria polymerase γ), which causes multiple 
mitochondria DNA deletion (Davidzon et al.  2005; Nguyen et al.  2005). Besides these 
mutations, aberration of chromosome structure  is another cause of epilepsy  syndromes, 
such  as  ring  chromosome  20  syndrome,  (Ville  et  al.    2006)  and  ring  chromosome  17 
(Ricard Mousnier et al.  2007). Patients with ring chromosome 20 syndromes and ring 
chromosome  17  syndrome  have  refractory  seizures  and  delayed  of  psychomotor 
development.  
       Familial genetic linkage studies have been carried out to explore the genetic of many 
familial  epilepsy  syndromes.  In  some  of  the  studies,  the  gene  mutations  have  been 
successfully  identified,  the  results  were  replicated  in  families  with  the  same  epilepsy 
syndromes and the mechanisms were further elucidated with subsequent functional studies 
of  these  gene  mutations.  Such  epilepsy  syndromes  include  familial  lateral  temporal 
epilepsies, febrile seizures, Generalized Epilepsy with Febrile Seizures Plus (GEFS+), and 
Severe Myoclonic Epilepsy of Infancy (SEMI, or Dravet disease) (Audenaert et al.  2003;  
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Berkovic et al.  2004; Kalachikov et al.  2002; Wallace et al.  2002; Wallace et al.  1998). 
However,  for  many  familial  epilepsies,  their  genetic  basis  has  not  yet  been  fully 
understood.  Such  epilepsy  syndromes  include  familial  mesial  temporal  lobe  epilepsy 
(fMTLE) (Striano et al.  2008b), photosensitive epilepsy (PhE)(Kasteleijn Nolst Trenité, 
2006; Pinto et al.  2005), and familial partial epilepsy with variable foci (FPEVF) (Scheffer 
et al.  1998). In each of these familial epilepsies, one or more disease loci may have been 
reported without replications, and in some studies a few candidate genes were sequenced 
without disease causing mutations found. (Andermann et al.  2005; Pinto et al.  2007; 
Vadlamudi et al.  2003).      
 
1.1 Familial Temporal Lobe Epilepsy (fTLE) 
      For decades, partial epilepsies have been recognized to have genetic predispositions 
(Andermann, 1982), but not until recently was familial Temporal Lobe Epilepsy (fTLE) 
recognized  as a well defined epilepsy syndrome (Engel, 2001).  Familial TLE was first 
described by Berkovic in a twin study (Berkovic et al.  1996). It was first described as a 
relatively benign syndrome with late onset seizures without history of prolonged febrile 
seizures. However, in subsequent families indentified, some had a less benign course and a 
higher  portion  of  hippocampal  atrophy  or  sclerosis.  In  some  resective  surgery  was 
necessary to control their intractable seizures (Cendes et al.  2007; Kobayashi et al.  2001).   
      In terms of diagnosis, it is not possible to differentiate familial temporal lobe epilepsies 
from sporadic temporal lobe epilepsies solely by clinical presentation. In many studies, 
familial TLE has been considered to be present when at least 2 members in the same family 
are diagnosed with temporal lobe epilepsy. This criterion however has not been consistently 
employed, and particular studies have varied as to whether the term should be restricted to 
first degree relatives or whether the familial tag can also be applied if there are affected 
second or third degree relatives (Picard et al.  2000).  
      The classification of familial temporal lobe epilepsy is the same as sporadic temporal 
lobe epilepsy. Based on the origin of seizure discharge, it is divided into familial mesial 
temporal lobe epilepsy (fMTLE) and familial lateral lobe epilepsy (fLTLE). A strand of 
evidence supporting the view that fLTLE is different from fMTLE is the fact that the gene 
mutation in Leucin rich Glioma Inactive 1 gene (LGI1) which causes fLTLE has never  
  27 
been found in families identified with fMTLE (Berkovic et al.  2004; Vadlamudi et al.  
2003). Although the symptoms of fLTLE and the symptoms of fMTLE often overlap, there 
are differences in their clinical presentations. 
 
1.1.1 Familial Mesial Temporal Lobe Epilepsy  
 
Epidemiology 
       A preliminary hospital based study found that familial MTLE represented 7% of all 
MTLE patients (Kobayashi et al.  2001). However, the true incidence and prevalence of 
familial  mesial  temporal  lobe  epilepsy  is  still  unknown  as  there  are  not  enough 
representative studies (Cendes et al.  2007). 
 
Clinical presentation 
      The clinical presentation of familial temporal lobe epilepsy cannot  be differentiated 
from sporadic temporal lobe seizures. Typical seizures of mesial temporal lobe take the 
form  of  simple  partial  seizure,  complex  partial  seizures,  and  secondary  generalized 
seizures.  A  typical  complex  partial  seizure  has  three  components:  aura,  absence,  and 
automatism.  Simple  partial  seizures  comprise  motor,  autonomic,  somatosensory,  and/or 
psychic manifestation. Complex partial seizures have an indistinct onset and may last for 2 
10 minutes while simple partial seizure is often brief and typically evolves within seconds. 
The details of the symptoms in mesial temporal lobe epilepsy are presented in Table 1.1 
and Table 1.2. 
 
Diagnosis and differential diagnosis 
      The diagnosis of familial mesial temporal lobe epilepsy is largely history based. High 
resolution  Magnetic  Resonance  Imaging  (MRI)  and  Electroencephalography  (EEG)  are 
used to assist in diagnosis, but it is not uncommon for both investigations to be normal in 
those  patients.  Typical  EEG finding of  mesial  temporal  lobe epilepsy include interictal 
epileptiform  discharge  over mid and  infero mesial  temporal  regions, and a  similar ictal 
EEG  findings  to  sporadic  mesial  TLE.  MRI  may  show  hippocampal  atrophy  or 
hippocampal sclerosis (other pathologies would exclude a diagnosis of idiopathic familial  
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TLE) which are also similar to sporadic TLE. It is worth noting that normal MRI and EEG 
findings do not exclude the diagnosis of fMTLE. 
      The differential diagnosis of fMTLE include lateral temporal lobe epilepsy, GEFS+, 
febrile seizures (FS), familial partial epilepsy with variable foci (FPEVF), and a type of 
partial epilepsy recently identified in a large Brazil family with several family members 
consistent with MTLE, which showed linkage to chromosome 4p15 (Kinton et al.  2002). 
These epilepsies can have seizures that have the characteristics of temporal lobe epilepsy.  
 
Treatment 
 Most of the patients can achieve seizure remission either with adequate medical control 
or  with  surgical  intervention.  The  majority  of  patients  with  fMTLE  are  usually  well 
controlled  by  anti epileptic  drugs  indicated  for  partial  epilepsies  based  on  individual 
responses and tolerability. For those with hippocampal sclerosis or atrophy and those who 
are refractory to medical treatment, surgery may be necessary. In a seizure outcome study 
of fMTLE, around 24% of patients were refractory to medical treatment (Kobayashi et al.  
2001). 
 
 
 Table 1.1 Complex partial seizure of mesial temporal lobe origin (Shorvon, 2005)
  Duration  Descriptions of seizures 
Aura 
 
Brief, usually 
a few 
seconds 
Aura are simple partial seizures, can be in any form of the 
simple partial seizure in Table 1.2  
Absence 
 
Seconds  Dreamy state. Arrest of the activities. Sometimes speech 
continues but may just be only repetitive vocalization. 
Absence could also be seen in extra temporal lobe 
epilepsy 
Complex 
partial 
seizures  
Automatism  Can last for 
minutes 
1.  Oro alimentary: such as lip smacking, chewing, 
and swallowing. 
2.  Gestural: such as fumbling, fidgeting, repetitive 
motor action, undressing, walking or running. 
3.  Automatism of temporal lobe origin is much less 
violent than those of frontal lobe origin. 
(often with contralateral spasm of tonic posturing 
in unilateral hippocampal seizures)  
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Table 1.2 Simple partial seizures and secondary generalized seizures of mesial 
temporal lobe origin (Engel and Williamson, 2007; Shorvon, 2005) 
 
 
 
1.1.2 Familial lateral temporal lobe epilepsy (fLTLE) 
History 
        Familial lateral temporal lobe epilepsy is also known as familial TLE with auditory 
features or “Autosomal Dominant Partial Epilepsy with Auditory Features”. It was first 
described by Ottman in a gene mapping study (Ottman, 1995), which identified the disease 
locus  on  chromosome  10q.  Subsequent  studies  mapped  the  gene  (Leucine rich  Glioma 
Inactivate  1,  LGI1)  in  this  locus  either  the  same  gene  mutation  or  new  mutations 
(Kalachikov et al.  2002; Rosanoff and Ottman, 2008; Striano et al.  2008a). Since its 
clinical manifestation is similar but different from mesial temporal lobe epilepsy, and the 
site of discharge can be located at lateral temporal lobe, it is now recognized as a well 
established  epilepsy  syndrome  that  is  considered  to  be  distinct  from  (familial)  mesial 
temporal lobe epilepsy (Cendes et al.  2007). 
 
 
Seizures type  Duration  Description 
Motor: speech arrest, or aphasia (dominant lobe) 
 
Autonomic: epigastric raising sensation, flushing, 
palpitation, tachycardia, bradycardia,  hyperventilation 
Somatosensory: tingling, paresthesia, pain  
 
 
 
 
 
 
Simple partial 
seizures  
 
 
 
 
 
 
Brief, usually 
seconds  Psychic:  
1.  Perceptual hallucination: could be visual, or 
olfactory 
2.  Dysmnestic: such as déjà vu, panoramic 
experience, jamais vu. 
3.  Cognitive impairment: such as change in reality, 
depersonalization, dreamy states or forced 
thinking. 
4.  Affection: fear, anger, distress, or pleasure. 
Secondary 
generalized 
seizures 
Minutes, usually 
less than 5 mins).  
Generalized seizures, usually tonic clonic type. The 
aura is indicative of the partial onset.  
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Epidemiology 
      Accurate figures of the prevalence and incidence of both fMTLE and fLTLE are not 
available, but it is roughly estimated that fMTLE is more common than fLTLE (Cendes et 
al.  2007). There is currently no figure showing any preponderance in either gender or in 
any ethnic group for both types of familial TLE. The prognosis of fLTLE is quite benign. A 
detailed  family  history  is  necessary  to  confirm  the  diagnosis;  the  current  estimated 
prevalence of familial LTLE may be underestimated. 
 
Clinical presentation  
      The clinical presentations of both types of familial TLE are similar, but there are subtle 
clues to distinguish one from the other. The cardinal feature of fLTLE is the auditory aura 
which  is  comprised  of  roaring,  buzzing,  and  distortions  in  sounds  or  words  (Shorvon, 
2005). This suggests that the discharge origin is located at superior or lateral temporal lobe, 
involving neocortex. Occasionally cephalic symptoms or visual hallucinations may occur in 
lateral temporal lobe epilepsy but are less common. Many of the manifestations of mesial 
temporal lobe epilepsy can also be seen in lateral temporal epilepsy, which may suggest 
anatomical  overlap  of  the  epileptogenic  area  or  the  discharge  may  rapidly  spread  from 
lateral temporal lobe to mesial temporal lobe. Symptoms suggestive of fLTLE that may 
help in differentiating it from fMTLE are summarized in Table 1.3. 
 
 
 
Table 1.3 Symptoms suggestive of Familial Lateral Temporal Lobe Epilepsy (Shorvon, 
2005) 
 
Auditory  Roaring, buzzing, music like, radio or motor like broadcasting sound, or 
distorted sounds of words, suggesting involvement of Herschel gyrus. 
Cephalic aura  Headache, light headedness, non vertigineous dizziness, pulling pressure of 
head (Although these are more common in frontal lobe seizures)(Palmini and 
Gloor, 1992) 
Hallucination or 
illusion 
More complex hallucinations than in occipital lobe epilepsy. These can be  
either visual or auditory, such as complex visual pattern, illusion of size, 
shape, and distance 
Trigger factor  can be triggered by environmental sound or noise (although this feature is 
more common in seizures of central origin)  
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Diagnosis and differential diagnosis 
      The diagnosis of familial lateral TLE is largely history based. Often the EEG is normal, 
but posterior temporal epileptiform discharge can be seen. The MRI findings are usually 
normal, but recently there are studies indicating the volume of lateral temporal lobe in 
individuals  with  LGI1  mutations  are  larger  than  healthy  controls,  in  particular  with 
protrusion and small  gyri (Kobayashi et al.  2003a; Tessa et al.  2007).  In contrast to 
Familial MTLE, there is no hippocampal atrophy or sclerosis.  
      The differential diagnosis of fLTLE includes fMTLE, GEFS+, FS, and other types of 
partial epilepsies.  
 
Treatment 
      The  control  of  familial  lateral  TLE  is  usually  quite  satisfactory  by  low  dose  anti 
epileptic drugs indicated for partial epilepsies, based on individual response. If seizures 
relapse after adequate control, usually these are induced by precipitating factors, such as 
sleep deprivation or alcohol. For those individuals that the gene mutations of LGI1 have 
been confirmed, it is advised to stay on medication rather than coming off even if seizure 
free for years. 
 
1.2 Genetics of familial temporal lobe epilepsy 
      The  genetics  of  familial  temporal  lobe  epilepsy  are  little  understood,  especially  in 
fMTLE.  From  most  of  the  published  family  studies,  the  inheritance  mode  is  usually 
autosomal dominant with incomplete penetrance for both types of familial temporal lobe 
epilepsies (Chabrol et al.  2007a; Gambardella et al.  2000; Hedera et al.  2007; Picard et 
al.  2000; Rosanoff and Ottman, 2008), but it is possible that other types of inheritance may 
be found in the future.  
      There are currently no genes identified for fMTLE, but several possible loci have been 
reported. In recent genetic studies of fLTLE, mutations in Leucine rich Glioma Inactivated 
1 gene (LGI1) have been identified both in familial and sporadic type of lateral temporal 
lobe epilepsy, but only half of such families identified had these particular gene mutations 
(Ayerdi Izquierdo et al.  2006; Michelucci et al.  2007). This suggests that more than one 
susceptible gene or unidentified non genetic factors are responsible in developing fLTLE.    
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1.2.1 Genetics of mesial temporal lobe epilepsy  
      The susceptibility genes in mesial temporal lobe epilepsy in human being have yet to be 
discovered.  Several  animal  studies  have  indicated  that  mutations  of  potassium  channel 
(KCN) may contribute to mesial temporal lobe epilepsy (Wenzel et al.  2007) but this has 
not been confirmed in human epilepsy.  
 
1.2.1.1. Genetic association studies in MTLE  
      There are a few candidate genes based association studies, some have reported position 
associations  but most  did not  identify any associations.  Even  in  studies  which  positive 
associations have been reported, most findings have not been replicated in independent 
studies, which are mandatory in confirming the association. 
 
1.2.1.1.1. Association studies with positive results 
     The  polymorphism  of  the  gene  encoding  Apolipoprotein  ε  4  (APOE  4)  has  been 
suggested  to  have  its  impact  on  temporal  lobe  epilepsy,  especially  on  memory  and 
cognitive functions (Yeni et al.  2005). Whether this  gene  also has a causative role in 
MTLE or its existence merely influences the memory and cognitive function of MTLE 
patients has yet to be clarified (Kumar et al.  2006). A case control study and meta analysis 
of mesial temporal lobe epilepsy with hippocampal sclerosis showed that the polymorphism 
of prodynorphin (an opioid peptide precursor) with the allele L is associated with mesial 
temporal  lobe  epilepsy  with  a  p  value  <  0.0001,  in  comparison  to  another  allele  H 
(Kauffman  et  al.    2008a).  In  another  meta analysis  of  association  studies  in    mesial 
temporal lobe epilepsy with hippocampal sclerosis, a positive association was shown with  
Interleukin 1 β polymorphism (IL  1β) with an odds ratio of 1.92 (95% CI 1.11 2.08), when 
comparing 2 genotypes (TT vs CT) of the IL 1β gene (Kauffman et al.  2008b). This might 
suggest that the variants of IL 1β gene could contribute to hippocampal sclerosis but more 
epidemiological evidence is needed to support this finding.  
      Other candidate genes based genetic association studies that reported positive findings 
include  GABBR1  polymorphism  G1465A  (Gambardella  et  al.    2003b; Johnson,  2003), 
CHRNA4 polymorphism (Ser543Ser) C/T (Chou et al.  2003), prion protein (PrP
C) gene  
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PRNP (Walz et al.  2003), and a 5 Htt polymorphism (Manna et al.  2007). These studies 
are summarized in Table 1.4. Only in the case of the IL1 β polymorphism 511C>T has 
replications been performed to confirm the association with mesial temporal lobe epilepsy. 
Furthermore, none of the genes (including IL1 β) identified through genetic association 
studies have been identified in genetic linkage studies of familial mesial temporal epilepsy. 
 
1.2.1.1.2. Association studies with negative results 
      The majority of the candidate gene based association studies in temporal lobe epilepsy 
reported negative association results. Such studies are summarized in Table 1.5. Cavalleri 
et al (Cavalleri et al.  2005) investigated 752 patients with temporal lobe epilepsy. These 
patients were stratified according to the criteria used in several original candidate gene 
association  studies  which  investigated  interleukin  1   β,  PDYN,  GABBR1,  PRNP, 
CHRNA4, and GABRG2 and showed associations with mesial temporal lobe epilepsy. The 
stratified population were genotyped accordingly (and in some of the patients might be 
genotyped more than twice for different candidate genes), the results were compared to 
previous studies which reported the associations. However, Cavalleri and colleagues failed 
to replicate any of the reported positive association results. Other candidate genes that had 
been  investigated  in  other  association  studies  of  temporal  lobe  epilepsy  with  negative 
association results include 5 HTT polymorphisms, BDNF, and ATP1A2 (Table 1.5).  
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1.2.1.2 Genetic Linkage study in fMTLE  
Although the association studies of sporadic mesial temporal lobe epilepsy, suggests that 
the Interleukin β gene might be the susceptibility gene, this has not been identified in any 
familial linkage studies, whether with or without hippocampal sclerosis. Even in the genetic 
linkage studies of familial MTLE, no single study has replicated the results of the others.  
 
1.2.1.2.1Genetic Linkage analysis with positive findings 
Baulac (Baulac et al.  2001b) suggested that the there could be more than one disease 
locus in familial TLE. Recently in 2 genetic linkage studies which reported a LOD score > 
3 mapped 2 different new loci that linked to familial temporal lobe epilepsy independently, 
but no genes have been mapped so far in these two regions. Claes et al (Claes et al.  2004) 
in the linkage analysis of a family with familial TLE associated with FS mapped the disease 
locus to 12q22 q23.3 based on a 2 point LOD score of 6.9 and a multipoint LOD score of 
7.8 at the same marker. No disease gene was found in this locus, and the result has not been 
replicated. In the familial linkage study of Hedera (Hedera et al.  2007), a LOD score of 4 
was obtained at 4q13.2 q21.3. Two candidate genes were identified and sequenced even if 
no known ion channel genes exist in this region. The sodium bicarbonate co transporter 
(SLC4A) gene is in the linked region and plays
 an important role in tissue excitability. The 
cyclin I (CCNI) gene is also in the region and plays a role in the cell migration which may 
contribute to subtle cortical abnormalities. These 2 genes were sequenced but no disease 
causing mutations were found. A whole genome wide scan was carried out in both linkage 
analysis studies, with an average 10 cM distance in Claes’s study and an 8cM average 
distance in Hedera’s study.  
 
1.2.1.2.2 Genetic Linkage analysis with negative findings  
Other  recent  linkage  analyses  reporting  negative  linkage  findings  include  Santo’s 
familial linkage study on several candidate loci (Santos et al.  2003), Strianos’ linkage 
analysis of 15 Italian family studies (Striano et al.  2008b), and Maurer  Morelli’s genetic 
linkage study of 2 families with fTLE  (Maurer Morelli et al.  2006). In Depondt’s linkage 
analysis of a large Belgium family with familial TLE, the phenotyping in this study was not 
specific to mesial temporal lobe epilepsy but it seemed that there were no lateral temporal  
  41 
epilepsy subjects included (Depondt et al.  2002). This study did not show positive disease 
linkage.  In  Picard’s  autosomal  dominant  partial  epilepsy  family  series,  7  families  with 
temporal lobe seizures were included however he did not specified whether these were 
fMTLE (Picard et al.  2000). His genetic analysis did not show positive linkage, either. 
Whole genome wide scan was not carried out in these genetic linkage studies, but only 
several candidate microsatellite markers were investigated. 
 
1.2.2 Genetics of familial lateral temporal epilepsy  
1.2.2.1 LGI1 gene and familial lateral TLE 
      In contrast to mesial temporal lobe epilepsy, mutations of a glioma suppressor gene, the 
Leucine–rich Glioma Inactivated 1 (LGI1) gene, have been found in lateral temporal lobe 
epilepsy,  or  “autosomal  dominant  partial  epilepsy  with  auditory  features”  (ADPEAF) 
(Morante Redolat et al.  2002; Staub et al.  2002). The details of these studies are presented 
in  Table  1.4.  Until  2008,  twenty  two  different  mutations  causing  fLTLE  have  been 
published (Brodtkorb et al.  2002; Chabrol et al.  2007b; Fertig et al.  2003; Hedera et al.  
2004; Kalachikov et al.  2002; Kobayashi et al.  2003a; Kobayashi et al.  2004; Michelucci 
et al.  2000; Ottman, 1995; Ottman et al.  2004; Pizzuti et al.  2003; Poza et al.  1999; 
Striano  et  al.    2008a;  Winawer  et  al.    2002).  In  these  22  mutations,  nine  provoke  a 
truncation of the protein either by altering the reading frame of the  mRNA due to the 
existence  of  insertions  (1  mutation),  or  deletions  causing  a  nonsense  mutation  (4 
mutations), or by a single base mutation affecting a consensus splice site (4 mutations) 
(Table 1.6). Another 13 mutations are amino acid exchanges found in different domains of 
the  protein  (Table  1.7),  which  either  caused  the  function  loss  of  the  LGI1  protein,  or 
decreases its secretion. However, polymorphisms in around 50% of families identified with 
fLTLE no such mutations of LGI1 were identified (Ayerdi Izquierdo et al.  2006). This 
suggests  that  either there  are other  genetic  mutations  yet  to be  found  or  that  there  are 
nongenetic factors involved in familial lateral temporal epilepsy. 
 
1.2.2.2 LGI1 Gene and sporadic lateral TLE 
      Sporadic (non familial) cases with apparently idiopathic partial epilepsy with auditory 
features (IPEAF) have been described (Bisulli et al.  2004). These patients appear to be  
  42 
clinically indistinguishable from ADPEAF cases with the only difference being that they 
lack a family history. Gene sequencing analysis of LGI1 exons in  IPEAF patients have 
revealed  two  de  novo  LGI1  mutations  (Bisulli  et  al.    2004;  Michelucci  et  al.    2007); 
providing  a  link  between  familial  and  sporadic  patients  partial  epilepsy  with  auditory 
features. The percentage of LGI1 mutations in sporadic lateral TLE is not yet known, one 
study investigated 16 patients with sporadic lateral TLE but did not find any mutations on 
LGI1(Flex et al.  2005).  The value and the application of this gene in screening sporadic 
types of patients awaits more study.  
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1.2.2.3 Structural and functional studies of LGI1 Gene 
The structure of LGI1 has been well studied (Staub et al.  2002). the protein contains a 
hydrophobic  segment  representing  a  putative  transmembrane  domain  with  the  amino 
terminus  located  outside  the  cell.  It  also  contains  leucine rich  repeats  with  conserved 
cysteine rich flanking sequences. This gene is predominantly expressed in neural tissues 
and its expression is reduced in low grade brain tumours and significantly reduced or absent 
in malignant gliomas (Gu et al.  2005), and is rearranged as a result of translocations in 
glioblastoma cell lines (Chernova et al.  1998). 
The function of the gene LGI1 in relation to ion channel has been investigated (Schulte 
et al.  2006). In their study by proteomic analysis, it showed that LGI1 is tightly associated 
with Kv1.1 containing channel complexes when the complexes were affinity purified from 
rat  brain.  The  LGI1 mediated  modulation  of  A type  K
+  currents  in  hippocampal 
presynapses may provide a reasonable explanation for both epileptogenesis and inheritance 
in autosomal dominant lateral temporal lobe epilepsy (ADTLE, or fLTLE). This research 
showed that the LGI1 protein could be a subtype of Kv1.1 channel associated protein, and 
the mechanism underlies  LGI1 product in causing fLTLE may be related to potassium 
channel dysfunction. Based on this study and the fact that potassium channel had been 
reported to cause epilepsy (Singh et al.  1998; Singh et al.  2003), Diani et al (Diani et al. ) 
screened several potassium channel genes on patients with either sporadic or familial types 
of lateral TLE, including KCNA1, KCNA4, and KCNAB1 which encode potassium ion 
channel Kv1.1, Kv 1.4 and Kv β1, respectively, but no mutations were found.  
      Fukata  (Fukata  et  al.    2006)  demonstrated  that  a  transmembrane  protein  ADAM22 
serves  as  a  receptor  for  LGI1  in  rat  brain.  When  mutated  itself,  ADAM22  may  cause 
seizures by altering the regulation of the glutamate AMPA neurotransmission. LGI1 may 
enhance  AMPA  receptor mediated  synaptic  transmission  in  hippocampal  slices  but  the 
mutated form of LGI1 fails to bind to ADAM22. Based on this study, Chabrol (Chabrol et 
al.  2007a) sequenced the ADAM22 receptor gene on several fLTLE families, and Diani 
(Diani et al. ) sequenced the ADAM22 gene on both sporadic and familial LTLE patients. 
No disease causing mutations were found in either study, although several synonymous and 
non synonymous polymorphisms were identified.   
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1.2.2.4 Temporal lobe structural anomaly caused by LGI1 
     One report (Tessa et al.  2007) showed that in LGI1 mutated individuals, both with 
sporadic and familial LTLE, there were abnormalities of the left middle temporal gyrus. 
This brain imaging study was performed by using voxel based analyses of T1 weighted, 
diffusion tensor, and magnetization transfer (MT) images in 8 patients (3 women and 5 
men, mean age 49  ±  13 years) with both fLTLE and LGI1 mutations and compared to 24 
healthy control subjects (14 women and 10 men, mean age 43  ±  7 years). Another study 
showed that in one family, among those who underwent MRI investigation, 53% of those 
who  had  LGI1  mutations  showed  a  temporal  lobe  anomaly,  either  malformation  with 
enlargement of temporal lobe or a combination of temporal lobe enlargement and abnormal 
shape  of  fusiform  gyrus,  temporal  lobe  enlargement  and  parahippocampal  gyrus 
malformation, or abnormal hippocampal shape. In contrast to fMTLE, none of them had 
hippocampal atrophy or sclerosis. Another remarkable finding was that all the temporal 
lobe anomalies found and reported in these fLTLE patients were located on the left side.  
 
1.3 Febrile seizures and its genetics in temporal lobe epilepsy 
      Febrile seizures have long been noticed to have an important role in the causation of 
mesial temporal lobe epilepsy and probably hippocampal sclerosis. A history of antecedent 
febrile seizures is often found in those who developed hippocampal sclerosis and refractory 
seizures. Whether genes causing febrile seizures (which have been identified) may also be 
implicated in the causation of familial mesial temporal lobe epilepsy has not been fully 
clarified.  
 
1.3.1 Definitions of febrile seizures, febrile seizures plus, and generalized epilepsy with 
febrile seizures plus (GEFS+) 
      Febrile seizures (FS) are defined as convulsive seizures which occur with fever above 
38
◦C between three months and 6 years of age at their broadest limits. The term febrile 
seizures plus (FS+) refers to a numbers of different presentations: febrile seizures which 
continue to take place either after the age of 6 or rarely, before three months old; and the 
situation where afebrile seizures occur with febrile seizures during the typical age range 
(within 3 moths to 6 years) (Scheffer and Berkovic, 2007). FS+ may occur with afebrile  
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generalized  or  partial  seizures,  such  as  absence,  myoclonic  seizure,  atonic  seizures  or 
generalized tonic clonic seizures.  
      Generalized  epilepsy  with  febrile  seizures  plus  (GEFS+)  is  defined  as  a  “familial 
epilepsy syndrome”, which is diagnosed when more than one individual within a family has 
a history of seizures that fit into the category of febrile seizures or febrile seizures plus. In 
other words, GEFS+ is a spectrum of phenotypes seen within a family ranging in severity 
from  mild  to  severe  seizure  disorders.    Recently,  the  spectrum  of  GEFS+  has  been 
expanded  to  include  febrile  seizures  only,  FS+,  FS/FS+  and  absences,  FS/FS+  and 
myoclonic seizures, FS/FS+ and atonic seizures, FS/FS+ and partial Epilepsy, Myoclonic 
Astatic  Epilepsy,  and  Dravet’s  Syndromes  (Scheffer  and  Berkovic,  2007;  Mulley  et  al 
2005)  (Figure.1).  According  to  another  review  of  21  families  with  GEFS+  which  the 
underlying genetics defects had been identified (Baulac et al.  2004), 42% of them had FS, 
48%  had  FS+,  and  only  10  %  of  them  had  afebrile  seizures.  Generalized  tonic clonic 
seizures  were  the  most  common  types  of  seizures,  followed  with  absence,  myoclonic 
seizure, atonic seizures and partial seizures.  
 
Figure 1.1 Spectrum of GEFS+ Syndromes  
[Adapted from (Mulley et al 2005) with permission] 
 
 
 
FS 
FS+ 
FS/FS+ and myoclonic Seizures 
FS/FS+ and atonic seizures 
Myoclonic Astatic 
Epilepsy 
Dravet Syndromes 
FS/FS+ and absences 
FS/FS+ and partial Epilepsy  
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1.3.2 The genetic basis of GEFS+  
      GEFS+ is a complex disease with polygenic involvement, although the discovery of its 
genetic basis was through linkage analysis of multiplex families with autosomal dominant 
inheritance (Scheffer and Berkovic, 2007). Current studies showed that GEFS+ are related 
to sodium channel and GABA receptor mutations: SCN1A and SCN1B (Colosimo et al.  
2007; Wallace et al.  2002), and GABAA receptor γ 2 subunit gene (GABRG2) (Baulac et 
al.  2001a). The mutations in these susceptibility genes have been repeatedly found in many 
genetic studies of families with GEFS+  and the functional studies of these  genes have 
demonstrated that they can contribute to epileptogenesis. More recently, mutations in the 
GABAA receptor δ subunit gene (GABRD2) (Lenzen et al.  2005) and calcium channel 
subunit gene (CACNA1H) have also been reported (Heron et al.  2007), but have not been 
replicated in other studies and await functional confirmation. A new locus on chromosome 
8p23 p21 was recently identified in a few French families, but within this locus there are no 
ion channel genes and no susceptibility genes have been identified  (Baulac et al.  2008). 
      Not  all  GEFS+  can  be  explained  by  the  gene  mutations  described  above.  Bonanni 
(Bonanni et al.  2004) investigated 7 Italian families with GEFS+ pedigrees, but did not 
find any mutations of SCN1A, SCN1B and GABRG2. Sun et al (Sun et al.  2008) reported 
the combine frequency of SCN1A, SCN1B and GABRG2 in GEFS+ was only around 8.7% 
in a Chinese GEFS+ families study. Overall, the genes currently known for GEFS+ account 
for < 20% of large families studied (Meisler and Kearney, 2005; Wallace et al.  2001). 
These facts suggest that there are unknown susceptibility genes or as equally likely there 
are unknown environmental factors which may contribute to GEFS+. 
 
1.3.3 Familial mesial temporal lobe epilepsy and febrile seizures 
      Epidemiological research has demonstrated that febrile seizures are associated with the 
development of temporal lobe epilepsy during teens or adulthood. Around 25% of temporal 
lobe epilepsy patients were found to have antecedent febrile convulsions (Hamati Haddad 
and Abou Khalil, 1998). In refractory mesial temporal lobe epilepsy, the percentage with 
antecedent febrile convulsion during infancy can be as high as 50 80% (French et al.  1993; 
Sagar and Oxbury, 1987). In families with history of febrile seizure, or febrile seizures plus 
(GEFS+), it is common to find individuals with temporal lobe epilepsy, with or without  
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hippocampal  sclerosis.  It  is  also  common  to  find  individuals  in  families  with  familial 
mesial  temporal  lobe  epilepsy  who  had  history  of  febrile  seizures  (Claes  et  al.    2004; 
Kobayashi et al.  2003a; Striano et al.  2008b). In one recent report, SCN1A mutation was 
found in a family with febrile seizures, and three of the family members went on to develop 
temporal lobe epilepsy (Colosimo et al.  2007). In another study which investigated SCN1B 
gene mutations in 4 families, 5 individuals with temporal lobe epilepsy were found to have 
C121W mutation on SCN1B (Scheffer et al.  2007).  
      However,  none  of  the  genes  identified  in  GEFS+  has  been  found  in  families  with 
familial  temporal  lobe  epilepsy.  Furthermore,  the  extent  to  which  these  genes  also 
contribute to temporal lobe epilepsy has not been fully investigated. Besides, many patients 
with  temporal  lobe  epilepsy  or  hippocampal  sclerosis  do  not  have  history  of  febrile 
seizures. 
 
1.3.4 Genetic relationship between FS and TLE 
1.3.4.1 Sporadic MTLE and FS 
      Association  studies  of  sporadic  temporal  lobe  epilepsy  with  hippocampal  sclerosis, 
found that the homozygous state of Interleukin 1 –β gene to be more frequent with patients 
who had antecedent febrile seizures than those patients who did not (Kanemoto et al.  2000; 
Kanemoto et al.  2003). Another association study  reported that the low expression L 
alleles of the prodynorphin gene (PDYN) promotor confer an increased risk for temporal 
lobe epilepsy in patients with a family history for febrile seizures, and irrespective of the 
familial  background,  L homozygote  display  a  higher  risk  for  secondarily  generalized 
seizures and status epilepticus as well as in the TLE patients with febrile seizure, especially 
those with more severe complex seizures (Stögmann et al.  2002). However, except for the 
IL1 β  polymorphism  which  has  shown  weak  association  with  sporadic  temporal  lobe 
epilepsy through meta analysis, there has no replication of the PDYN gene polymorphism 
in TLE genetic studies.  
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1.3.4.2 Familial MTLE and FS 
      Subtle  hippocampal  abnormality  could  lead  to  febrile  seizures  and  subsequent 
hippocampal sclerosis and temporal lobe epilepsy, as described in 2 pedigrees (Fernandez 
et al.  1998). Kobayashi (Fernandez et al.  1998) further confirmed that individuals in 
families with fMTLE who were not epileptic could have subtle hippocampal abnormalities. 
Such  abnormalities  might  be  caused  by  a  combination  of  genetic  predisposition  and 
subsequent  environmental  influences,  and  could  have  contributed  to  febrile  seizures  in 
some individuals, leading to later development of temporal lobe epilepsy.  
      In contrast to GEFS+ in which several susceptibility genes were identified, the familial 
genetic  studies  of  mesial  temporal  lobe  seizures  have  not  identified  any  susceptibility 
genes. Nonetheless, the fact that febrile seizures are closely related to mesial temporal lobe 
epilepsy may suggest that they share genetic mechanisms or perhaps interactions between 
susceptibility genes.  
  
1.4 Susceptibility genes in other epilepsy syndromes 
      For  other  idiopathic  generalized  epilepsy  syndromes,  several  genes  have  been 
identified. Most of them are ion channel genes or receptor genes. Several sodium channel 
genes have been frequently reported as the major susceptibility genes in IGEs, especially 
GEFS+. Only a few non–ion channel genes have been reported in epilepsy genetic studies, 
and so far not much is understood about how these non ion channel genes contribute to the 
susceptibility  of  epilepsy.  Table  1.8  is  a  brief  summary  of  these  genes,  their  possible 
mechanism, and their corresponding epilepsy syndromes.  
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Section 2: Photosensitive Epilepsy and Its Genetics 
 
 
2.0 Overview and terminology 
      The term photosensitive epilepsy commonly refers to epilepsies that can be evoked by 
flickering light. It is not usually considered to constitute an epilepsy syndrome on its own, 
because such phenomenon can be found on many well established epilepsy syndromes, 
such as Juvenile Myoclonic Epilepsy, and Childhood Absence Epilepsy (De Bittencourt, 
2004).  The  term  photosensitivity,  strictly  applied,  refers  exclusively  to  the 
electroencephalographic  phenomenon  of  a  photoparoxysmal  response  (PPR)  on  EEG 
recording.  
      Of all the photosensitive epilepsies, only one form of focal idiopathic photosensitive 
epilepsy,  the  Idiopathic  Photosensitive  Occipital  Lobe  Epilepsy  (IPOLE)  is  currently 
classified as a unique entity under the category of reflex epilepsy according to the ILAE 
classification  proposed  in  2001  (http://www.ilae 
epilepsy.org/Visitors/Centre/ctf/CTFtable1.cfm).  Other  photosensitive  epilepsies  are 
included  within  existing  well defined  epilepsy  syndromes,  such  as  the  Idiopathic 
Generalized Epilepsies, or as other visual sensitive epilepsies.  
      The use of terminology in photosensitive epilepsy can be confusing as there is yet no 
officially standardized terminology scheme. Different authors and researchers in the past 
were (and still are) using different terms to define the same phenomenon, or have different 
definitions. Examples are described in later sections (2.1.3). To avoid misunderstanding, 
there are a few terms that need to be clarified before considering photosensitive epilepsy. 
Some different terms are summarized in Table 2.1.  
      In  this  section,  the  ILAE  classification  is  applied,  and  the  term  “photosensitive 
epilepsies” is used to include both IPOLE and other forms of visual sensitive epilepsies. 
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Table 2.1 Terminology of Photosensitive Epilepsy 
 
2.1 Photosensitive Epilepsies 
2.1.1 History  
      The first reliable record and description of photosensitive epilepsy can be traced back in 
1885 (Gowers, 1885), with a reference of a girl whose seizures was induced by walking 
Term  Definition 
Photic induced-seizure 
(Visual sensitivity, or     
Visually induced 
seizures) 
A  seizure  provoked  by  visual  stimulation.  The  usual  stimulus  is  a 
flashing light, but can be patterns of lines, gratings, checkerboards or 
other configurations. The seizures can be in any form by the majorities 
are generalized tonic clonic epilepsy, 
Occurrence  of  Seizures  provoked  by  visual  stimili  in  daily  life 
(Kasteleijn Nolst Trenité, 2006) (Verrotti et al.  2002). 
Photosensitive epilepsy  A reflex epilepsy that is evoked by flickering light, TV, video games, or 
moving  water  under  sunshine.  It  does  not  constitute  an  epilepsy 
syndrome by its own. 
Iiopathic Photosensitive 
Occipital Lobe Epilepsy 
A  typical  disorder  of  adolescence,  with  female  predominance 
characterized  by  occipital  seizures  provoked  by  visual  stimuli 
(http://www.ilae epilepsy.org/ctf/gloss_frame.html). 
Photoparoxysmal 
response (PPR) 
An  abnormal  EEG response to light or pattern, consisting of spikes, 
spike waves, or intermittent slow waves. The spikes are not confined to 
occipital  regions  only  and  should  not  be  confused  with  the  normal 
visual evoked response that is phase locked to the flash.  
Photosensitivity  An  abnormal  response  of  the  EEG  to  light  or  pattern  stimulation, 
consisting of a PPR. Photosensitivity does not constitute an epileptic 
syndrome  on  its  own,  because  it  can  be  found  in  all  the  main 
categories of epileptic disorders. 
Photomyoclonic 
response = Orbifrontal 
photomyoclonus 
response 
1.  Forehead  and  muscle  twitching  in  response  to  light  flash, 
disappearing with eye opening. 
2. The intermittent photic stimulation (IPS) can trigger in adult patients 
and, in particular in elderly, rapid myoclonic jerking of the periorbital 
muscles, which produce eyelid fluttering and blinking, synchronous with 
the  flashes  (Kasteleijn Nolst  Trenite´  et  al.,  2001).  This  normal 
response  to  photic  stimuli  is  called  orbifrontal  photomyoclonus  (or 
frontopolar, recruiting, photomyogenic responses)  
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into bright sunshine, and a man whose aura and subsequent fit could be evoked by looking 
into bright sunlight. Subsequent records include absence seizures and eyelid myoclonus 
induced when looking into bright light with the effect of eye closure (Rodovic et al.  1932).  
Goodkind  (Goodkind,  1936)  later  demonstrated  a  method  that  induced  fits  in  a 
photosensitive patient by using sunlight coming through a wire window screen. The effect 
of intermittent photic stimulation (IPS) during EEG recording was described by Adrian and 
Matthew (Adrian and Matthew, 1934), but its clinical relevance in inducing seizures was 
not  described  until  Cobb  reported  that  flickering  light  can  be  a  precipitant  of  seizures 
(Cobb, 1947). The application of IPS as an activating technique in EEG recording dates 
back to Grey Walter (Walter et al.  1946), who introduced the electronic stroboscope.  
      With  the  invention  and  availability  of  television  during the  1950s,  the first  case  of 
seizures induced by television was reported by Livingston (Livingston, 1952). Since then, 
such cases have been documented in many reports (Binnie and Wilkins, 1998; Jeavons and 
Harding, 1975; Zifkin and Kasteleijn Nolst Trenité, 2000). The first case study of seizures 
induced by TV was reported by Gastaut and colleagues (Gastaut et al.  1962), who studied 
35 patients with seizures induced by watching television. They distinguished patients who 
had  seizures  from  those  who  had  fainting  episodes  as  well  as  those  who  had  frequent 
seizures  and  likely  to  be  coincidentally  related  to  watching  TV  and  not  induced  by 
watching TV. In the remainder, they believed that some relation existed between evoking 
seizures and watching TV. In late 1990, several TV programs that contained flashing light 
of certain frequencies induced seizures in children and some adults who watched those 
programs,  such  as  Pocket  Monster  that  was  broadcast    in  Japan  in  1996,  and  an 
advertisement shown on commercial TV in the United Kingdom (Harding and Harding, 
1999).  The  latter  led  to  an  official  guideline  solicited  by  the  Independent  Television 
Commission  (ITC)  for  advertisements  and  TV  programs  in  the  UK. Besides  television, 
video games and flashing computer screens can also induce epilepsy (Fish et al.  2005).  
      After video games and computers became widely available, the flickering light coming 
from the screen and monitors has triggered seizures in cases with photosensitivity. The first 
case of such epileptic seizures was reported by Rushton (Rushton, 1981). Such cases were 
documented in may other subsequent reports (Graf et al.  1994; Kasteleijn Nolst Trenité, 
1994; Quirk et al.  1995).  
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      Pattern  sensitivity  in  photosensitive  subjects  was  first  reported  by  Bickford,  who 
noticed that patterns such as stripes also induced seizures (Bickford et al.  1953). Such 
cases were documented in several reports but little is understood about their relation to 
photosensitivity. Radhakrishnan (Radhakrishnan et al.  2005) studied 73 patients diagnosed 
with  pattern  sensitive  epilepsy,  evaluated  their  EEG  both  with  intermittent  photic 
stimulation and different patterns. Their data showed that only 11% of patients did not have 
epileptiform discharge during IPS, but all of them had epileptiform discharge during pattern 
stimulation  and  those  epileptiform  discharges  were  similar.  This  suggests  that  pattern 
induced epilepsy is closely related to photosensitive epilepsy and both may share similar 
pathogenesis. 
 
2.1.2 Epidemiology 
      The  Epidemiology  of  photosensitivity  can  be  more  thoroughly  described  in  three 
different ways: the epidemiology of photosensitivity itself, its epidemiology in relation to 
epilepsy syndromes, and the epidemiology in the newly defined IPOLE. 
 
2.1.2.1 Epidemiology of Photosensitivity 
      The prevalence of photosensitivity in non epileptic subjects ranges from 0.5 to 8.9% 
(Quirk et al.  1995; Takahashi et al.  2001; Verrotti et al.  2002). Doose and Gerken (Doose 
and Gerken, 1973) found PPR in 7.6% of 662 normal children, including those children 
with  headache  or  had  a  family  history  of  epilepsy.  Several  studies  showed  the  visual 
sensitivity  is  age  dependent  and  is  highest  in  late  childhood  and  early  adolescence 
((Jeavons and Harding, 1975; Kasteleijn Nolst Trenité, 1989). Some authors (Shiraishi et 
al.  2001; Wolf and Goosses, 1986) reported a higher prevalence of PPR in the age group of 
11–15 years and noted that the incidence suddenly decreased after the age of 20. The same 
age dependency was also found in studies in patients with common epilepsy syndromes, 
showing that an epileptiform response to IPS is found in about 10–20% of children and 5–
10% of adults, and that response is more common in females at any age group compared to 
males,  in  a  female  to  male  ratio  of  approximately  2:1  (Kasteleijn Nolst  Trenité,  1998; 
Kasteleijn Nolst Trenité, 2006).  
 
  61 
      Ethnic factors may be contributory to photosensitivity. In a study, Africans were shown 
to be more sensitive than Indians, and Europeans were the least sensitive (Familusi et al.  
1998). This finding is in contrast with another research carried out approximately in the 
same time (De Graaf, 1992). In the latter, amongst 1493 epileptic patients in Namibia with 
PPR were found in only 0.4% of Africans, 4% of Indians, and 5.2% of Europeans subjects. 
These findings may indicate that visual sensitivity depends primarily on genetic rather than 
on environmental factors. 
 
2.1.2.2 Epidemiology of Photosensitivity in different Epilepsy Syndromes 
      Photosensitivity can be found in patients presented with various epilepsy syndromes, 
but  especially  in  Idiopathic  Generalized  Epilepsy  (IGE).  Wolf  and  Goosses  (Wolf  and 
Goosses,  1986)  found  that  in  the  generalized  epilepsies  group,  15%  of  patients  were 
photosensitive  and  in  the  localization   related  epilepsies  group,  only  3%  were 
photosensitive. Among the different epilepsy syndromes, the highest prevalence of a PPR 
was found in Juvenile Myoclonic Epilepsy (JME) (30%), followed by childhood absence 
epilepsy  (CAE)  (18%),  and  West  and  Lennox  syndromes  (17%).  In  Juvenile  Absence 
Epilepsy (JAE) only, 8% showed PPR. Shiraishi et al. (Shiraishi et al.  2001) studied a 
similar type of cohort using the same criteria, among a total of 2187 unselected patients 
from  a  Japanese  epilepsy  centre  (age  range  1–81;  mean  24.2  years;  56%  male,  44% 
female), thirty seven patients (1.7%) were found to have a generalized PPR. Most of the 
PPR positive  patients  were  found  among  IGE  patients  (5.6%),  compared  to  0.7%  in 
localization related epilepsies. Within the IGE group, both JME (17.4%) and grand mal on 
awakening (7.6%) had a significant higher percentage than other types of IGE,  while in the 
group  of  localization  related  epilepsies,  occipital  lobe  epilepsy  (6.1%)  had  the  highest 
percentage.  
      Beside IGEs, PPR can also be found in progressive myoclonic epilepsy (Rubboli et al.  
1999), and very rarely in mesial temporal lobe epilepsy (Fiore et al.  2003). PPR is found in 
other less common epilepsy syndromes, such as Neuronal Ceroid Lipofuscinoses (Berkovic 
et al.  1988), Lafora Disease (Tinuper et al.  1983), Unverricht Lundborg Disease (Guerrini 
and Genton, 2004; Kasteleijn Nolst Trenité, 2001), and also mitochondria disease, such as  
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MERRF (So et al.  1989). The prevalence and incidence of PPR in each of these epilepsy 
syndromes is unknown.  
 
2.1.2.3 Idiopathic photosensitive occipital lobe epilepsy (IPOLE) 
      The  Idiopathic  Photosensitive  Occipital  Lobe  Epilepsy  (IPOLE)  is  a  type  of  reflex 
epilepsy  that  is  exclusively  triggered  by  visual  stimuli  with  a  peak  incidence  around 
puberty.  The  syndrome  is  now  recognized  as  an  independent  entity  within  the  reflex 
epilepsy category by the ILAE force task on classification and terminology in 2001. The 
diagnosis of this photosensitive epilepsy can be quite challenging, as its symptoms largely 
overlap with other epilepsy syndromes, especially Juvenile Myoclonic Epilepsies (Taylor et 
al.  2004), and also many other photosensitive epilepsies (Parra, 2006).        
      The epidemiology of this photosensitive epilepsy is much less understood. One study 
estimated that patients with idiopathic photosensitive occipital lobe epilepsy represented 
0.4% of 2,447 consecutive epilepsy patients seen in 2 specialized centres (Guerrini et al.  
1995). In these series, there was girl preponderance in a ratio of 4:1. Age  and sex related 
trends overlap with those seen overall in photosensitive patients, with a peak at around 
puberty to adolescence.  
 
2.1.3 Classification 
      In 2001, the ILAE has proposed a new diagnostic scheme for “people with epileptic 
seizures and epilepsy” (http://www.ilae epilepsy.org/Visitors/Centre/ctf/CTFtable1.cfm) to 
replace  the  old  classification.  In  this  classification,  visual  sensitive  epilepsies  are 
categorized under Reflex Epilepsies, and within these visual sensitive epilepsies the “pure 
photosensitive reflex epilepsy” which is exclusively triggered by visual stimuli is isolated 
and is named as “Idiopathic Photosensitive Occipital Lobe Epilepsy” (IPOLE), which is 
now considered an independent syndrome, within the category of reflex epilepsy.  
      Before this classification was introduced, there were several different classifications on 
photosensitive epilepsies, either based on the clinical manifestations, or based on the IPS 
induced  PPR  patterns  on  electroencephalography.  Even  after  this  new  classification 
proposal was introduced, most researches have not yet adopted this classification and old 
terminologies are still in use.   
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2.1.3.1 Classification by clinical manifestation 
      Initially, Harding and Jeavons in their large case study of photosensitive epilepsy in 
Birmingham classified their patients into three separate classes, based on the severity of the 
patient’s sensitivity to light: (1) “a clinically sensitive group in which light of the intensity 
encountered in daily life is capable of inducing clinical attacks”; (2) “a less sensitive group 
in  which  clinical  seizures  can  be  induced  only  under  conditions  of  high  intensity  of 
illumination and rapid flicker” and (3) “a group in which the only evidence of sensitivity is 
the  occurrence  of  epileptiform  discharges  on  IPS,    unaccompanied  by  any  detectable 
clinical evidence of a seizure” (Kasteleijn Nolst Trenité et al.  2001). 
      More recently Kasteleinjn et al (Harding and Jeavons, 1994a) proposed a relatively 
more comprehensive classification, based on the clinical presentations of visual sensitivity 
(Table 2.2).        
 
Table 2.2 Classification by clinical symptoms (Kasteleijn Nolst Trenité et al.  2001) 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.3.2 Classifications by EEG findings 
      EEG findings have been applied to the classification of photosensitive epilepsy and are 
widely used. A widely used EEG classification system was proposed by Waltz and Doose,  
who classified the PPR into 4 different types based on the distribution of the slow waves 
and spikes induced by IPS (Waltz  et al.  1992). This classification has been widely used as 
1. Mild subjective symptoms (SS) 
2. Orbitofrontal photomyoclonus (OPM)                              
3. Eyelid myoclonus (EM) 
    a. Eyelid myoclonus with absences (EMA) 
    b. Self inducing behavior (SI) 
4. Focal, asymmetrical, myoclonus (FM) 
5. Generalized myoclonus (GM) 
    a. Without loss of consciousness, often isolated 
    b. With impairment of consciousness 
6. Tonic, versive phenomena (TVP) 
7. Absence seizures (A) 
8. Generalized tonic–clonic seizures (GTCS) 
9. Partial seizures (PS) 
    a. With simple visual symptoms 
    b. With complex visual symptoms 
    c. With limbic symptoms  
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the  basis  for  phenotyping  in  the  genetic  study  of  photosensitivity  and  photosensitive 
epilepsies. This classification is summarized in Table 2.3 
 
 
Table 2.3 PPR classification by Doose (Waltz  et al.  1992) 
Type  Description 
1  Spike within the occipital rhythm,  
2  Parietal occipital spikes with biphasic slow waves 
3  Parieto occipital spikes with biphasic slow waves and spread to the frontal region 
4  Generalized spike and waves or polyspikes 
        
 
      Another classification introduced by Jeavons and Harding was also based on the PPR 
on EEG (Harding and Jeavons, 1994a). In their classification, occipital spikes were not 
considered as a PPR response or epileptiform discharge as was classified in the Waltz and 
Doose classification. Their classification is summarised in Table 2.4 and Table 2.5. 
 
 
Table 2.4 PPR classification by Jeavons and Harding (Harding and Jeavons, 1994a) 
 
Classification 1: Photomyoclonic responses (PMRs)  Responses seen only in the anterior regions 
Classification 2: Photoparoxysmal responses (PPR)  Widespread, involve anterior and posterior, 
bilateral  response 
Classification 3: Photic driving, (visual evoked 
potentials, occipital spikes) 
Response seen only in the posterior region 
  
 
      Classification 1 Photomyoclonic responses (PMRs) were extremely rare. The PPR are 
confined  to  the  anterior  region  only.  Classification  2  (PPR)  of  Jeavons  and  Harding’s 
described above were further divided into six types (Table 2.5). In contrast to the scheme of 
Doose classification, Photic driving was considered normal in the Jeavons and Harding’s 
classification, included occipital spikes that did not persist or spread. Although occipital 
spikes  may not be  epileptiform  and are considered normal in the Jeavons and Harding 
classification, they have been considered as a phenotype in some studies and could useful 
as biomarkers for genetic studies.   
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Table 2.5 Sub classification of Classification 2 in Table 2.4 by Jeavons and Harding 
 
Type  description 
1  Spike wave bursts, usually with a slow component around 3/sec 
2  Theta spike waves burst at 4 7 (theta) frequencies 
3  Burst of polyspikes or polyspike waves 
4  Spikes coinciding with the flash rate, but extending widely to the anterior region 
5  Spike waves at 3Hz lasting at least 5 seconds after the flashing has ceased, and associated 
with a clinical absence 
6  Bilateral, diffuse high amplitude slow waves without spikes, seen in all channels 
 
 
      Besides the PPR classifications of Doose and Jeavons, Kasteleijn Nolst Trenité et al 
(Kasteleijn Nolst Trenité et al.  2001) have proposed another 2 classifications, based on the 
EEG  response  to  IPS  (Table  2.6)  and  the  electro clinical  phenomena  (Table  2.7).  The 
classification  based  on  the  electro clinical  phenomena  takes  into  account  the  different 
phenotypes which are often seen clinically, and has been used as the basis of phenotyping 
in several unpublished genetic studies. However, there is currently no evidence of which 
classification is superior to the others in clinical or genetic studies. 
 
Table 2.6 Classification by EEG responses to IPS by Kasteleijn Nolst Trenité 
(Kasteleijn Nolst Trenité et al.  2001) 
 
1. Photic following 
          a. At flash rate 
          b. At harmonics 
2. Orbitofrontal photomyoclonus (OPM) 
3. Posterior stimulus dependent response 
4. Posterior stimulus independent response 
          a. Limited to the stimulus train 
          b. Self sustaining 
5. Generalized photoparoxysmal response 
          a. Limited to the stimulus train 
           b. Self sustaining 
6. Activation of pre existing epileptogenic area 
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Table 2.7 Classification of electro clinical phenomena by Kasteleijn Nolst Trenité 
(Kasteleijn Nolst Trenité et al.  2001) 
 
 
       
2.1.4 Assessment of Photosensitivity  
      Photosensitivity or PPR are usually assessed by EEG with IPS. Different facilities and 
protocols in applying photic stimulation may result in different responses, as some are more 
effective in triggering PPR and some are not. As discussed below, lack of standardisation in 
IPS frequency, strength of illumination, position of equipment (and so on) can result in 
significant  variations  in  findings  and  in  sensitivity.  As  more  diagnostic  tools  become 
available, criteria for photosensitivity may change.  Positron Emission Tomography (PET), 
visual  evoked  potential  (VEP),  magnetoencephalography  (MEG),  and  other  functional 
imaging such as fMRI have been recently applied to the assessment of photosensitivity and 
photosensitive epilepsies, and the importance of a universal standard protocol in assessing 
photosensitivity has been discussed (Kasteleijn Nolst Trenité et al.  2001). 
 
2.1.4.1 Assessment by IPS and EEG 
      Visual sensitivity (VS) can be assessed with different diagnostic procedures, but the 
most common method is intermittent photic stimulation (IPS). This procedure can provide 
information on seizure susceptibility of the individual exposed to intermittent lights, as well 
as the degree of photosensitivity and the relation between VS  and  epileptic syndromes 
(Rubboli et al.  2004). The effectiveness of IPS is indicated by the capability of inducing an 
abnormal EEG response in the highest number of patients in whom visual stimulation can 
potentially precipitate a seizure, but reducing to a minimum the chance of obtaining such 
responses in normal subjects (Rubboli et al.  2004; Zifkin and Kasteleijn Nolst Trenité, 
2000).  This  effectiveness  depends  largely  on  the  methodology.  Since  in  different 
1. Individuals with a photoparoxysmal response (PPR) in the EEG, and no history of   epileptic 
seizures 
2. Patients with spontaneous seizures, but with a PPR in the EEG 
3. Patients with an isolated visually induced seizure in special circumstances, with or without a 
PPR in the EEG 
4. Recurrent visually induced seizures and no spontaneous seizures, with or without a PPR in the 
EEG 
5. Visually induced and spontaneous seizures, with or without a PPR in EEG  
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laboratories different protocols and photic stimulators are used, it is difficult to evaluate and 
compare the IPS effects across different laboratories. Therefore, a standardized protocol 
may be necessary to provide a fair evaluation and comparison of researches across different 
laboratories  as  well  as  to  facilitate  collaboration.  In  1999,  recommendations  for  a 
standardized protocol to perform and to report results of IPS were made in a European 
expert  panel  (Kasteleijn Nolst  Trenité,  1998).  In  this  proposal,  it  was  suggested  that 
photostimulator, montage and the procedure of IPS during EEG could be standardized and 
at the same time to provide the best result in testing. A 13 cm  circular Grass lamp is 
preferred  as  it  has  the  best  potency  compared  to  other  products.  At  least  16  channel 
montages are necessary to record sufficient data. 
      According to the standard protocol proposed in 1999 and later to some adjustments, the 
IPS  should  be  performed  in  the  EEG  laboratory,  preferably  in  an  artificially  dimmed 
environment and artificially lit at a constant level. The IPS must be done  ≥3 min after 
hyperventilation with the patient placed 30 cm from the photic stimulator. This distance 
provides a sufficiently large visual field with the13 cm circular Grass lamp, and enables the 
examiner to detect subtle clinical phenomena. Ten second trains of flashes are given for 
each frequency with intervals of at least 7 seconds between stimulus trains. Eyes should be 
kept open for the first 5 seconds of each train of flashes, fixing the center of the lamp 
(Rubboli et al.  2004). The patient should then close the eyes and remain in the eyes closed 
condition  for another  5  seconds  of  stimulation.  Stimuli  start  at  1 and  progresses  to  20 
flashes/s; recommended frequencies and their order of delivery are 1, 2, 3, 4, 6, 8, 10, 12, 
14, 16, 18, and 20 Hz ((Zifkin and Kasteleijn Nolst Trenité, 2000). Should a generalized 
epileptiform discharge occur, the stimulator must be switched off and the IPS procedure 
should be stopped? If PPR does not appear, a second sequence of stimulation is resumed at 
60 Hz, decreasing to 20 Hz with the same precautions (60, 50, 40, 30, and 20 Hz). Total 
screening time should be 6 min or less. For clinical purposes, it may be important to report 
(1)  if  the EEG  response  can  outlast the  stimulus  and,  if  yes,  whether  it  is  blocked  by 
monocular occlusion; (2) whether clinical signs/symptoms are observed; (3) alertness and 
eventual  sleep  deprivation  of  the  patient;  and  (4)  antiepileptic  drugs  (AED)  or  other 
medicaments ((Rubboli et al.  2004).  
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      Photosensitivity  can  be  expressed  at  a  range  of  frequencies  which  induce  a  PPR 
(Harding and Jeavons, 1994a); with lower and upper limits being usually between 10 and 
30 Hz. Around 90% of patients are sensitive at 16 Hz, whereas 49% are sensitive at 50 Hz, 
only around 15% are sensitive to 60 Hz, which are also the frequencies of TV in Europe 
and  North  America,  respectively  (Harding  and  Harding,  1999).    About  3%  of  the 
photosensitive population with some degenerative disorders is sensitive to IPS at 1–3 Hz 
(Zifkin and Kasteleijn Nolst Trenité, 2000). Therefore, a flash rate ranging from 1 to 60 Hz 
during EEG recording should be able to detect almost all patients with photosensitivity.  
      It  is  worth  mentioning  that  many  different  factors  (individual  factors  and  external 
factors) have a marked influence on photosensitivity. Therefore, it is incorrect to conclude 
that a patient is not sensitive to IPS from a single test session. Higher light intensity, lower 
background illumination, longer duration of photic stimulation, and grid pattern stimulation 
will enhance PPR (Harding and Jeavons, 1994a). Also the properties of the stimulator, how 
it is used, and the frequencies and intensity of the flashes influence photosensitivity. For 
example, the flashes must be sufficiently bright and the photostimulator must be able to 
deliver  consistently  bright  flashes  throughout  the  required  frequency  range  of  1–60 
flashes/s to have the best effectiveness (Kasteleijn Nolst Trenité,, 1999).  
 
2.1.4.2 Other diagnostic methods 
      Several  new  diagnostic  tools  have  been  tested  to  detect  photosensitivity  and  visual 
sensitive epilepsies, both in diagnosis or in localization of the epileptogenic zone. Some 
tools have shown good  results, but their validity  and accuracy have not  yet been fully 
verified. 
 
MEG 
      Magnetoencephalography (MEG) has been used to assist EEG recording in picking up 
abnormal  signals.  A  study  combining  EEG  and  MEG  in  detecting  signal  change  on 
photosensitive patients has shown that MEG was able to detect the epileptiform discharges 
during IPS before they were shown on the EEG, that an enhancement could be seen on the 
phase clustering index at the gamma frequency band, compared with that at the driving 
frequency  (Kalitzin  et al.   2002).  Another  study  used  EEG,  MEG  and  functional  MRI  
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(fMRI) in evaluating the focally stimulated visual cortex to validate the use of MEG in 
assisting EEG (Sharon et al.  2007). In this study, the author concluded that combining 
MEG and EEG data is important for high resolution spatiotemporal studies of the human 
brain and would improve the localization accuracy. 
 
Visual evoked potential (VEP) 
      A  recent  study  investigated  whether  VEP  could  predict  if  a  subject  could  be 
photosensitive  and  whether  it  can  be  a  non   provocative  test  for  photosensitivity 
(Vermeulen et al.  2008). VEP was carried out in 17 patients who had photosensitivity but 
with  different  epilepsy  syndromes  (including  2  individuals  whose  photosensitivity  had 
disappeared), 2 patients with epilepsy only without photosensitivity, and 3 controls. Based 
on their analysis and results, the authors concluded that VEP may be able to provide more 
information than just EEG with IPS, and it may be possible to predict whether a patient is 
likely to be photosensitive or not from the analysis of VEP. In the future, this may assist the 
diagnosis of photosensitivity and may provide more information about the physiology of 
photosensitivity (Wilkins et al.  2004).  
 
Imaging studies 
PET 
      Positron Emission Tomography (PET) has been tested on detecting photosensitivity on 
baboons in a case control study (Akos Szabó et al.  2007). The PET was performed on both 
photosensitive  baboons  as  well  as  non photosensitive  baboons.  This  preliminary  study 
showed that PET can pick up signals in anterior cingulate gyrus and orbitofrontal cortex, 
especially at 25 Hz of IPS, but failed to pick up any significant signal change from the 
occipital  cortex.  Whether  PET  can  be  used  in  the  study  of  photosensitivity  and 
photosensitive epilepsies in human awaits further investigations. 
 
SPECT 
      One  study  has  used  SPECT  to  detect  the  changes  of  regional  cerebral  blood  flow 
(rCBF) when PPR was induced during IPS in photosensitive epilepsy patients. The results 
did not demonstrate any significant signal change in the occipital area, but did so in the  
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frontal  cortex  (Kapucu  et  al.    1996).  Another  2  studies  used  SPECT  to  localize  the 
epileptogenic zone on refractory occipital lobe epilepsy patients (Kim et al.  2001; Sturm et 
al.  2000), but both studies showed that SPECT was not helpful in picking up signals of 
PPR or in localization. 
 
Functional Magnetic Resonance Imaging (fMRI) 
      fMRI has been used to assist the diagnosis and localization of epilepsy by detecting 
regional blood flow changes during ictal or post ictal period. However there are no reports 
yet specifically on visual sensitive epilepsies or IPOLE.  
 
2.1.5 Clinical presentation of photosensitive epilepsies 
      Currently available information for IPOLE was largely adopted from Guerrini’s studies 
and  review  (Guerrini  et  al.    1995;  Guerrini  and  Genton,  2004)  and  cases  study  from 
Destina Yalçin  (Destina  Yalçin  et  al.    2000).  In  other  studies,  although  information 
regarding the clinical presentations in photosensitive epilepsies was provided, it is difficult 
to tell whether other visual sensitive epilepsies were included as the symptoms of these 
syndromes often overlap. 
 
2.1.5.1 Idiopathic photosensitive occipital lobe epilepsy 
      Idiopathic photosensitive occipital lobe epilepsy is characterized clinically by partial 
seizures beginning around puberty, and which are exclusively triggered by visual stimuli. 
Television  and  video  games  are  the  most  commonly  reported  triggers.  Secondary 
generalized  seizures  are  common,  and  these  may  be  difficult  to  differentiate  this  from 
photosensitive IGEs (Guerrini et al.  1995). Other environmental stimuli have been reported 
less often, such as flickering or bright sunlight, sunlight reflected by water or other surfaces 
discotheque lighting, and computer screens. Precipitation by visual patterns is reported by 
some patients. Unlike photosensitive generalized epilepsy, there is no clear evidence for 
self induction of seizures (Guerrini et al.  1995). 
      Visual phenomena or hallucinations are the initial ictal manifestation in most patients, 
which are usually described as bright and colourful, in the shapes of rings or spots that are 
fixed or  flashing  in  the periphery  of  the  visual  field,  rotating or  moving  slowly to  the  
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opposite  half field,  vomiting  were  common  following  the  visual  phenomena  (Destina 
Yalçin  et  al.    2000).  Following  visual  aura,  head  and  eye  deviation  without  lost  of 
consciousness  were  often,  either  toward  the  ispilateral  or  contralateral  side  of  the  ictal 
discharge  (Guerrini  et  al.    1995).  If  the  seizures  progress,  some  patients  may  have 
paroxysms of sharp or piercing cephalic pain during their seizures. Epigastric discomfort or 
nausea is reported in about half of the patients (Walker et al.  1995).  
      From the available EEG reports in studies and case reports (Destina Yalçin et al.  2000; 
Guerrini et al.  1995; Walker et al.  1995), it can be concluded that the majority of cases 
have normal background EEG, with unilateral or bilateral occipital spikes or spike and 
wave discharges which may or may not be reactive to eye opening.  
       
2.1.5.2 Other visual sensitive epilepsies 
      For  all  other  visual  sensitive  epilepsies  (photosensitive  epilepsies  excluding  the 
IPOLE),  earlier  studies  revealed  that  the  majority  seizure  types  were  tonic clonic 
generalized seizures (84%), followed with absence seizures (6%),  partial motor seizures 
(possibly asymmetric myoclonus in some cases) in 2.5%, and myoclonic seizures in 1.5% 
of patients (Jeavons and Harding, 1975). However, as this study was done before IPOLE 
was classified as a specific form of reflex epilepsy, and it is possible that several IPOLE 
cases were included in the analysis.  
      Because photosensitivity and visual sensitive seizures are frequently seen as part of the 
symptoms  in  epilepsy  syndromes,  such  as  IGE,  some  researchers  classified  this  entity 
(visual sensitive epilepsies) according to the epilepsy syndromes that the photosensitivity is 
related to. These include epilepsy syndromes in the IGEs, progressive myoclonic epilepsies 
(PMEs),  mitochondrial  epilepsies,  some  focal  epilepsies  and  undetermined  epilepsies 
(Kasteleijn Nolst Trenité et al.  2001).  
 
2.1.6 Differential diagnosis  
      The main challenge in the differential diagnosis is to differentiate IPOLE from all other 
visual sensitive epilepsies. Based on currently available information, the comparison of 
IPOLE and other visual sensitive epilepsies are summarized in Table 2.8. To differentiate  
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visual  sensitivity  from  other  non visual sensitive  epilepsies  should  be  a  less  problem 
through careful history taking and if optimal EEG testing can be obtained.  
 
2.1.7 Prognosis and treatment 
2.1.7.1 Anti epileptic drugs (AEDs) treatments 
      The prognosis of both visual sensitive epilepsies and IPOLE is in general quite good 
(Harding and Jeavons, 1994b). In the past, sodium valproate was frequently prescribed as a 
monotherapy,  and  favourable  control  were  reported  especially  in  cases  with  pure 
photosensitive epilepsy in Hardings’ study (Harding and Jeavons, 1994c). A less favourable 
outcome was reported by Covanis et al (Covanis et al.  2004) in patients presented with 
eyelid myoclonia and absence.  
     
 
Table 2.8 Comparison of IPOLE and other visual sensitive epilepsies 
 
Epilepsy syndrome  IPOLE  Other visual sensitive epilepsies 
Trigger factors  Mostly television and video 
games, less frequent from 
flickering lights or bright light 
Flickering light, bright light on 
running rivers or water, shadows 
under bright sunshine, reflections 
from glasses, or patterns, less TV 
and video games 
Aura  Visual hallucination or 
phenomena, in the shape of dots 
or ring, could be in multiple colour 
depends on the type of epilepsy 
syndrome the visual sensitivity is 
involved 
Clinical 
presentations 
Partial epilepsies with frequent 
secondary generalization, 
conscious eye and head 
deviations are common. 
Myoclonus is not a feature. All 
seizures are exclusively induced 
by photic stimili 
Mostly generalized seizures, less 
frequent partial seizures or 
absence. Seizures can be induced 
by photic stimili but not exclusively, 
other triggering factor may also 
contribute. 
EEG findings  Normal back ground EEG, with 
spikes or spikes and wave 
discharge at unilateral or bilateral 
occipital area 
Depends on the epilepsy 
syndrome detected with 
photosensitivity 
       
 
      The efficacy of Lamotrigine in the treatment of photosensitive epilepsies was evaluated 
by Binnie (Binnie et al.  1986) and Covanis (Covanis et al.  2004). Their preliminary data 
showed  that  lamotrigine  abolished  PPR  in  many  patients  and  also  improved  seizures  
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control  in  most.  All  Binnie’s  subjects  showed  reduced  photosensitivity  and  reduced 
seizures frequency. In Covanis report, 62.5% of his patients with photosensitive generalized 
tonic clonic epilepsy and intolerant to the adverse effects of valproate became seizure free 
on treatment with lamotrigine monotherapy. 
      Benzodiazepines, such as clonazepam and clobazam, are also effective according to 
Harding’s study (Harding and Jeavons, 1994c).  Phenytoin and phenobarbital have been 
proved  to  have  little  or  poor  effect  in  reducing  photosensitivity  or  to  control  the 
photosensitive  epilepsies,  and  ethosuximide  had  only  intermediate  effect  (Jeavons  and 
Harding, 1975).  
      Some new generation AEDs such as Zonisamide, Levetiracetam, and Topiramate have 
been  reported to have good effect on visual sensitive epilepsies (Covanis et al.  2004). 
Levetiracetam  has  been  reported  effective  in  suppressing  both  photosensitivity  and 
myoclonic  jerks.  Some  case  reports  noted  that  withdrawing  levetiracetam  resulted  in 
increased photosensitivity and relapse of myoclonic seizures (Kasteleijn Nolst Trenité et al.  
1996). Other new or candidate AEDs, such as brivaracetam, a novel SV2A ligand, and 
carisbamate,  a  novel  carbamate  antiepileptic  drug,  have  been  studied  in  patients  with 
photosensitive epilepsy and both showed good effect in controlling photosensitive seizures 
in these small series (Kasteleijn Nolst Trenité et al.  1996; Kasteleijn Nolst Trenité et al.  
2007).  
      Some AEDs have been shown no or negative effect on photosensitive epilepsies, such 
as carbamazepine. Although carbamazepine may reduce PPR, it can exacerbate myoclonus 
in photosensitive epilepsies and so should be avoided in such patients (Genton, 2000).  
      Although there is a lack of large scale controlled long term prospective studies, it is 
clear from the existing accumulative reports, that sodium valproate is the most effective 
AED  in  monotherapy  of  photosensitive  epilepsies  (Covanis  et  al.    2004;  Harding  and 
Jeavons,  1994c).  It  often  abolishes  both  photosensitivity  and  seizures  very  effectively.   
Other  new  AEDs have  promising  effects,  but  more  experience  and  evidence is needed 
before their role in this indication, relative to valproate and other conventional therapy, is 
fully established. 
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2.1.7.2 Non AEDs treatment 
      Besides drug treatments, there are a few general protective rules that can effectively 
prevent evoking seizures in patients with photosensitive epilepsies. These are summarized 
in Table 2.8. Most of these are ways to avoid encountering flickering light, and adequate 
suppression of triggering factors when engaged in certain activities, such as watching TV, 
using computers or walking under the sun. 
 
Table 2.9 Non AED treatment of photosensitive epilepsy (Covanis et al.  2004; Verrotti 
et al.  2002) 
 
1. Avoid relevant stimuli, such as discotheque lighting, striped clothing, and other striped patterns; 
sunlight on water; flickering sunlight; sudden changes in light and contrast; and flashing TV 
programs and video games 
2. Use small TV, 12 inch set 
3. Use 100 Hz, LCD, or thin film transistor (TFT) screens 
4. Use remote control 
5. Do not adjust the controls or fast run the video 
6. Avoid getting close to the screen: keep a distance of ≥3 times the width of the TV screen 
7. Cover one eye if exposed to provoking stimuli 
8. Wear spectacles: polarized lenses, dark glasses, or colored glasses (dark blue/green or 
precision tints) 
9. Avoid stress, extreme fatigue, sleep deprivation 
 
 
2.2 Genetic of photosensitive epilepsies 
       Since late 1940s (Walter et al.  1946), family and twin studies have clearly shown that 
there is a genetic predisposition for PPR. Case reports of monozygotic twins have shown 
high  concordance  between  identical  twins,  and  family  studies  have  indicated  a  sibling 
recurrence  risk  of  20–30%,  and  this  increased  to  40%  if  one  of  the  parents  was  also 
affected. This risk increased to almost 50% if a restriction of age was made to 5 15 years 
old in the study group (Doose and Waltz, 1993; Rabending and Klepel, 1970; Waltz  and 
Stephani,  2000;  Waltz,  1994).  Several  factors  however  make  the  mode  of  inheritance 
difficult to evaluate, such as the dependence of age, preponderance of female gender, and 
the  relevance  of  different  PPR  patterns  on  EEG.  However  most  have  believed  the 
heritability figures from the above reports suggest that the mode of inheritance is likely to 
be an autosomal dominant (AD) inheritance with age related reduced penetrance (Davidson  
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and Watson, 1956; Herrlin, 1960; Waltz and Stephani, 2000).  In spite of this, it has proved 
difficult to map the disease locus of photosensitivity.  
      Recently, several case reports, familial linkage studies, and genetic association studies 
have identified a few candidate loci, however, no susceptibility genes of photosensitivity or 
photosensitive epilepsy have been mapped within those loci.  
 
2.2.1 Case report  
      A locus in chromosome 2 has been suggested to be a susceptible locus based on a single 
case report of a child showing refractory myoclonic photosensitive epilepsy and a complex 
chromosomal rearrangement (Van Esch et al.  2002). However, subsequent studies have not 
yet successfully replicated the results nor have any genes been identified from this locus.  
 
2.2.2 Genetic linkage analysis studies 
       A candidate loci based, familial genetic linkage study of 37 PPR families failed to find 
any evidence for linkage to the dopamine receptors gene regions DRD1 to DRD5, located 
on loci EPM1 (21q22.3) and EPM2 (6q24); nor was there any evidence suggesting linkage 
with the idiopathic generalized epilepsy (IGE) loci previously reported, including 1p, 2q36, 
3p14, 3q26, 4p, 6p11, 6p21.3, 8p11 and 15q14 (Neubauer et al.  2005). Another linkage 
study  located  a  candidate  locus  at  6p21.2  in  19  families  with  PPR  and  photosensitive 
seizures, and at 13q31.3 in 25 PPR/IGE families (Tauer et al.  2005). However, no genes in 
those 2 regions have been mapped or proposed as candidate genes, nor have the results 
been replicated. Pinto et al (Pinto et al.  2005) reported another 2 newly found loci through 
linkage analysis in 16 PPR multiplex families with a prominent myoclonic seizure back 
ground,  including  their  proband  and  first  degree  relatives.  The  two  loci  were  7q32  at 
D7S1804 (Doose classification PPR class 1, P=0.004) and 16p13 at D16S3395 (Doose 
classification PPR class 2, and P=0.01) (P represent genome wide significance). These data 
were  re analyzed  in  a  two  locus  linkage  analysis  using  2  models,  the  multiplicative 
(MULT) epistasis model and the heterogeneity (HET) model. The multiplicative (MULT) 
epistasis model encompasses the situation where disease is only caused by a combination of 
alleles at both loci, and the heterogeneity (HET) model assumed that disease can result 
from  the  presence  of  alleles  at  either  single  locus.  However,  these  two  locus  linkage  
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analyses did not substantially give greater evidence for linkage than did the single locus 
analyses, nor did they improve the location estimates (Pinto et al.  2007). 
 
2.2.3 Genetic association studies 
      Based  on  the  finding  of  linkage  analysis  of  Juvenile  Myoclonic  Epilepsy  (JME),  a 
genetic association study of the photoparoxysmal response was carried out focusing on the 
BDR2 gene and its polymorphisms in a German population (Lorenz et al.  2006b). The 
preliminary results showed that BDR2 could be an underlying susceptible gene for both 
JME and PPR (including Doose type 1 4), based on the comparison of 666 healthy control 
cases. Another candidate gene based association study, which included 218 JME and 95 
photosensitive  IGE  patients,  78  PPR  probands  without  IGE,  and  662  healthy  German 
population as controls,  however failed to show any association evidence with the  gene 
succinic semialdehyde dehydrogenase gene (ALDH5A1) in either IGE syndromes or visual 
sensitive epilepsies (Lorenz et al.  2006a). 
       
2.2.4 Other genetic studies in photosensitive epilepsies 
      Grosso  (Grosso  et  al.   2006)  studied  photosensitivity  in  children  with  epilepsy  and 
chromosome anomalies. He found that 4 in 28 children with chromosome anomalies had 
photosensitivity  that  all  of  them  had  Waltz  and  Doose  type  4  PPR.  The  chromosome 
anomalies  were:  one  trisomy13,  one  with  45,XY,  t(14–21)  (q31.1–q22.11),  one 
46,X,t(10;X)(qter;p11.3)+del(X)(p11.3;qter),  and  one  46,XY,del(3)(p25 pter).  However 
this  study  did  not  look  at  molecular  genetic  data  and  did  not  seek  possible  loci  for 
photosensitivity. Taylor (Taylor et al.  2007) investigated the genetic aspects of the female 
preponderance  in  photosensitive  epilepsies  by  studying  the  photo  pigment  gene  on 
chromosome  X.  The  comparison  of  the  allele  frequency  made  between  38  males  with 
photosensitive epilepsies and 84 healthy male control cases did not support the hypothesis 
that this photo pigment gene is the main cause of the female preponderance. 
      A  proposed  susceptible  gene  of  epilepsy,  the  NEDD4 2  (Neuronally  Expressed 
Developmentally Down regulated 4) gene was screened in 80 families with photosensitive 
epilepsies (Dibbens et al.  2007). They found that 4 (5%) out of these 80 families carried 
three different variants (S233L, E271A, and H515P) of this gene. This gene encodes an  
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ubiquitin protein ligase to regulate cell surface levels of several ion channels, receptors and 
transporters which are involved in regulating neuronal excitability, including voltage gated 
sodium  channels  (VGSCs).  However,  none  proved  to  play  a  major  role  in  causing 
photosensitive epilepsies, although the possibility of these variants causing interaction on 
an unidentified target protein was said not to be ruled out.  
 
2.3 Inheritance of “photosensitivity only” without epilepsies      
      Some of the genetics of photosensitivity were investigated in families with one member 
presented  with  visual  sensitive  epilepsies,  becuase  it  is  impossible  for  an  individual  to 
realize that one is photosensitive without other accompany symptoms. One such study was 
done by Waltz and Stephani (Waltz  and Stephani, 2000). They  inspected the inheritance 
of photosensitivity by dividing families into two groups, group 1 were families with one 
photosensitive epileptic patient and a photosensitive parent, and group 2 were families with 
one photosensitive proband but neither of the parents were photosensitive. They concluded 
form the comparisons that PPR in parents is a major determinant for the risk of PPR in 
offspring, which is compatible with an autosomal dominant transmission. No molecular 
genetic study has been carried out on photosensitivity alone.  
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Section 3: Kohlschütter Tönz Syndrome 
 
3.1 History  
      The Kohlschütter Tönz syndrome is a rare hereditary disease which is comprised of 
early  onset  seizures,  abnormal  enamel  development  and  delay  or  deteriorations  of  the 
psychomotor  and  neuromotor  development.  This  syndrome  was  first  described  by 
Kohlschütter in 1974 on 5 affected brothers in a farmer family  from  a small valley in 
central Switzerland (Kohlschütter et al.  1974). The seizures onset in these 5 brothers was 
between 11 months and 4 years of age. Their teeth were yellowish with hypoplasia of the 
enamel. Significant mental deterioration was noticed as they grew older and none of them 
survived into their teens possibly because they were severely handicapped and prone to 
complications, and adequate nursing was not available. In the following years, Kohlschütter 
observed another 2 Swiss families with similar clinical presentations. The seizure onset was 
between 11 month and 4 years of age in these 2 pedigrees. The neurological developmental 
were  normal  before  the seizure  onset,  but  mental  deterioration  and  spasticity  gradually 
developed after the onset of intractable seizures. No female patients were reported in the 
three pedigrees Kohlschütter reported, and he suspected that this syndrome might be an X 
linked disease or autosomal recessive disease (AR). 
      Later  on,  Christodoulou  (Christodoulou  et  al.    1988)  documented  a  Sicilian  family 
which  4  male  and  2  female  family  members  were  affected  with  early  onset  seizures, 
spasticity,  mental  retardation  or  deterioration  after  onset  of  intractable  seizures  with 
amelogenesis  imperfecta  (AI).  The  clinical  presentations  were  similar  to  the  kindred 
described  by  Kohlschütter.  Besides  the  6  affected  individuals,  there  were  another  4 
maternal female relatives who had mental retardation of unknown cause. There was no 
consanguity in this pedigree. Several basic biochemistry and urine screen investigations 
were carried out on some of the affected family members and all the investigations were 
normal. EEG and CSF examination was carried out on one of the affected child, which 
showed excessive slow activities on EEG and slightly elevated lactate level and mildly 
elevated glycine and alanine level in CSF. Because both male and female were affected in  
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this  pedigree  and  parents  were  normal,  the  inheritance  pattern  appeared  autosomal 
recessive. 
      Zlotogora in 1993 (Zlotogora et al.  1993) reported a Druze family with 2 affected 
individuals. In this pedigree, the parents were unaffected and they had 4 children, only 2 
younger children were affected. The parents were said to be first cousins. Both the affected 
children  had  intractable  febrile  seizures,  spastic  gait,  increased  deep  tendon  reflex, 
amelogenesis  imperfecta  with  yellow  teeth  (amelogenesis  imperfecta),  and  intellectual 
learning disability. The seizures onset was between 12 months and 3 years old. The EEG 
showed excessive slow activities and the basic laboratory investigations were all normal in 
these  2  subjects.  In  one  of  the  affected  individuals,  the  seizures  were  always  febrile 
seizures. The inheritance mode of this pedigree was AR. Another German pedigree with 
similar clinical presentation was reports by Petermöller (Petermöller et al.  1993). In this 
pedigree, there were 2 affected individuals. Their clinical presentations were similar to the 
kindred reported before and included febrile seizures and later afebrile seizures with jerks 
mainly  on  the  left  side,  psychomotor  deterioration,  and  amelogenesis  imperfecta  with 
yellow teeth. The parents were unaffected unrelated healthy individuals. The inheritance 
pattern appeared to be AR. 
      A variant of Kohlschütter Tönz syndrome was reported by Guazzi in a Sicilian family 
(Guazzi et al.  1994).  In this family, the clinical presentations were different from the 
pedigrees described above. The neurological deficit occurred in the second decade, and 
seizure onset was not in early infancy or childhood, and in some individuals the seizures 
were  well  controlled.  Muscle  cramps  and  pain  were  the  first  symptoms  in  one  of  the 
affected individuals which started at the age of 10, with gradual psychomotor deterioration. 
Other  symptoms  in  this  individual  were  ataxia,  yellow  teeth,  hyperactive  deep  tendon 
reflex, and degenerative muscular change of the calves in lower limbs. This pedigree was 
quite complicated as there were 4 different phenotypes and the parents were first cousins. 
Some of the individuals in this pedigree had amelogenesis imperfecta only, some of them 
had abnormal neurological symptoms only such as delay of psychomotor development or 
seizures only without amelogenesis imperfecta, and some of them had both but without 
signs of mental retardation. Although Guazzi concluded that the inheritance pattern of this 
pedigree was autosomal dominant (AD), it could also be an autosomal recessive pattern  
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depending on the phenotype defined. This pedigree was included in our linkage analysis 
and the discussion of the phenotype and its mode of inheritance is discussed in Section 10. 
Another variant of Kohlschütter Tönz Syndrome was described by Musumeci in another 
Sicilian family (Musumeci et al.  1995). In this pedigree, in addition to seizures, abnormal 
enamel, and mental retardation which are frequently reported, these individuals also had 
broad  thumbs,  toes  and enlargement  of  the  lateral ventricles,  cerebellum  malformation. 
Similar to the pedigree reported by Guazzi, they also had ataxia and spasticity. There were 
consanguity in this pedigree and the mode of inheritance was AR. 
      More recently, an UK family with the diagnosis of Kohlschütter Tönz Syndromes were 
documented by Donnai (Donnai et al.  2005). As better medical care became available, the 
cases  reported  by  Donnai  were  able  to  live  into  their  teens  but  with  severe  handicap. 
Besides  seizures,  mental  retardation,  and  amelogenesis  imperfecta,  abnormal  crystal 
sediments  were  found  in  the  urine  of  these  cases.  The  parents  were  healthy  unrelated 
individuals in this pedigree and the mode of inheritance was AR. The latest case report was 
that documented by Haberlandt and appeared to be another variant of Kohlschütter Tönz 
Syndrome (Haberlandt E et al.  2006). The neurological deficits in his case were milder 
than the previous cases reported, and the seizures in this case showed good response to 
medical treatment with phenobarbital and vigabatrin. His seizures onset was at 8 months 
and developmental delay was noted at the same times. There were no consanguity reported 
in  this  pedigree however  parents  were  from  neighbouring  villages,  and  inbreeding  was 
possible. Only one child in this pedigree was affected. MRI showed moderate ventricle 
enlargement and cerebellum hypoplasia.  The mode of inheritance in this pedigree appeared 
to be AR, although it was not specified in the article.  
      Until now, according to Haberlandt, there were only 19 cases in 6 pedigrees that have 
been reported, including a patient described by Wygold (Wygold et al.  1996), who had 
progressive mental retardation, enamel defect of teeth, pathological activities on EEG, and 
cerebellar atrophy on MRI scan. 
 
3.2 Clinical presentation 
      The major clinical presentation of Kohlschütter Tönz Syndrome is early onset seizures, 
intractable seizures, mental retardation or deterioration, spasticity, ataxia, and amelogenesis  
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imperfecta. Cerebellum hypoplasia is frequent, and enlargement of lateral ventricles were 
seen in most of the affected subjects. The pregnancies are usually uneventful. Other minor 
symptoms reported include broad toes and thumbs, skull deformities, and muscle cramps. 
Because this syndrome is quite rare, the epidemiology and pathogenesis remain largely 
unknown and the differential diagnosis is quite limited. Treatment is limited to seizure 
control and supportive nursing care only. 
 
3.3 Genetics of Kohlschütter Tönz Syndrome 
      In  Kohlschütter’s  report,  he  noticed  that  geographical  isolation  could  accidentally 
contribute to the development of Kohlschütter Tönz Syndrome, although no consanguinity 
was  found.  The  other  phenomenon  he  noticed  was  there  were  no  female  cases.  He 
concluded that the inheritance mode could either be autosomal recessive or X linked.  
      As more families were reported, it appeared that consanguinity existed in some of the 
affected families and most of the families exhibited autosomal recessive inheritance pattern, 
except the one reported by Guazzi, which was complicated by several different phenotypes. 
Donnai reviewed that 25 cases from 8 families have been reported (including 2 pedigrees 
with mainly amelogenesis imperfecta), and Haberlandt reviewed that till now 19 cases in 6 
pedigrees have been documented. The genetics of this syndrome is largely unknown, except 
from  the  observations  of  the  cases  reported  that  the  inheritance  mode  is  likely  to  be 
autosomal recessive, and the fact that consanguinity and geographical isolation are two 
main factors contributing to this syndrome. No disease locus or susceptibility genes have 
been identified.  
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Section 4: Statistical aspects of linkage analysis 
 
4.1. The beginning of genetic statistics 
      The first genetic statistic analysis was that of Gregor Johann Mendel, who calculated 
the probability of the pea offspring having different phenotypes in his peas hybrid studies 
conducted during 1856  – 1863, in the garden of the Augustinian Convent in Brno. He 
discovered that in the pea offspring he bred, 25% had pure recessive alleles, 50% had 
hybrid alleles, and 25% had pure dominant allele. These findings led to the establishment of 
Mendel’s laws. His research and publication was little appreciated at the time, and it was 
not until 3 decades later that the importance of his research was rediscovered by Hugo de 
Vries and Carl Correns in 1900 (Henig, 2000). Based on  Mendel’s discovery,  William 
Bateson, a British geneticist whose research led to the discovery of genetic linkage with 
Reginald Punnett, first introduced the term “genetic” to describe the study of inheritance 
and science of variation (Harper, 2005).  
 
4.2. Genetic linkage and recombination    
      Genetic linkage occurs when particular genetic loci or alleles for genes are inherited 
jointly,  or  co segregate  during  meiosis.  This  means  that  the  genetic  loci  on  the  same 
chromosome are physically connected and tend to segregate together during meiosis, thus 
they  are  genetically  linked  (Strachan  and  Read,  2004a).  Alleles  for  genes  on  different 
chromosomes are usually not linked, because of independent assortment of chromosomes 
during  meiosis.  A  segment  of  chromosome  may  crossover  during  meiosis  when  the 
chromosomes  segregate,  so  alleles  on  the  same  chromosome  may  end  up  in  different 
daughter  chromosomes,  and  alleles  originally  located  on  different  chromosomes  may 
eventually segregate into the same daughter cell. The re arrangement of these alleles during 
segregation  at  meiosis  is  called  recombination  (Strachan  and  Read,  2004b).  The 
probability of recombination is greater if the alleles are far apart on the chromosome. Based 
on this concept, Sturtevant proposed that the relative distance between two genes can be 
calculated by working out the number of recombinants (Lorentz et al.  2002). This distance 
is defined as the genetic map unit (m.u.). A centimorgan (cM) is defined as the distance 
between  genes  for  which  one  product  of  meiosis  in  100  is  recombinant  (Tefferi  et  al.   
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2002). Based on the relative distance between 2 genes or loci, a genetic map can be drawn 
up. Examples are the Marshfield genetic map, and Decode genetic map.  
      Genetic linkage analysis can be used to identify regions of the genome that contain 
genes that predispose to disease. The application of genetic linkage has contributed to the 
identification of many disease genes in epilepsy syndromes (Table 1.8).   
 
4.3. Modern genetic linkage statistics 
      The most widely used statistic in linkage analysis is the logarithm of the odd score 
(LOD  score)  of  Newton  Morton  (Morton,  1955).  It  is  defined  as  the  logarithm  of  the 
likelihood ratio (odds score), and is a way of  presenting the result of linkage analysis. 
Genetic linkage analysis can be roughly divided into parametric (model based) and non 
parametric (model free) methods. 
 
4.3.1 Parametric (model based) analysis   
4.3.1.1. History 
          Parametric  linkage  analysis  was  initially  performed  by  direct  observation  and 
calculation. Valid scoring procedures were first  applied to human linkage by Bernstein 
(Bernstein, 1931), who showed that each family can be assigned a score, and the sum, 
expected  value,  and  variance  of  the  score  can  provide  a  test  of  the  null  hypothesis. 
Bernstein’s  scores  were  further  developed  by  Hogben  (Hogben,  1934)  and  Haldane 
(Haldane, 1934). However the evolution by Fisher (Fisher, 1935) of a maximum likelihood 
scoring procedure (the u score) proved to be more efficient than Bernstein’s scores for all 
linkage intensities. However, the u score has certain disadvantages. It is not feasible for 
pedigrees larger than 2 generations and when the parental genotypes are unknown (Smith, 
1953). To overcome the disadvantages, Morton proposed the logarithm of odd score system 
(LOD scores), which is based on a sequential test to detect linkage (Morton, 1955).  
 
4.3.1.2 Basic concept and application 
      Parametric  or  model based  linkage  analysis  is  the  analysis  of  the  cosegregation  of 
genetic loci in pedigrees. Loci that are close enough together on the same chromosome 
segregate together more often than do loci further apart or on different chromosomes. The  
 
  84 
further  apart  the  two  loci  are  on  the  same  chromosome;  the  more  likely  that  a 
recombination event will occur during meiosis and this will break up the cosegregation. 
      In the situation where microsatellite markers are used for genotype, each genotype for 
one genetic marker or locus is made up of two alleles, one inherited from each parent. 
Based on the concept of segregation and recombination described above, if a disease locus 
is close enough to a microsatellite marker, it is likely that they will almost always segregate 
together. This tendency can be detected through linkage analysis, where ideally all affected 
individuals  in  a  pedigree  will  exhibit  a  particular  marker  allele  while  the  unaffected 
individuals will not have that marker allele. Many sets of linkage mapping markers are 
available in which markers are regularly spaced across the genome. Usually the more the 
markers in a set, the shorter is the space in between 2 markers and the more informative is 
the marker.  
      Parametric linkage analysis is suitable for pedigrees with Mendelian inheritance. In the 
past two decades, many rare disease genes have been indentified by parametric linkage 
analysis. Defining the mode of inheritance (autosomal dominant, autosomal recessive, or 
X linked) is a necessary pre requisite in parametric analysis. Some estimation before the 
analysis might be necessary, such as the penetrance rate of the disease, and gene frequency. 
Because the mode of inheritance has to be specified before the analysis, it is also referred as 
model based linkage analysis. 
 
4.3.1.3 Heterogeneity (admixture) LOD method 
       The heterogeneity LOD method is a modified parametric linkage analysis. It allows 
locus heterogeneity to be assessed in the analysis. There have been a number of studies 
indicating that this  modified parametric  LOD score models can be more powerful than 
“nonparametric”  techniques (see  below),  as  long  as  the  mode of  inheritance  is  at  least 
approximately  correct.  The  heterogeneity  LOD  scores  (HLOD)  are  calculated  under  a 
simple dominant as well as a simple recessive model at a fixed intermediate penetrance 
(Greenberg et al.  1998; Hodge et al.  2002; Huang and Vieland, 2001; Vieland and Logue, 
2002).  
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4.3.2 Non parametric (model free) approach 
      The ability of parametric linkage to detect linkage is significantly reduced in diseases 
where the modes of inheritance are not certain and for those pedigrees that do not exactly 
follow the Mendelian laws (Greenberg et al.  1998). For situations in which modes of 
inheritance cannot be defined, alternative methods of analyses have been developed. The 
simplest of such methods utilizes pairs of affected relatives, most commonly siblings, the 
so called Affected Sib Pair (ASP) analysis.  
      Currently, the main approach of current ASP analyses is the likelihood ratio method of 
Risch (Risch, 1990). This concept was introduced as early as 1975 by Hill and Smith (Hill, 
1975; Smith, 1975), who both introduced this method independently and with different 
mathematical  methodologies.    The  basic  concept  of  this  method  is  “allele  sharing”,  or 
identical by descent (IBD), which means to seek alleles shared by the affected individuals 
which are descended from the same founder in a pedigree. By testing whether the chance of 
alleles (haplotype) shared by the affected individuals are identical by descent is statistically 
greater  than  the  expected  values  under  the  null  hypothesis  provides  another  way  of 
inferring  linkage.  Because  the  mode  of  inheritance  needs  not  to  be  specified  for  the 
analysis, it is referred as model free linkage  analysis or nonparametric linkage analysis 
(NPL). 
       
4.3.2.1 Sib pair (Spair ) NPL analysis  
      At any locus, according to the null hypothesis of no linkage, the number of alleles 
shared identical by decent (IBD) by a pair of siblings is none with probability 0.25, one 
with probability 0.5, or two with probability 0.25. If IBD sharing in the families is known, 
the observed proportions of pairs sharing no, one, and two alleles at a candidate locus can 
be compared with these expectations. Linkage would be suggested if the pairs of siblings, 
both of whom are affected by a disease, share significantly more alleles IBD than expected 
by chance. For pedigrees in which more relatives are affected, the sibling pair analysis can 
be extended to include more affected individuals, such as uncle nephew pair, or two first 
cousins, and not necessarily confined to sibling pairs (Risch, 1990). The calculation of Spair 
analysis  has  been  implemented  in  several  linkage  analysis  programs,  such  as 
GENEHUNTER (Kruglyak et al.  1996), and SimWalk2 (Sobel and Lange, 1996).  
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4.3.2.2 Sall NPL analysis 
      Spairs measures the number of alleles shared IBD by a pair of affected relatives, whereas 
Sall captures information regarding the sharing between larger sets of affected relatives, thus 
can avoid the disadvantage of Spair measures which is restricted to paired relatives only 
(Whittemore  and  Halpern,  1994).  Sall  calculates  the  observed  IBD  probability  over  all 
possible configurations and puts extra weight on families in which three or more affected 
individuals share the same allele. Therefore, for sibships with only two affected siblings, 
the two statistics are equal, but for Sall, sharply increasing weight is given to families as the 
number of affected individuals sharing a particular allele increases. The Sall statistic is best 
suited to analysis of dominant loci, since more affected individuals per family are likely to 
share the same allele with this type of inheritance (Nyholt, 2000).  
 
4.3.3 Quantitative trait mapping 
      Both parametric and non parametric linkage analysis were designed to detect single 
gene  diseases.  Non parametric  linkage  analysis  is  less  restricted  in  that  a  specific 
inheritance model is not necessary. However, for quantitative trait disease, the inheritance 
of a phenotypic characteristic varies in degree  and can be attributed to the interactions 
between two or more genes and their environment. Therefore, neither parametric nor non 
parametric analysis can be applied to map the disease genes in such diseases. Although 
quantitative trait locus mapping was designed to suit such circumstances, however, it is not 
as simple a way of detecting linkage when compared with parametric or NPL analysis. 
      The basic concept of quantitative trait mapping is the measured genotype approach. 
Supposed  that  a  few  microsatellite  markers  adjacent  to  candidate  genes  are  presumed 
potential  quantitative  loci  which  may  alter  the  gene  expressions  and  may  give  rise  to 
different phenotypes in a pedigree; for each marker, each of its genotypes is considered a 
class,  and  all  of  the  members  of  the  population  with  that  genotype  are  considered  an 
observation for that class. The mean value of the quantitative trait in individuals who have 
either specific alleles or specific genotypes are compared by either by ANOVA, regression 
model (Haseman and Elston, 1972), or variance component linkage method to assess the  
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degree of linkage. However, not all the disease models of quantitative traits are observable, 
and a segregation analysis is often necessary before carrying out such analysis. 
 
4.3.3.1 Variance components linkage method 
      One such method to map quantitative trait is the Variance component analysis. There 
are  another  2  methods  available  in  quantitative  trait  mapping,  which  are  the  ANOVA 
method and the regression method. The idea of variance component analysis is to partition 
the trait variance into components that attribute to the genetic and environment factors, so 
the trait variance among a group can be analyzed via statistics (Goldgar, 1990; Schork and 
Guo, 1993).  
      The variance model can be easily expanded from a simple equation to a more complex 
one to include variable components, such as the effect of environmental factors on samples 
at the time collected, effects of individuals to each other by living together, or a component 
modelling a correlation among spouse. The genetic components of the model can also be 
expanded  to  incorporate  dominance  effect,  so  that  gene gene  and  gene environment 
interaction can be taken into account (Almasy and Blangero, 2008). However, to set up the 
partition  of  variance  components,  certain  degrees  of  estimation  are  needed.  Although 
variance  component  analysis  is  complicated,  programs  such  as  SOLAR  (Almasy  and 
Blangero, 1998), or MERLIN (Abecasis et al.  2002) are available for carrying out the 
analysis.  
 
4.3.4 Comparison between model based and model free linkage analysis 
      The best analysis to detect linkage in a pedigree depends on the characteristics of the 
pedigree (such as mode of inheritance) and the extent of the genetic effect underlying the 
disease. In reality, it is uncommon that an inheritance mode of a pedigree of a common 
disease to be discernable, which often makes NPL the favourable choice for genetic linkage 
analysis. However, there are exceptions. Because NPL is based on IBD, it often ignores 
existing information from relatives who are unaffected in a pedigree, which makes it less 
precise in placing the genes than parametric linkage analysis (Forabosco et al.  2005). Some 
researchers found that in some circumstances, using HLOD method based on the highest 
LOD score from 2 simple model based linkage analysis, one assuming a recessive mode  
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and one assuming a dominant mode of inheritance at a fixed intermediate penetrance, can 
be  at  least  as  powerful  as  NPL  alone  in  identifying  disease  locus,  and  non parametric 
analysis might equal to a parametric analysis using a simple recessive model in mapping 
complex disease or quantitative traits (Abreu et al.  1999; Hodge, 2005). However, NPL is 
often routinely used in linkage analysis as it has its advantages in assisting identifying the 
susceptibility genes in complex disease.  
      A parametric analysis is a powerful way of detecting a disease locus in Mendelian 
traits, if the inheritance and penetrance pattern can be defined correctly or nearly correctly. 
However  the  power  of  parametric  linkage  analysis  in  gene  mapping  is  significantly 
compromised in detecting a disease locus in complex disease trait. It can be successful 
occasionally in finding a locus when a complex disease has the “Mendelian sub form”, in 
which a major disease gene is responsible for the major phenotype. Such examples include 
finding the breast cancer gene BRCA1. However such examples are rare. Besides, if a false 
disease inheritance mode is used for the analysis, it can easily result in false positive result. 
Other advantages of parametric analysis include the ability to accommodate complications 
derived  from  genetic  heterogeneity  (when  the  same  clinical  phenotype  is  caused  by 
mutations  in  different  independent  genes),  incomplete  penetrance  and  presence  of 
phenocopies  (Morton,  1955)  by  alternating  the  parameters  needed  in  the  parametric 
analysis. 
     However,  both  influence  of  gene gene  and  gene environment  interactions  cannot  be 
properly  taken  into  account  either  in  parametric  or  non parametric  analysis.  A  simple 
comparison of the parametric and nonparametric linkage analysis is presented in Table 4.1. 
 
4.4 The LOD (logarithm of odd) scores 
      Logarithm  of  odd  score  (LOD  score)  is  a  standard  way  to  present  the  results  of  a 
linkage analysis. Depending on the analysis methods used, different types of LOD score are 
generated and they are not equivalent to each other. The statistic threshold for declaring a 
positive linkage can differs from one method to another. Careful interpretation of the LOD 
scores is necessary to avoid false claim or rejection of linkage results (Nyholt, 2000). 
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Table 4.1 Comparisons of parametric and non parametric linkage analysis  
 
 
4.4.1 Maximum LOD Score 
      The maximum LOD score (MLOD, or LOD/MLS) is an extended application of the 
LOD scores method of Morton. It has been implemented in the genetic analysis programs 
LINKAGE which was further modified and upgraded in the latest package of FASTLINK. 
The calculation of Logarithm of Odd (LOD) is defined as the decimal logarithm of the 
likelihood ratio, and the likelihood ratio is defined as the ratio of 2 recombination fractions: 
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          θ = recombination fraction  
             = observed recombination event / total recombination event,  
          n = the number of non recombinants of meiosis. 
Thus the LOD score can be presented as 
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1
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 (Terwilliger and Ott, 1994).  
i.e the logarithm of the likelihood ratio when θ2 = ½  (which denotes of no linkage). 
 
  Parametric analysis  Nonparametric analysis 
Power in locus 
mapping 
Robust and powerful if the 
inheritance mode can be 
correctly observed 
Conservative in Mendelian traits, but may 
relatively superior in complex trait compared 
to model based analysis 
Mode of 
inheritance 
Need to be specified   Model free 
Application  Preferably Mendelian 
pedigrees, or its sub form 
Complex trait disease/ non Mendelian 
inheritance where a dominant gene 
inheritance is likely 
Limitations  1. Effect of gene gene and 
gene environment interaction 
cannot be analyzed. 
2. Unsuccessful in polygenic 
disease.  
1. Ignores genotype information of unaffected 
individuals, which makes it conservative in 
finding disease linkage. 
2.  Effect of gene gene and gene 
environment interaction cannot be analyzed.  
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      The maximum LOD score is then obtained by alternating the value of θ (from 0 to 0.5). 
Traditionally, a LOD score of 3 signifies a linkage while a score of  2 rejects the hypothesis 
of a linkage. If the value falls between  2 and 3.0, it is considered inconclusive. However, 
as Lander and Kruglyak (Lander and Kruglyak, 1995) pointed out, these threshold should 
be adjusted in the genome wide level as genotyping is usually done by a genome wide scan 
nowadays, and the point wise p value should be quoted with the corresponding LOD score 
to assist the interpretation. For converting the maximum LOD score to its corresponding P 
value, times the LOD score with 4.6, the product is equal to the Chi square value when the 
degree of freedom is 1 (LOD score x 4.6= Chi Square value). The P values can then be 
looked up from the Chi square table (Ott, 1999b). 
 
4.4.2 Heterogeneity (Admixture) LOD score (HLOD, or MMLShet) 
       The heterogeneity LOD score (or Admixture) method is a modified parametric linkage 
analysis. It allows any heterogeneity of the locus to be taken into account during analysis. 
When linkage analysis is carried out allowing for more than one disease locus, the LOD 
score is maximized with respect to two parameters, α (= the proportions of families linked 
to this locus ) and θ (recombination fraction). Because the LOD score obtained by this way 
is a mixture of  X
2 distributions with 1 and 2 degrees of freedom (df), resulting from the 
introduction  of  an  additional  free  (heterogeneity)  parameter,  this  will  increase  the 
probability of a type I error,  so the threshold for declaring positive linkage is modified by 
adding 0.3 (=3.3) to the traditional LOD score threshold (Hodge et al.  2002). The HLOD 
can be presented as: 
 
]
) 2 / 1 , 1 (
) , (
[ ) , ( 10 = =
=
θ α
θ α
θ α
L
L
Log HLOD (Ott, 1999a; Vieland and Logue, 2002) 
 
α = the proportions of families linked to this locus. The maximum HLOD score is then 
decided by alternating θ, when α is calculated and given a fixed value. 
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4.4.3 NPL LOD scores 
4.4.3.1 LOD Spairs (NPLpair) 
     The NPL LOD scores are LOD scores obtained from NPL analysis, which includes the 
nonparametric sib pair linkage analysis LOD scores (LOD Spairs) and the Sall LOD scores. 
Both calculations has been implemented in GENEHUNTER (Kruglyak et al.  1996). The 
Spairs calculation can be presented as followed: 
( )
) 2 / 1 , 4 / 1 (
) , (
log 2 ,
1 0
1 0
1 0 = =
=
Z Z L
Z Z L
Z Z LR ε  (Teare and Barrett, 2005) 
 
Where Z0 = the likelihood of IBD sharing 0 allele, and Z1 = the likelihood of IBD sharing 1 
allele. The maximum LOD score (Spairs) is found by maximizing the ratio with respect to Z0 
and Z1. 
 
      Holmans  (Holman  and Clayton,  1995)  and  Faraway  (Faraway, 1993)  independently 
showed  that  maximization  of  the  likelihood  ratio  in  this  way  (Spairs)  could  result  in 
parameter  values  that  are  not  biologically  plausible.  Therefore,  Holmans  and  Faraway 
suggested that maximization be restricted to the set of sharing probabilities consistent with 
these possible genetic models; denoted as the “possible triangle” (PT). The set is defined by 
Z1≤ 0.5 and Z0≤0.5xZ1. Such NPL LOD scores are shown as NPL MLSPT.   
 
4.4.3.2 LOD Sall (NPLall) 
           In contrast  to  LOD  S  pair, the  LOD  Sall  score  takes  into  account  all  the affected 
individuals in a pedigree and put extra weight on pedigrees with three or more affected 
individuals  sharing  the  same  allele  IBD.  The  LOD  Sall  score  equation  of  Kruglyak 
(Kruglyak et al.  1996) is presented as: 
 
∑
∑
=
= =
m
i
i
m
i
i i
r
Z r
Z
1
2
1
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Where m is the number of pedigrees, Zi denotes the normalized score for the ith pedigree, 
and the r, are weighting factors.  
 
      Kong  and  Cox  (Kong  and  Cox,  1997)  consider  that  the  NPL  Sall  LOD  scores  of 
Kruglyak might be too conservative to detect linkage. They proposed that by maximization 
of a single parameter (δ) in the numerator on the basis of observed genotype data can avoid 
such disadvantage. The δ represents the degree of allele sharing in a pedigree, where, under 
the  null  hypothesis  of  no  linkage,  δ  =  0;  where  δ  >  0  corresponds  to  the  alternative 
hypothesis  of  excess  sharing.  Therefore,  these  nonparametric  LOD  scores  are 
asymptotically distributed in the same manner as the standard LOD score of Morton. The 
Kong and Cox LOD score method has been implemented in the program MERLIN.  
        
4.5 Interpretation of the LOD scores 
      All LOD scores are not created equal when different methods are used. Moreover, as 
whole genome assessment becomes available either by the use of sets of microsatellite 
markers or by different single nucleotide polymorphism (SNPs) platforms, the standard for 
declaring linkage has to be modified. Furthermore, it is suggested that the point wise p 
value is quoted with LOD scores in the interpretation (Lander and Kruglyak, 1995). In 
general, based on the LOD scores obtained, the result of linkage analysis is interpreted as 
suggestive of linkage, significant linkage, and highly significant linkage. Table 4.2 and 
Table 4.3 are summaries of the interpretations of several different LOD scores obtained by 
different linkage analysis methods.  
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Table 4.2 
Interpretation of different LOD scores and its corresponding P values 
adapted from (Lander and Kruglyak, 1995; Nyholt, 2000) with permission 
 
p value  LOD/MLS  (NPL) MLSPT  MMLShet  Interpretation 
p <0.05
  0.59  0.74  1.09  region of potentially interest 
p < 0.01  1.18  1.38  1.71  region of potentially interest 
p < 0.005  1.44  1.66  1.99  region of potentially interest 
p < 0.001  2.07  2.32  2.63  suggestive of linkage 
p < 7.4 x10
 4  (a)  2.10  2.45  2.75  suggestive of linkage 
p < 2.2 x10
 5  (b)  3.63  3.93  4.20  significant linkage 
p < 3 x10
 7       occurred  5.3  5.76  5.99  highly significant linkage 
 
a: Suggestive linkage threshold when allele sharing methods in sib pairs are used 
b: Significant linkage threshold when allele-sharing methods in sib pair are used 
c: Highly significant threshold when allele-sharing methods in sib pair are used  
MLS: maximum LOD score of Morton (traditional) 
NPL MLSPT: NPL LOD scores, using possible triangle of Holmans. 
MMLShet: maximized maximum LOD score, same as heterogeneity LOD scores (HLOD) 
 
 
 
 
Table 4.3 Modified interpretation of LOD of Morton’s based on genome wide level 
(Lander and Kruglyak, 1995; Nyholt, 2000)  
 
P value  LOD   Interpretation 
p =0.05  0.5875  Region of potential interest in human parametric linkage analysis  
p = 1.7x10
 3  1.86  suggestive of linkage in human parametric linkage analysis  
p = 4.9x 10
 5  3.3  confirmed of linkage in human parametric linkage analysis  
 
 
4.6 Common Software for linkage analysis 
      Genetic linkage analysis involves massive amount of data and complicated statistical 
calculations.  The  best  way  in  analyzing  such  data  is  to  implement  the  algorithm  and 
calculation  protocol  from  a  computing  program.  Some  of  the  commonly  used  analytic  
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programs  are  LINKAGE,  GENEHUNTER,  Simwalk2  and  MERLIN.  Their  major 
functions, platform of operation system, advantages and disadvantages are summarized in 
Table 4.4.  
      Many  programs  cover  more  than  one  analysis  methods.  For  example,  SimWalk2 
provides parametric and Non parametric linkage analysis as well as MERLIN. However, 
the algorithm implemented in each program varies, and the ability to handle the size of 
pedigree also differs in each program. It is advised that programs for linkage analysis are 
selected according to the characteristic of the pedigree being investigated, its inheritance 
pattern of the disease, and the genotyped method. If the pedigree is genotyped via SNPs, 
many conventional analytic programs will not be able to handle such massive amount of 
data. 
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Section 5: Saccades and Anti epileptic Drugs (AEDs) 
 
5.0 Introduction  
   Saccades  are  discrete  ballistic ocular  movements  that  direct  the  eyes  toward  a  visual 
target and fix the image to the fovea within tens of milliseconds. Saccades can be classified 
into several subtypes, depending on the stimuli and the cortex responded to such stimuli in 
generating saccades (Table 5.1 and Table 5.2).  
   In  medical practice, saccades provide important clues leading to diagnosis of various 
neurological disorders. Recently, different types of saccades and their unique parameters 
have  been  investigated  to  see  whether  they  can  be  surrogate  biomarkers  for  common 
diseases in determining their phenotypes or to evaluate their treatment outcome, such as in 
schizophrenia, bipolar disorder or Parkinson disease (Reilly et al.  2008). 
 
5.1 The control pathway of saccades 
5.1.1 Cortex 
   Cortical areas, including primarily the frontal eye fields (FEFs), the supplementary eye 
fields (SEFs), dorso lateral prefrontal cortex (DLPFC), parietal eye fields (PEF) and the 
cingulate cortex, are the highest–level control centres of saccades (Pierrot Deseilligny et al.  
2004).  In general, all these cortical areas are involved in  generating saccades, but the 
characteristics of saccades generated from different areas differ slightly. For example, the 
frontal eye fields are especially involved in voluntary saccades while the parietal eye filed 
is more likely to be involved in reflexive saccades. Table 5.2 summarizes the cortical areas 
currently known which are responsible for different types of saccades. 
   The cortex controls saccades through several different pathways. First, there are direct 
projections to eye movement related structures in the brain stem and superior colliculus 
(SC). A less direct pathway passes through the pontine nuclei to eye movement regions of 
the cerebellum (mainly ventral paraflocculus and oculomotor vermis), which in turn access 
the  output  motor  nuclei  for  eye  movements,  via  projections  to  brainstem  motor  nuclei 
(Krauzlis, 2005). Secondly, there are descending pathways involving nuclei of the basal 
ganglia,  such  as  the  caudate  nucleus  and  the  substantia  nigra  pars  which  exert  their  
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influence on eye movements through the SC (Hikosaka et al.  2000). Figure 1 shows a 
simple illustration of saccades control pathways. Figure 5.2 is a simplified model showing 
the inter relationship between cortical areas in controlling saccades.  
 
Table 5.1 Types of saccades, adopted form Leigh et al. (Leigh and Zee, 2006) 
 
Types  Description 
Spontaneous saccades  Seemingly  random  saccades  that  occur  when  the  subject  is  not 
required to perform any specific behavioural task 
Reflexive saccades  Saccades generated to novel stimuli (visual, auditory or tactile) that 
occur unexpectedly 
Express saccades  Short latency saccades that can be elicited when the novel stimulus 
is presented after the fixation stimulus has disappeared 
Voluntary  (intentional) 
saccades 
Elective saccades made as part of purposeful behaviours 
Memory guided saccade  Saccades  generated  to  the  location  in  which  a  target  has  been 
previously present 
Predictive or anticipatory 
saccades 
Saccades generated in anticipation of the appearance of a target 
Eye head saccades  Saccades recorded without head fixed in a position (Freedman, 2008) 
Anti saccades  Saccades generated voluntarily in the opposite direction to a sudden 
appearance of a target 
 
Table 5.2 Functions of cortex in saccades control 
 
FEF  Intentional, voluntary saccades 
DLPFC  Inhibit reflexive saccades, spatial memory saccades,  
 
Frontal 
SEF  Target selection, motor planning of intentional saccades 
Parietal  PEF  Reflexive saccades 
ACC  Intentional (voluntary) saccades  Cingulate  
PCC  Reflexive saccades 
FEF: frontal eye field, DLPFC: dorsal lateral prefrontal cortex, SEF: supplementary eye field 
PEF: parietal eye field, ACC: anterior cingulated cortex, PCC: posterior cingulated cortex 
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5.1.2 Superior colliculus  
The superior colliculus (SC) is critically involved in generating saccades. Besides direct 
motor control of saccades, researchers have demonstrated that there are sensory and motor 
maps in the superior colliculus (King, 2004). The dorsally located superficial layers of the 
superior colliculus are pure sensory  maps which receive direct input from retina visual 
stimuli  and  indirect  input  from  visual  cortex.  The  underlying  deep  layers  respond  to 
auditory,  tactile  and  visual  stimuli  and  receive  converging  modality specific  input  that 
enable them with multisensory response properties. These new findings suggests that SC 
might act as a modulating centre of saccades according to various visual inputs in different 
conditions (Krauzlis, 2005). 
 
5.1.3 Brainstem 
   The neuronal activities within a circuit which spreads across the brainstem are directly 
involved in the generation of saccades. Such areas include the paramedian pontine reticular 
formation  (PPRF)  and  rostral  interstitial  nucleus  of  the  medial  longitudinal  fasciculus 
(riMLF), (Scudder et al.  2002). These neuronal activities arise mainly from three different 
types of burst neurons. 
Short lead burst neurons 
   The short lead burst neurons (SLBNs) emit burst activities of which their precise timing 
determines  the  amplitude  of  the  saccade.  They  include  both  excitatory  (EBNs)  and 
inhibitory  burst  neurons  (IBNs).  A  group  of  SLBNs  located  in  the  PPRF  and  medial 
reticular formation (mRF) are responsible for the generation of horizontal saccades, while 
another group of SLBNs located in the riMLF and the interstitial nucleus of Cajal project to 
oculomotor and trochlear nuclei to generate vertical saccades (Moschovakis et al.  1991; 
Scudder et al.  2002). It is generally accepted that the EBN of the SLBNs receive inhibition 
from  omnipause  neurons  (OPNs),  and  when  OPNs  cease  firing,  EBN  will  activate  to 
generate saccades (Figure 5.1) 
Long lead burst neurons 
   The long lead burst neurons (LLBNs) demonstrate their activities 100 ms prior to the 
emission of a saccade related burst of activity, and continue to fire during saccadic activity 
(Scudder et al.  1988). Observations regarding the timing of firing between omnipause  
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neurons (OPNs, see below) and LLBNs has led to a hypothesis that this “prelude” activity 
represents inhibitory signals for OPNs to cease firing (Scudder et al.  2002). 
 
      Figure 5.1 Model of saccades control 
 
                PPRF: paramedian pontine reticular formation; mRF: median reticular formation 
                riMLF: medial longitudinal fasciculus 
Superior 
colliculus 
Cortex       
PPRF, mRF 
Omnipause 
neurons 
riMLF 
Horizontal 
saccades 
Vertical 
saccades 
Cerebellum 
Basal 
ganglia 
Temporarily 
pause firing to 
allow saccades 
 
Pontine 
nuclei 
Direct pathway 
Indirect pathway 
Inhibitory control  
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Figure 5.2. The relationship between cortical areas in controlling saccades. SEF receives impulses 
from visual cortex and processes motor planning, sends signal to frontal cortex to elicit intentional 
(voluntary) saccades. DLPFC and CEF assist FEF in target selection, inhibit unnecessary reflexive 
saccades signals coming from PEF. PCC assists PEF in reflexive saccades generation and ACC 
helps in eliciting intentional saccades in the FEF. 
OC: Occipital cortex, SEF: Supplementary eye field, FEF: Frontal eye field, CEF: cingulate eye filed, 
comprise of ACC and PCC.  
ACC:  Anterior  ٛ cingulateٛ   cortex,  PCC:  Posterior  ٛ cingulateٛ   cortex,  DLPFC:  Dorsolateral 
prefrontal cortex. PEF: parietal eye filed, IPA: intraparietal area. 
 
Pause neurons 
   Pause  neurons,  the  so  called  omnipause  neurons  (OPNs),  discharge  steadily  but  stop 
firing  during  some  or  all  saccade  generation.  Of  particular  interest,  OPNs  have  been 
intensively studied recently not only because of their relationship to the superior colliculus 
in controlling saccades but also because they are thought to act as a gating system for both 
saccadic and pursuit eye movements. New  models suggest that OPNs probably receive 
signals from the superior colliculus to cease firing momentarily and disinhibit the EBNs of 
the SLBNs to generate saccades (Scudder et al.  2002). 
 
 
 
SEF 
FEF 
PEF        IPA 
DLPFC 
ACC  PCC 
OC OC OC OC       
CEF 
Facilitory 
 
Inhibitory  
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5.2 Modulation of saccades 
   There are two structures which are not directly involved in generating saccades; but act as 
modulating centres.  
 
5.2.1. Cerebellum 
   The ventral paraflocculus (VPF), and fastigile oculomotor region (FOR) are the main 
structures involved in modifying saccades, especially in modulating the accuracy of the 
voluntary saccades (Krauzlis, 2005). Clinical observations have demonstrated that damage 
of  the  cerebellum  does  not  abolish  saccadic  eye  movements  but  makes  them  highly 
inaccurate. Damage of the VPF and FOR will interrupt the timing, accuracy, dynamics and 
the adaptation of saccades (Klein et al.  2003). Without the regulatory activity of FOR, the 
brainstem burst generator produces grossly dysmetric saccades that exhibit considerable 
variation in amplitude and deviant saccadic trajectory.    
 
5.2.2 Basal ganglia  
   The key role of the basal ganglia is to send inhibitory signals to the superior colicullus 
(SC) after receiving stimuli from cortical areas, including FEF, IPA and DLPFC, mainly 
via the substantia nigra pars reticula (SNr) (Hikosaka et al.  2000). Hikosaka, who had 
studied in detail the influence of the basal ganglia on saccades, concluded that the basal 
ganglia may be an integration centre for saccades. As the SC receives multisensory signals 
from  the  cortex,  a  specific  structure  is  expected  to  filter  useful  signals  from  multiple 
sensory inputs, so that saccades can be elicit efficiently and correctly within mini seconds 
to any stimuli. Because SNr acts as the main inhibition input to the SC, and may be able to 
“select” relevant inputs in generating oriented movements, the basal ganglia may be the 
structures that have evolved to be the integration centre of saccades between the cortex and 
the SC. 
 
5.3 Characteristics of Saccade and localization   
   Several  physiological  studies  have  demonstrated  that  measuring  the  behaviours  of 
saccades  provide  good  information  for  localization.  For  example,  cortical  lesions  have 
complicated influences on saccades involving high cortical functions. Voluntary and visual  
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guided saccades are usually impaired if the visual cortex or the frontal lobe are damaged. 
The latency of spontaneous saccades in monkeys with hemianopsia is prolonged. During 
experiments, those targets falling in the impaired visual field would fail to elicit any visual 
guided saccades (Lynch and McLaren, 1989; Tusa et al.  1986). Lesions in the prefrontal 
cortex decrease the accuracy of memory guided saccades (Curtis, 2005), while slow and 
dysmetric saccades in individual with impaired cerebellar function are characteristics and 
are  easily  detected  during  clinical  examinations.  Such  dysmetric  saccades  are  found  in 
patients  with  multiple  sclerosis,  schizophrenia,  and  stroke  involving  the  deep  vermis 
nucleus,  especially  the  fastigile  nucleus.  Lesions  in  the  basal  ganglia  will  not  abolish 
saccades, but alter their characteristics. Patients with Parkinson disease may have abnormal 
saccades which tend to be hypometric, slow with prolonged latency, and a large saccade 
may be broken into several smaller saccades (stepped). More detailed studies showed that 
the major characteristic of saccades in basal ganglia disorders are impaired memory guided 
saccades and difficulties in suppressing visually guided saccades (Hikosaka et al.  2000). 
   Because different part of the brain can either demonstrate their unique impact on saccades 
or exert their influence on saccadic regulation, it is not only possible that observing the 
altered saccadic characteristics to locate the damage to the brain, but also measuring the 
parameters unique to each types of saccades can provide further information, such as the 
severity of the damage, the responses to treatment, and the functional state of the brain. In 
fact, voluntary saccades that involve simple psychomotor functions, such as anti saccades 
or memory guided saccades have been applied to evaluate the effects of alcohol, nicotine 
and sleep deprivation (Khan et al.  2003; Larrison Faucher et al.  2004; Porcu et al.  1998).  
 
5.4 Methods in recording saccades 
   Leigh and Zee have summarized methods available for measuring eye movements in their 
book  (Leigh  and  Zee,  2006).  Among  those,  electro oculography,  infrared  reflection 
method, video based tracking systems and magnetic scleral search coils are frequently used 
in modern laboratories. Recent researches done by Träisk and colleagues had made further 
comparisons between infrared reflection method and magnetic scleral search (Träisk et al.  
2005; Träisk et al.  2006). These findings suggest that recordings of maximum velocity of  
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saccades by infrared reflection exhibited higher variability compared with magnetic scleral 
search coil. The advantages and disadvantages of these methods are summarized in Table 3.  
   As  expected,  the  parameters  of  saccades  measured  using  different  facilities  will  be 
different. Most of the parameters of saccades were measured by electro oculography before 
other  facilities  were  widely  available,  and  more  recent  researches  in  saccadic  eye 
movements are mostly done either by video based tracking or infra red reflection method. 
Such differences made comparisons of some research results difficult.  
 
Table 5.3.Summary of eye movements recording methods [adopted from (Leigh and 
Zee, 2006)] 
Method  Advantages  Disadvantages 
Electro oculography  Non invasive, cheap, able to 
record large amplitudes of 
saccades up to ±40°. Widely used 
in clinical laboratory. 
Unsteady baseline that requires 
repeated calibration. Affected by 
lighting, lid movements, electrical 
and electro myographic noises. 
Not reliable in recording vertical 
saccades. 
Infrared reflection  Non invasive, little noise, 
resolution of 0.5° 
Limited range,± 20°horizontal 
and ±10°vertical.  
Higher variability. 
Video based tracking  Non invasive, resolution of 0.5° or 
better. 
Bulky head gear, limited in 
analyzing slow saccades 
Magnetic scleral search 
coil 
Sensitive and accurate, capable 
in recording all directions of eye 
movements. 
Need topical anaesthesia and 
wearing a scleral coil. Invasive 
and uncomfortable. Expensive. 
 
 
5.5 Parameters of Saccades 
      There are several parameters that measure saccadic eye movements, such as latency, 
peak velocity, duration and amplitudes. Between some parameters, there are mathematical 
relationships. For example, the main sequence is the mathematical equation that describes 
the  relationships  between  peak  velocities,  and  amplitudes.  The  Q  value  evaluate  the 
skewness by the ratio of maximum velocity and mean velocity. This value is approximately 
1.6, even for slow saccades because of fatigue. For certain types of saccades, they have 
unique  parameters.  For  example,  anti saccades  and  memory  guided  saccades  can  be 
evaluated by error rates. Saccades trajectory is a graph illustrating the track of the eye 
movements, although it is not considered a parameter; it has been very useful in various  
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neurophysiological studies. Table 5.4 is a summary of parameters in saccades and their 
definitions.  
 
Table 5.4 Parameters of saccades 
 
Parameter  Definition 
Latency (Reaction 
time) 
The time between the appearance of the stimuli and the beginning of 
a saccade (sec). 
Duration  The time between the beginning and the end of a saccade (msec) 
Peak Velocity  The maximum velocity measured during a saccade (deg/sec) 
Acceleration velocity  The measurement of how fast a saccade can reach the peak velocity 
(deg/sec
2) 
Deceleration velocity  The measurement of how fast a saccade can stop from its peak 
velocity (deg/sec
2) 
Mean velocity  The averaged velocity of a saccade (deg/sec) 
Amplitude   The magnitude of a saccade, usually in the measurement by degree 
(deg) 
Accuracy (visual 
guided saccades, 
memory guided 
saccades) 
The ratio of the amplitude of a saccade generated to the stimuli 
amplitude. (i.e the ratio of the actual amplitude to the amplitude that it 
should have to foveate the target in interest) (%). 
Error rate (anti 
saccades, memory 
guided saccades) 
The percentage of errors made during in performing memory guided 
saccades or anti saccades (%). 
Q value  Peak velocity/ mean velocity ≈ 1.6, measure skewness. 
Main sequence  Peak Velocity =Vmax x (1 e
 Amplitude).  
 
 
5.5.1 Main Sequence of saccades 
      The term “main sequence” was originally used to describe the relationship between the 
brightness of a star and its surface temperature in Astronomy. Such relationship can be 
illustrated  as  the  “Hertzsprung Russel  Diagram”, using  colours  to  represent  the  surface 
temperatures  of  stars.  In  early  1960,  when  accurate  measurement  of  saccadic  eye 
movements  was  successfully  carried  out  (Cook  and  Stark,  1968;  Robinson,  1964a;  
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Robinson, 1964b), this term was adopted to describe the relationships between the duration, 
the peak velocity, and the magnitude (amplitude) of human saccades. Since the discovery 
of a constant mathematical relationship between the three saccades parameters (duration, 
peak velocity, and amplitudes), the Main Sequence of human saccades has been used as a 
diagnostic  tool  for  assessing  eye  movement  disorders  (Bahill  et  al.    1975).  Recently, 
measuring  the  Main  Sequence  of  human  saccades  has  been  extended  as  a  measure  of 
treatment outcome in psychomotor and neurological disorders (Chan et al.  2005; Griffiths 
et al.  1984).  There is more than one mathematical model that describes the main sequence 
of human saccades. Two of the most widely used mathematical models are the exponential 
equation and the modified square root equation models.  
 
5.5.1.1 The exponential model (equation) 
       In the exponential equation model, the saccadic duration is approximately proportional 
to the amplitude. The relationship between the peak velocity and the amplitude of human 
saccades can be fitted with an exponential function: 
 
Peak Velocity = VMAX(1 e
 amplitude/c) (Baloh et al.  1975), 
 
Where VMAX is the velocity at the point where it does not continue to increase in spite of 
increased amplitude (the asymptotic maximum velocity). The constant C is the amplitude 
value corresponding to a peak velocity equal to 63% of VMAX. This equation model has 
been widely used in many modern studies especially those using the scleral coil method to 
record and analyse saccadic eye movements (Irving et al.  2006; Träisk et al.  2006; van 
Beers, 2007). 
 
5.5.1.2 The square root model (equation) 
      In the square root equation model, the mathematical relationship between peak velocity 
or duration and the magnitude of saccades is presented as:  
 
F=F1 *  A (Lebedev et al.  1996),  
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Where F is either the duration or the peak velocity of a saccadic eye movement, and F1 is 
the corresponding parameter value when the amplitude (A) is equal to 1°. For horizontal 
saccades, in a range of amplitudes from 1.5° to 30°, it is possible to approximate both the 
saccade duration and the peak velocity in this square root form (Lebedev et al.  1996). In 
this study, the square root equation was chosen for the analysis, as it is easier to make 
comparison  between  the  Main  Sequence  recorded  under  different  batteries,  and  for 
horizontal saccades of small magnitude, it is as accurate as the exponential equation model. 
 
5.6 AEDs that affect saccades  
   Although  it  has  been  known  for  decades  that  certain  conventional  AEDs  affect  eye 
movements,  the  exact  mechanisms  are  not  yet  fully  understood.  Among  all  AEDs, 
benzodiazepines  (mainly  diazepam)  were  frequently  studied  because  their  psychomotor 
effects were easily recognized and measuring saccadic parameters  was originally thought 
to be a good technique to monitor their effects. The second commonly studied AED is 
carbamazepine, as its clinical detectable effects in toxic serum levels are impressive and 
observation of saccadic changes has been  reliable in detecting adverse effects in patients.    
 
5.6.1 Conventional AEDs 
5.6.1.1 Benzodiazepines 
Most research on saccades and anti epileptic drugs has focused on diazepam. One of the 
earliest studies was carried out some 40 years ago by Ashcoff (Ashcoff, 1968). Several new 
studies, using more accurate eye movement recording techniques (magnetic search coil) 
were recently published (Wang et al.  2005). Even though the methodologies varied and the 
recording of the saccadic eye movements were carried out by various techniques, at least 15 
studies  have  reported  that  the  peak  velocity  of  saccades  were  significantly  affected  by 
benzodiazepines (Ashcoff, 1968; Ball et al.  1991; Bittencourt et al.  1981; Fafrowicz et al.  
1995; Gentles and Thomas, 1971; Griffiths et al.  1984; Hofferberth et al.  1986; Hommer 
et al.  1986; Jurgens et al.  1981; Rothenberg and Selkoe, 1981; Roy Byrne et al.  1990; 
Tedeschi et al.  1983; Tedeschi et al.  1986; van der Mayden et al.  1989; Wang et al.   
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2005). Some of the studies even reported that these effects could be dose related (Ball et al.  
1991; Bittencourt et al.  1981).  
Padoans (Panoan et al.  1992) reported that besides decreased peak saccadic velocity, 
the  latency  was  prolonged  and  the  amplitude  was  decreased  after  administration  of 
diazepam. The effects were maximal 1 hour after taking the drug. However, no significant 
correlation between the effects and the serum drug concentrations was reported. Jurgens 
and co workers (Jurgens et al.  1981) reported that the peak saccadic velocity and duration 
of saccades were influenced by diazepam, but the accuracy and latency remained almost 
constant before and after taking diazepam. In contrast to these, Blau (Blau et al.  2005) 
found  that  saccades  latency  is  the  most  sensitive  parameter  in  measuring  the  effect  of 
diazepam,  but  accuracy  and  peak  velocity  of  saccades  are  less  reliable.  These  authors 
concluded  that  this  finding  may  reflect  a  dose  of  diazepam  and  a  longer  time  interval 
between  eye  movements  recording,  although  using  electronystamogaphy  in  recording 
saccades may also contribute to the differing results.  
   Lorazepam, which is widely used in status epilepticus, has been reported to have a similar 
effect to diazepam, i.e it prolonged saccadic latency (Salonen et al.  1986; Tedeschi et al.  
1983), increased the duration and decreased the peak velocity and amplitudes of saccades. 
Similar effects were also found in pursuit, that the latency (reaction time) prolonged and 
decreased gain (Masson et al.  2000).  
   Van  der  Mayden  (van  der  Mayden  et  al.    1989)  compared  the  side  effects  of  two 
benzodiazepines  on  saccades:  clonazepam  and  clobazam.  He  found  that  clonazepam 
markedly  slowed  peak  saccade  velocity,  while  clobazam  did  not  impair  saccadic  eye 
movements and had much less side effects on psychological functions such as cognition. 
    Two studies have investigated the effect of midazolam on saccades and reported slowed 
saccadic velocity (Ball et al.  1991; Salonen et al.  1986). Ball and co workers also found 
that the latency of saccades was not affected, but peak acceleration and deceleration and the 
ratio of acceleration to deceleration as well as accuracy were reduced. They also reported a 
correlation  between  the  magnitude  of  changes  of  parameters  measured  and  the  drug 
concentration,  while  Solanen  and  co workers found  no  such  correlation (Salonen  et  al.  
1986). 
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5.6.1.2 Phenytoin and Phenobarbital 
Although  it  has  been  frequently  observed  that  phenytoin  can  induce  nystagmus 
(especially down beating nystagmus) with both toxic and therapeutic serum drug levels, 
there are surprisingly few studies of saccadic eye movements and phenytoin. In a case 
report of a patient with a toxic serum level of phenytoin and phenobarbital (phenytoin 27.5 
mg/ml,  phenobarbital  18.8  mg/ml),  it  was  demonstrated  that  the  patient  exhibited 
hypometric saccades (Thurston et al.  1984). In a review, the slowing of saccades and 
saccadic pursuit by phenytoin were  mentioned  (Esser and Brandt, 1983). No study has 
focused on describing the effects of phenytoin on other parameters of saccades.  
Tedeschi  (Tedeschi  et  al.    1989)  compared  the  influences  of  carbamazepine  and 
phenobarbital on saccades. It was concluded that both drugs exhibited a marked influence 
on  saccades,  with  a  reduction  of  peak  velocity,  poor  saccades  accuracy  and  prolonged 
latency.  However,  there  were  no  significant  diurnal  changes  of  saccades  in  the 
phenobarbital group compared to the carbamazepine group. 
 
5.6.1.3 Carbamazepine and oxcabazepine 
   Although  widely  recognized,  only  a  few  studies  have  demonstrated  the  effects  of 
carbamazepine  on  saccades.  Early  studies  found  that  carbamazepine  slowed  the  peak 
saccadic velocity (Mühlau et al.  1987; Tedeschi et al.  1989), while more recent work in 
patients  on  steady  carbamazepine  therapy  did  not  demonstrate  significant  changes  of 
saccades  parameters  (including  peak  velocity,  reaction  time  [latency]  and  accuracy) 
compared to the age matched control  group (Pieters et al.  2003).  The fact that serum 
concentrations measured across the time interval of the experiment were relative stable in 
these patients probably contributed to this result. Another study quantitatively compared the 
effects  of  carbamazepine  and  oxcarbazepine  on  saccades,  concluded  that  both  drugs 
produced a significant reduction in the peak velocity of saccades, and carbamazepine had a 
greater  effect  than  oxcarbazepine  (Zaccara  et  al.    1992).  Noachtar  and  co workers  
(Noachtar et al.  1998) confirmed this finding in a study investigating carbamazepine and 
gabapentin and additionally noted that the duration of saccades was prolonged and the gain 
(accuracy) were reduced. However, no further detail about the quantitative relationship or  
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any  statistic  analysis  between  the  serum  drug  levels  and  the  magnitude  of  change  in 
saccades parameters were available from these studies. 
 
5.6.2 New generation AEDs 
   For most of the new generation AEDs, their effects on eye movements have not yet been 
observed or established. Only Gabapentin, Tiagabine, and Lamotrigine have been studied 
so far.  
 
5.6.2.1Gabapentin and Tiagabine 
   There is only one report about gabapentin and saccades, which showed that gabapentin 
mildly slowed the peak velocity and prolonged the latency of saccades (Noachtar et al.  
1998). The effects of gabapentin were not as strong as carbamazepine on parameters of 
saccades. In a recent study of tiagabine in healthy volunteers, it showed that this drug had 
no significant effect on peak velocity and the amplitude of saccades, although a trend was 
found for increased latencies after tiagabine treatment (Zwanzger et al.  2005).  
 
5.6.2.2 Lamotrigine 
   Hamilton et al (Hamilton et al.  1993) reported that lamotrigine did not have significant 
influences on peak velocity or duration of saccades at the dose of 150 mg and 300 mg 
compared to placebo group. In his study, eye movements were tested ½ hour before taking 
lamotrigine and then repeated every 1.5 hours after taking the drug up to 6 hours after 
medication.  Another  study  comparing  the  psychomotor  effects  of  phenytoin  and 
lamotrigine and reported the same result (Cohen et al.  1985). 
For all other novel anti epileptic drugs, even those that have been widely prescribed for 
epilepsy treatment such as levetiracetam and topiramate, there  are no published reports 
available.  
 
5.7 Evidence that AEDs may affect saccades through ion channels and receptors  
   Complicate networks within the brain are required to generate saccades. Neuronal activity 
depends on sophisticated neuron networks across various parts of cortex, superior colliculus 
and brainstem with modification by the cerebellum and the basal ganglia. These activities  
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rely on the interactions of neurotransmitters, receptors and ion channels. The role of ion 
channels in the generation of saccades remain ill defined, but recent research has provided 
some indirect evidence that ion channels, especially calcium channels, sodium channels and 
GABA receptors may have their role in saccadic eye movements.  
 
5.7.1. Ion Channels 
5.7.1.1 Calcium channel 
   Mutations of the calcium channel gene CACN1A which encodes the α12.1 subunit of the 
Cav2.1 (P/Q type) voltage gated calcium channel is known to be involved in four inherited 
neurological  disorders:  generalized  epilepsy  with  febrile  convulsion  plus  (GEFS+), 
progressive spinocerebellar ataxia, familial hemiplegic migraine, and episodic ataxia type 2 
(also  named  spinocerebellar  ataxia  type  6,  SCA  6).  There  is  one  study,  which  has 
demonstrated that patients with Cav2.1 mutation are more likely to have selective floccular 
atrophy leading to impairment of smooth pursuit, although saccadic velocity remain normal 
(Ying et al.  2005). In another study, Subramony and colleague (Subramony et al.  2006) 
found that SCA6 patients with a new CACN1A mutation have slow, hypometric saccades 
together  with  markedly  impaired  smooth  pursuit.  It  was  also  reported  that  9 out  of 11 
subjects in this study, fever was a trigger factor for ataxia, suggesting that the function of 
the mutated calcium channels was sensitive to high temperature. This could be a possible 
explanation for febrile seizures caused by calcium channel mutations. A more recent study 
using the scleral coil search method showed that besides hypometric saccades, impaired 
peak saccadic velocity of the upward saccades could be an early manifestation of SCA 6 
and might help in determining the time for treatment (Christova et al.  2008). However, the 
most direct evidence demonstrating that there is an association between slow saccades and 
ion  channels  was  reported  by  Miura  and  Optican  (Miura  and  Optican,  2006).  Using  a 
conductance based saccades generating model, they proved that lesions of the omnipause 
neurons  (OPN)  caused  slow  saccades,    because  of  a  reduced  T   current  (the  transient 
current mediated by T –type calcium channel) and reduced NMDA currents (mediated by 
NMDA receptors),  which were caused by loss of glycine released from OPN. 
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5.7.1.2 Sodium channel 
    There is no direct evidence that sodium channels affect saccades. However, the fact that 
phenytoin  influences  saccades  and  exerts  its  anti epileptic  effect  through  the  sodium 
channel provides indirect evidence that the sodium channel may have its impact on saccade. 
A recent study showed that mice with β1 subunit mutation of the voltage gated sodium 
channel, which is associated with generalized epilepsy with febrile seizure plus (GEFS+) 
had reduced sensitivity to phenytoin (Lucas et al.  2005). This could be the first step in 
exploring the relationship between saccades, susceptible genes to epilepsy and AEDs. 
      The other indirect evidence that sodium channel may affect saccades came from another 
report of a familial disorder with limb tremor and saccadic oscillation (Shaikh et al.  2007). 
In this report, a conductance based simulated model with deficits on ion channel functions 
(including calcium, sodium and potassium ion  channels) were used to  explain both the 
oscillation of saccades and limb tremor. Although such hypothesis is yet to be proved, they 
nevertheless suggest new genetic, experimental and clinical approaches to such disorders 
which may involve ion channels. 
 
5.7.2 GABA Receptors  
   The relationship of saccades and GABA receptors has been well defined by Hikosaka and 
Wurtz (Hikosaka and Wurtz, 1985), who used muscimol (GABA agonist) and bicuculline 
(GABA  antagonist)  to  evaluate  their  effect  on  saccades.  They  were  injected  into  the 
monkey’s superior colliculus (SC) and the effects on saccades were measured. Injection of 
muscimol  markedly  slowed  peak  saccadic  velocities,  slightly  reduced  amplitudes  and 
prolonged latencies, while injection of bicuculline had the opposite effects. The effect of a 
GABA  antagonist  and  agonist  on  saccades  was  demonstrated  through  their  actions  on 
GABA receptors in the SC. A more recent study further confirmed that in addition to the 
SC, GABA agonists also have an effect on the nucleus reticularis tegmenti pontis (NRTP) 
(Kaneko  and  Fuchs,  2006).  Ipsiversive  saccades  were  difficult  to  elicit  following  the 
injection  of  muscimol  on  NRTP,  with  marked  slow  peak  saccadic  velocity,  prolonged 
latency, and moderately impaired accuracy. Further work showed that muscimol injection 
into the caudal fastigial nucleus produced hypermetric saccades of the ipsilesional site and 
hypometric saccades to the contralesional side of injection (Goffart et al.  2004).   
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      Although lack of direct evidence, the fact that conventional anti epileptic drugs act on 
sodium (such as phenytoin and carbamazepine) may indicate that their actions on these ion 
channels are crucial to saccadic generation. Some novel AEDs, such as lamotrigine, also 
acts on the sodium channel.  
      Lidocaine, a local anaesthetic drug, which has the same action on sodium channels as 
several AEDs has been used in various animal studies to suppress saccades (McPeek and 
Keller,  2004;  Sommer  and  Tehovnik,  1997).  Benzodiazepines  such  as  diazepam  and 
lorazepam are GABA agonists. Another novel AED tiagabine is a selective GABA blocker. 
Muscimol,  a  GABA  agonist,  has  been  used  in  numerous  studies  to  suppress  or  alter 
saccadic generation to elucidate saccadic control pathways. This provides some evidence to 
support the hypothesis that the mechanisms underlying the effects on saccades and the anti 
epileptic effects of many AEDs might exert such effect through actions on various ion 
channels and receptors. (Kuo et al.  2000; Lingamaneni and Hemmings Jr, 2003). Thus, 
measuring the change of saccadic eye movements in patients on AEDs therapy may be a 
good surrogate marker in evaluating the pharmacodynamic effect of an AED.  
 
5.8 Studies using saccades as clinical measurements 
    Saccadic parameters of saccades have been in common use as a clinical measurement to 
monitor disease progression and to predict disease genotype. Measuring express saccades 
and memory guided saccades have revealed their impairment in association with cognitive 
defects in patients with Parkinson disease (Chan et al.  2005). In the comparison of the 
differences of saccades characteristics between Alzheimer disease, Dementia with Lewy 
bodies and dementia of Parkinson disease, it showed that the latter two groups were similar 
in that they both had impaired complex saccadic performance and impaired execution of 
reflexive saccades compared to the control group,  and patients with Alzheimer disease 
were only impaired in complex saccades performance, thus impaired execution of reflex 
saccades  allowed  discrimination  between  dementia  with  Lewy  bodies  and  Alzheimer’s 
disease (Mosimann et al.  2005). The existence of abnormal saccades allows differentiation 
between brainstem or cerebellum involvement in patients with multiple sclerosis (Downey 
et al.  2002); dysmetric saccades suggest cerebellar lesions, while disconjugate saccades 
without  marked  dysmetria  favours  brainstem  lesion  (Serra  et  al.    2008).  In  Gaucher’s  
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disease,  measuring  peak  saccade  velocity  has  been  used  as  a  clinical  marker  of  the 
therapeutic  effects  of  enzyme  replacement  and  in  monitoring  the  disease  progression 
(Pensiero et al.  2005).  By measuring and comparing the latencies, the peak velocity and 
the accuracy of saccades, Ali et al (Ali et al.  2006) had successfully identified patients with 
chorea mimicking Huntington Disease who were later proved to be genetically uninvolved. 
These  studies  have  demonstrated  that  the  measurement  of  saccadic  parameters  and 
characteristics of saccades may be an useful tool for monitoring and evaluating various 
neurological diseases. 
  
5.9 Conclusion 
Measuring  parameters  of  saccades  is  very  useful  in  diagnosing  and  monitoring 
neurological diseases. Understanding the physiology of saccades and their characteristics 
are crucial. The application of saccadic eye movement measurements may be extended to 
monitor therapeutic effects and to predict disease genotype. Current digitalized laboratory 
facilities such as electro oculography, video oculography and magnetic search scleral coil 
are sensitive and reliable in detecting subtle changes of saccades which are difficult to 
detect in bedside examination.  
There have not been many studies investigating saccadic eye movements on patients 
taking anti epileptic drugs as a measurement to their therapeutic effects, especially those 
taking new generation AEDs. The use of saccadic eye movements seems promising as a 
biomarker for epilepsy therapy or as a marker of certain epilepsy phenotypes. However 
methodological  issues  need  to  be  clarified  including,  the  effects  of  (novel)  AEDs  on 
saccades, and the influences of epilepsy susceptible genes on saccades (if there is any). As 
the advances of eye movement recording facilities, accumulating knowledge on genetics of 
epilepsy,  pharmacokinetic  and  pharmacokinetic  on  AEDs,  measuring  parameters  of 
saccades  in  the  future  can  be  reliable and  robust in  monitoring  epilepsy  treatment  and 
possibly in the prediction of pharmocodynamic effects. 
 
[This chapter is adapted and modified from Saccadic Eye Movements and Anti-epileptic drugs (Lo et al, 
2008) with permission]. 
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Material And Methods 
 
Section 6  
6.0 Overview 
      The Ethic Approval of the linkage analysis study in familial epilepsy syndromes was 
granted  by  the  Central  Office  for  Research  Ethic  Committees  (COREC,  later  as  the 
National  Research  Ethic  Service)  and  the  Reference  Number  was  04/Q0512/57.  The 
methodology in this genetic linkage study was divided into three parts: the identification 
and recruitment of study subjects; laboratory based molecular genetics; and computational 
linkage analysis as well as other works involving bio informatics in genetics. 
 
6.1 Genetic linkage analysis  
6.1.1 Recruitment of subjects 
      The  recruitment  of  the  subjects  in  the  linkage  analysis  project  was  done  in  three 
different ways. For the  two families with  mesial temporal lobe epilepsy, subjects were 
recruited through probands identified in the out patient clinic in the NHNN, Queen Square, 
London, and Royal London Hospital, Whitechapel, London. Provisional drafts of the family 
pedigrees were obtained from the probands, and potential participants were identified from 
these drafts. The permission to contact these potential participants was made though the 
probands who contacted their relatives in advance before forwarding back their contact 
details and their agreement. Once the permission was obtained, visits to these subjects were 
arranged and visited all the subjects in person at their homes. This included travel to Great 
Yarmouth, Glasgow, Chingford, Romford,  Kent, East  London, Essex and several small 
villages in Swansea, South Wales, where these family members were based. 
      The  recruitment  of  the  subjects  in  the  Photosensitive  Epilepsy  pedigree  was  made 
around 15 years ago in Birmingham in a study in collaboration with Dr. Peter M Jeavons. 
The DNA samples in this pedigree were already in storage in the Neurogenetic Laboratory, 
Department  of  Molecular  Neuroscience,  Institute of Neurology,  Queen  Square,  London  
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when this study began. The access of the DNA samples and the permission to study these 
DNA  samples  was  made  by  collaborating  with  Professor  Nick  Wood,  Head  of  the 
Department. 
      The recruitment of the subjects in the five Kohlschütter Tönz pedigrees was made by 
collaborating with Dr Henry Houlden, who wrote to each family or the researchers studying 
these families  to  obtain their permission to  have  their  blood  samples  and  to use  DNA 
samples for further studies. The clinical investigations of these families and the details had 
been  previously  published  in  journals(Christodoulou  et  al.    1988;  Donnai  et  al    2005; 
Guazzi et al.  1994; Musumeci et al.  1995; Petermöller et al.  1993). 
 
6.1.2 Modification of the family pedigrees and taking consents 
      When a proband of was identified in the out patient clinic, a provisional draft of the 
proband’s family pedigree was made according to the proband. On each visit to the subjects 
identified according to the pedigree, the pedigree might be adjusted if there were mistakes 
recognized in the provisional draft by family members.  The amended draft was then shown 
to key members in the same family pedigree to ensure that the information was as correct as 
possible.  
      An information leaflet was given to each participating subject upon each visit, the aim 
of the study was explained orally if necessary and relevant questions were answered before 
the consent was signed.  
 
6.1.3 Interview and blood sample collection  
      The subjects recruited from the families with familial mesial temporal lobe epilepsy 
were interviewed in person with a questionnaire. This questionnaire was modified from The 
New Patient Questionnaire used in the Epilepsy Out Patient Clinic of NHNN, according to 
the  characteristics  of  the  pedigrees  identified.  The  questionnaire  gathered  back  ground 
information of each subject, their medical histories, seizure patterns and their characteristic, 
states of seizure control, medical investigations which had been done in the past, and their 
medications in controlling epilepsy.  
      Upon each visit, around 10  15 ml of peripheral blood were taken from each consenting 
subject and transferred into EDTA tubes. These EDTA tubes were brought back to the  
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Neurogenetic Laboratory in the NHNN to extract DNA. The DNA samples were stored in 
freezers at the temperature of  72
◦C until further use. 
 
6.1.4   Molecular biology techniques  
            The molecular biology techniques involved in this study included DNA extraction from 
peripheral blood, whole genome wide scan with microsatellite markers, fine mapping with 
microsatellite markers,  polymerase chain reaction (PCR) and allele sizing (genotyping), 
agarose gel electrophoresis, sequencing reaction and gene sequencing. With the exception 
of the 8 cM whole genome wide scan which was done in deCODE Genetics in Iceland, 
other molecular genetic work was carried out in the Neurogenetic Laboratory, National 
Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London.  
 
6.1.4.1 DNA extraction from blood 
      The material used in DNA extraction included blood samples collected from subjects, 
reagent A (320mM sucrose, 5mMMgCl2, 10mMTris HCL pH8, 1% Triton x 100), lysis 
buffer, proteinase K, phenol chloroform, chloroform, 100% ethanol, and 1x TE (10mM 
Tris pH8, 1mM EDTA) 
      10  15 ml Blood (in EDTA) was mixed with 40ml reagent A and centrifuged for 5 
minutes at 2600 rpm twice. The pellet was suspended in 4mls lysis buffer with proteinase K 
added  and  incubated  overnight  at  55
0C.  Two  phenol chloroform  extraction  and  two 
chloroform  extraction  were  performed.  The  genomic  DNA  was  precipitated  in  100% 
ethanol and was then removed into a tube containing 0.5 ml of sterile 1xTE. The extracted 
DNA samples were stored in freezers at  72
◦C until further use.   
 
6.1.4.2 Whole genome wide scans with microsatellite markers  
      Microsatellite markers (sometimes referred to as a variable number of tandem repeats, 
VNTRs) are short segments of DNA that have a repeated sequence, such as CACACACA, 
and tend to occur in non coding DNA. In some microsatellites, the repeats of the unit are 
highly variable and may be different from one individual to the other. In diploid organisms, 
each individual will have two copies of any particular microsatellite segment with one copy 
from  the  father  and  the  other  from  the  mother, thus  the  number  of the  repeats  can be  
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different in each copy. Such characteristics of the microsatellite marker have been applied 
to  genotype  individuals.  The  most  common  way  to  detect  microsatellites  is  to  design 
polymerase chain reaction (PCR) primers which are unique to one locus in the genome 
       The microsatellite marker  genome wide scan was divided into 2 steps: polymerase 
chain reaction (PCR) and sizing of the PCR product (genotyping). The majority of the 
microsatellite  genotyping  process  was  done  in  the  deCODE  Genetics  in  Iceland. 
Genotyping for fine mapping after computational linkage analysis was done by myself in 
the Neurogenetic Laboratory, National Hospital for Neurology and Neurosurgery, Institute 
of Neurology, Queen Square, London. 
 
6.1.4.2.1 Polymerase Chain Reaction (PCR) 
      The material needed for PCR includes DNA primers (both forward and reverse for each 
microsatellite  marker),  DNA  samples,  DNA  polymerase,  5x  Buffer,  dNTP 
(Deoxyribonucleotide triphosphate), sterile water, and PCR plate. The machine used for 
PCR in this study was the Applied Biosystems 9700 Thermocycling machine. 
      Prior  to  each  PCR,  gradient  block  might  be  necessary  to  determine  the  optimal 
temperature  and  reacting  condition  of  the  primers  for  microsatellite  markers.  The 
preparation of the reaction for gradient block was the same as ordinary PCR.  
      In the gradient block, there were 8 rows and each row contains 12 wells. Each well of 
the block was assigned a different temperature, stepwise ranging from a low temperature to 
a high temperature (for example, from 50
◦ C to 64
◦ C, with 50
◦ C in the first well, 51.4
◦ C 
for the second well, 52.8
◦ C for the third well… and so on, with 64 
◦ C for the last well). 
The mixture for PCR prepared in advance was evenly pipette into each well, so the content 
for  PCR in each  well of the  row  was the same but the  reaction was done in different 
temperatures,  depending  on  the  position  of  the  well  in  the  block.  Such  a  design  was 
necessary to figure out the most optimal temperature and reaction condition for primers 
used in PCR.  
      To make 25 ml of PCR product, mix 1ul of forward and reverse primers each with 5 ul 
of 5x buffer, 5ul of dNTP, 12.7ul of water, 1ul of DNA, and 0.3 ul of DNA polymerase 
(Taq). In order to avoid contamination, a master mix sufficient for the reactions up to one 
PCR plate was prepared instead of mixing the agents repeatedly for each well. The master  
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mix  contains  the  same  ratio  of  each  agent  needed  for  the  reaction.  Twenty five  ul  of 
mixture was pipette to each well on a PCR plate from the master mix prepared in advance. 
To  avoid  unnecessary  reactions  happening  before  the  PCR  plate  was  placed  onto  the 
thermocycling machine, the DNA polymerase was added last to the master mix. The plates 
were centrifuged after the mixture was evenly pipette to the wells and put onto the Applied 
Biosystems 9700 Thermocycling machine. Primers which had similar reacting temperature 
were organized in the same plates. The optimal temperature and the numbers of cycles 
needed for PCR was set on thermocycling machine before starting the PCR. Such setting 
might be different according to the DNA polymerase used in the PCR. For gradient block, 
the PCR plate was put onto the gradient block machine and the desired temperature range 
was set before starting the reaction. 
 
6.1.4.2.2 Allele sizing (genotyping using microsatellite markers) 
      Although  the  majority  of  the  genotyping  was  done  in  deCODE  Genetics,  if  fine 
mapping  was  necessary  after  linkage  analysis  such  genotyping  was  carried  out  in  the 
Neurogenetic Laboratory Queen Square. 
      The material needed for allele sizing included PCR products, Formamide, sizing ladder 
(Liz 500), PCR plate, Applied Biosystem 3730 DNA Analyzer. 
      For each well on a PCR plate, 1ul of PCR product, 0.3 ul of sizing ladder, and 12 ml of 
Formamide was added. To avoid contamination, a master mix was prepared first, which 
contains the same ratio of each agent needed for the reaction, and 12.3 ul of mixture was 
pipette into each well on a PCR plate. The prepared PCR plate was heated up to 95
0C for 5 
minutes then placed on top of ice for 1  2 minutes before centrifugation and loaded to the 
Applied Biosystem 3730 DNA Analyzer. 
      Before starting the  Applied Biosystem 3730 DNA Analyzer, the information of the 
subject including DNA sample numbers, sizing protocol, and the file path in saving the 
analyzed data were keyed in and set up on the computer operating the DNA analyzer. The 
analysis was then started after the analyzer was set. 
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6.1.4.3 Agarose Gel Electrophoresis 
      Agarose gel electrophoresis was used to examine the quality and quantity of extracted 
DNA and also to examine whether the PCR products were the expected products in the 
right size. The percentage of the agarose mixture (weight of agarose/volume of solvent) 
was  prepared  according  to  the  molecular  weight  of  the  element  being  analyzed.  For 
example, 1% (w/v) Agarose gel is suitable for larger molecule product (such as DNA) 
while 2.5 3 % (w/v) Agarose gel is suitable for small molecular product (such as PCR 
product). The percentage of the agarose gel is usually between 0.8% and 3 %. 
       The PCR products are fragments of DNA which are negatively charged. They migrate 
toward the positive electrode during electrophoresis. Thus the cable connecting the positive 
electrode is always connected to the electrode of the mini plates located at the far end of the 
mini wells used for electrophoresis, so the negatively charged PCR products will move 
downward  the  gel  during  the  electrophoresis  which  separates  fragments  of  different 
molecular weights. Ideal PCR products contain only fragments with the same product size 
projected during primer design. 
      The material used in agarose gel electrophoresis included 10x TBE, agarose powder, 
ethidium bromide, mini plates for electrophoresis, and transilluminator. To prepare 1 litre 
of 10x TBE, added 121.1 gram of Tris, 61.8 gram of boric acid (anhydrous) and 7.4 gram 
of EDTA to a flask, then water was added until the total volume was 1 litre. The agents 
were mixed well until all the components were properly dissolved.  
      Ten ml of 10x TBE was added to 90 ml of water to make 100 ml of 1 x TBE buffer. 
1.25 mg of agarose was added to 50 ml of the 1x TBE buffer and heated up in a microwave 
until the agarose powder was all dissolved. 2.5ul of ethidium bromide was added to the 
liquid form of agarose gel while it was still hot in the fume hood and then poured into a 
mini plate. Comb(s) with 16 teeth was (were) placed on the mini pate to form mini wells on 
the gel. After the gel was fully set, 50 70 ml of 1 x TBE was added to the mini plate and the 
combs were removed. To load the PCR product to the mini wells formed on the gel, 4 ul of 
5% orange loading dye was mixed with 5 ul of each PCR product and the PCR dye mixture 
was loaded to each mini well formed on the agarose gel. The 100 bp ladder was used to 
assess the fragments sizes. The mini plate was covered with a lid with cables which were 
connected to the electrophoresis machine. The cable connecting the positive electrode of  
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the electrophoresis machine was connected to the electrode of the mini plates located at the 
far end of the mini wells. The voltage for electrophoresis was set at 50 60 mV. The time 
needed to complete the electrophoresis was around 20 30 minutes. Once the electrophoresis 
had completed, the agarose gel was removed from the mini plate and placed under the 
ultraviolet light in the transilluminator to read the results. The image of the gel exposed 
under the ultraviolet light was saved to a computer for further interpretation. Under the 
ultraviolet light, the DNA fragments in the PCR products were seen as bands. Once the size 
of the PCR products were confirmed to be correct and the reactions were ideal, these PCR 
products were filtered to eliminate unwanted small fragments and excessive primers left 
during the reaction. These purified PCR products were then used as the templates in the 
sequencing reaction. 
 
6.1.4.4 Gene Sequencing  
6.1.4.4.1 Purification of PCR products 
      The PCR products may contain small molecular fragments, such as the primers that 
were not used up in the PCR process. These small fragments must be eliminated before the 
PCR products can be used as the templates in sequencing reaction.  
      The material needed for filtering PCR products are manifolds, vacuum, shaker, sterile 
water, and PCR filtering plates, and PCR plates.  
      First, 60 ul of sterilized water was added to each PCR product in each well on the PCR 
plate, then each of the PCR water mixture was pipetted into the wells of the PCR filter 
(clean – up) plate. The filter plates were placed onto a vacuum and left for 5 10 minutes, 
until all liquid had been sucked out. This procedure eliminated unwanted small molecular 
fragments in the PCR products and left the PCR products in the filter plates. The filtered 
plates were removed from the vacuum, 40 ul of water was added into each well, the plates 
were  placed  onto  shaker  and  left  to  re suspend  for  30  minutes.  The  cleaned  and  re 
suspended PCR products were then pipetted into clean, labelled standard 96 PCR plates for 
storage;  to be used as the templates in the sequencing reaction. 
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6.1.4.4.2 Sequencing reaction 
      The material needed for sequencing includes primers for each exon, both forward and 
reverse, Big dye, sequencing 5x buffer, filtered PCR product, and sequencing plate. 
      The mixture for sequencing reaction was 1 ul of cleaned PCR products, 1 ul of Big Dye, 
2 ul of 5x Sequencing Buffer, 1ul of primer (3.2 p mol), 3.5 ul of cleaned PCR product, and 
2.5 ul of sterile water. To avoid contamination, master mix excluding the templates (filtered 
PCR products) was prepared first, which contains the same ratio of each agent needed for 
the reaction, and 6.5 ul of mixture was pipette to each well on a PCR plate. Then 3.5 ul of 
templates were added to the wells using multi pipette. The loaded PCR plates were placed 
onto  the  Thermocycling  machine  and  the  program  “Big  Dye”  was  chosen  for  the 
sequencing reaction. The products of the sequencing reaction were filtered again to remove 
excessive Big Dye and unwanted fragments before loading into the 3730 DNA analyzer for 
sequencing.   
 
6.1.4.4.3 Purification of Sequencing Reaction products 
      The material needed to eliminate the unwanted residuals and excessive Big Dye from 
the products of the sequencing reactions were the BigDye Terminator kit and sterile water. 
First the Dye Terminator kit was centrifuged at the speed 950 RCF for 3 minutes to spin off 
the  buffer  in  each  well.  The  buffer  was  centrifuged  down  to  a  container  plate  placed 
underneath the BigDye Terminator kit and was removed after centrifugation. Fifty ul of 
sterile water was added to each well which contained the sequencing reaction product from 
the  sequencing  reaction  process  and  the  mixture  were  loaded  to  the  wells  in  BigDye 
Terminator  kit  by  using  multi pipette.  The  loaded  BigDye  Terminator  was  centrifuged 
again at 950 RCF for 3 minutes with a PCR plate underneath, and the cleaned sequencing 
reaction products were centrifuged down to the wells of the PCR plate, ready to be loaded 
to the 3730 DNA analyzer.  
      Before starting the Applied Biosystem 3730 DNA Analyzer, the subjects ID, gene ID, 
and exons information file which was prepared in advance were imported to the Applied 
Biosystem 3730 DNA Analyzer, and sequencing process was started after the computer 
was set up. .  
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6.1.4.4.4 Analysis of Sequencing Data   
      The data in gene sequencing were analyzed by SeqScape, version 2.5. Before importing 
the  data,  a  reference  data  group  which  contained  the  sequence  of  the  exons  and  the 
sequence of approximately 50 base pair of the introns flanking each exon of was set up for 
each gene sequenced. A project template was build using the reference data group later and 
serves as the reference in the project. The sequence of the exons and introns of genes were 
downloaded from the website http://www.ensemble.org. 
       
6.1.5 Computational Linkage Analysis and Genetic Bioinformatics 
      Software necessary for computational linkage analysis and genetic bioinformatics were 
downloaded  from  various  websites,  including  http://linkage.rockefeller.edu/soft/, 
http://www.ncbi.nlm.nih.gov/sites/entrez,  http://watson.hgen.pitt.edu/register/, 
http://www.sph.umich.edu/csg/abecasis/Merlin/index.html,  http://www.ensemble.org, 
http://www.soe.ucsc.edu/~kent/dnaDust/dnadust.html,  and  http://frodo.wi.mit.edu/cgi 
bin/primer3/primer3. 
      Both Model based and model free linkage analysis were carried out in this project. The 
model based (parametric) analysis was mainly done by using MLINK of the LINKAGE 
package, FASTLINK version. The model free (Non parametric) analysis was either done 
by MERLIN, version1.1.2 or Simwalk2, version 2.91. The file manipulating/constructing  
program Mega2 version 5.0 R1 (Mukhopadhyay et al.  2005) was used to format input files 
for MERLIN and SimWalk2. Software Cyrillic 2.1 was used for both pedigree drawing and 
haplotype analysis.  Some of the Genetic Bioinformatics such as primer design,  genetic 
maps, marker sequence, and candidate gene information were also carried out through the 
websites mentioned above.  
 
6.1.5.1 MLINK of the FASTLINK package 
       FASTLINK  package  version  4.1P(Lathrop  et  a.l  1984;  Cottingham  et  al.    1993; 
Schaffer et al.  1994) and the LINKAGE package version 5.2 were downloaded from the 
website http://linkage.rockefeller.edu/soft/. They were installed to a laptop partitioned with 
a  UNIX  operating  system.  The  input  files  in  the  LINKAGE  format  necessary  for  the  
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linkage analysis via MLINK were formatted by importing the genotype data to Microsoft 
Excel and transformed the files into LINKAGE format. 
      There are two types of basic LINKAGE input files. The pedfiles contain information of 
the  pedigree,  such  as  information  of  the  subjects’  parents,  sex,  affection  status,  and 
genotype data of each individual. The information of the pedigree in the pedfiles was based 
on the pedigrees obtained and the genotype data from deCODE Genetics. The affection 
states were assigned based on the results of phenotyping according to clinical diagnosis. 
The dat.files are parameter files which contain parameters used in the parametric linkage 
analysis,  such  as  mode  of  inheritance,  allele/gene  frequencies,  penetrance  rate,  liability 
class, and the increment of recombination fraction, etc. The dat.files were formatted by the 
PREPLINK program in the LINKAGE package. The gene/allele frequencies were taken 
from data provided by deCODE Genetics.  
      Before  entering  the  MLINK  analysis,  the  UNKNOWN  program  of  the  LINKAGE 
package  was  used  to  check  genotyping  errors  or  incompatibility  in  all  the  input  files. 
Genotyping errors were corrected by setting the data in question to unknown, because the 
original sizing figures from deCODE were not available. The LCP program of the MLINK 
was used to facilitate the calculation of the LOD scores, and the LRP program was used to 
generate tables for the output LOD scores. Multipoint analysis was performed by using 
LINKMAP when necessary. Detailed protocols of linkage analysis using MLINK can be 
found in Handbook of Human Genetic Linkage (Terwilliger and Ott, 1994) and Analysis of 
Human Genetic Linkage (Ott, 1999a).      
 
6.1.5.2 MERLIN 
       Part of the non parametric (model – free) linkage analysis in this project was done by 
MERLIN  version  1.1.2.    This  program  was  downloaded  from  the  website 
http://www.sph.umich.edu/csg/abecasis/Merlin/index.html and was installed to the laptop 
with a UNIX operating system. The formats of the input files are different from MLINK 
and were prepared by the file manipulating program Mega2. There are three basic types of 
input files in MERLIN. A map file which contains genetic map information, such as the 
genetic distance between each marker and the order of the markers on the chromosomes is 
necessary.  The  other  two  input  files  are  pedigree  files  which  contain  the  pedigree  
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information and genotype data, and the data files which contain parameters used in the 
analysis. Both types of files were constructed by Mega 2 using data stored in Linkage 
format  files.  The  map  files  were  formatted  directly  by  text  editor  in  UNIX  operation 
system.  
      The input files of MERLIN were checked by PEDSTATS to check genotyping errors. 
The genotyping errors were adjusted by setting the incompatible genotype data unknown. 
Because  MERLIN  cannot  analyze  large  pedigrees,  the  pedigree  files  were  adjusted  by 
trimming off some individuals to fit the analysis in MERLIN when necessary.  
      To do NPL by MERLIN, in the command prompt page of MERLIN, the file name of 
the pedigree file, the corresponding map files and data files, and the option “NPL analysis” 
were specified in the commands. The output format of the analysis results can also be 
elected in the command lines specifying which format was in favour of, choices include 
graph,  table,  or  plain  text  files.  The  LOD  score  generated  by  MERLIN  and  the 
corresponding pointwise p value is available, and the estimated maximum LOD score is 
also  provided.  The  details  of  using  Merlin  can  be  found  on  the  website: 
http://www.sph.umich.edu/csg/abecasis/Merlin/index.html. 
 
6.1.5.3 Simwalk2 
      Part of the NPL analysis in this project was done by Simwalk2 version 2.91. Simwalk2 
was downloaded from the website http://watson.hgen.pitt.edu/register/ and was installed to 
the laptop with an UNIX operating system.  
      The formats of the input files of SimWalk2 are different from MERLIN and MLINK. 
Similar to MERLIN, map files containing the information of genetic maps and the genetic 
distance between each marker are necessary in NPL analyses using SimWalk2. Other input 
files included were the locus data file, the pedigree data file, the penetrance data file, and 
the  BATCH2.DAT  control  file.  The  penetrance  files  are  only  necessary  for  parametric 
linkage  analysis.  The  BATCH2.DAT control  files  contain  the user specified  instruction 
parameters, but usually it has already been set by default. The input files were constructed 
from data stored in Linkage format files by Mega2, and was checked by Simwalk2 by the 
“setup” option before entering any specified linkage analysis. This option performed no 
likelihood based analysis on the data but merely checks that the data files are consistent and  
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that the pedigrees have no incompatibilities. If genotyping errors were found, the errors 
were adjusted by setting the genotype data in question to unknown.  
      After  all the  input  files were  ready  and  checked,  on the  command  prompt  page  of 
Simwalk2 the NPL analysis option was selected and the types of statistics was specified 
(including BLOCKS, MAX TREE, ENTROPY, NPLALL, and NPLPAIR) before starting the 
analyses.  The  data  output  of  the  analyses  were  all  in  plain  text  format  and  contained 
location scores at each marker under statistics selected. The corresponding P values were 
also available. Other information in the output data includes the estimated and observed 
recombination  events  between  each  marker,  its  P  value,  and  the  parameters  set  in  the 
BATCH2. DAT file. 
  
 6.1.6 Other computing works 
      Besides computational linkage analysis, other works involving Genetic Bioinformatics 
in this study were primer designs and to look up candidate gene. 
 
 6.1.6.1 Design of primers 
      Most of the sequence of the primers for microsatellite markers is available online. For 
fine mapping, primers design might be necessary if the primers sequence available from 
websites failed to work in PCR. Primers design was also necessary for the PCR of each 
exon before go on gene sequencing. All the software needed for primer design are available 
online  from  websites,  including  http://frodo.wi.mit.edu/cgi bin/primer3/primer3, 
www.gdb.org,  http://www.ensembl.org/, 
http://www.soe.ucsc.edu/~kent/dnaDust/dnadust.html,  and  http://genome.ucsc.edu/cgi 
bin/hgPcr?command=start.  
      The primers for exons were designed using sequence of introns flanking each exon. The 
sequence of the exons and up to 650 base pair of introns at the splice sites of each exon was 
retrieved  online  from  http://www.ensembl.org/.  A  segment  of  intron  sequence  which 
contained several hundreds base pair and at least 200 250 base pair away from the splicing 
site  was  selected,  copied  and  pasted  into  the  DNA  duster  on  the  website 
http://www.soe.ucsc.edu/~kent/dnaDust/dnadust.html  to  eliminate  unwanted  strings  or 
letters. This “dusted” sequence of the intron was copied and pasted to the primer picking  
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software on http://frodo.wi.mit.edu/cgi bin/primer3/primer3 to pick up primers. The criteria 
in picking up primers for the exons in gene sequencing were 23bp for minimum primer size 
and 28 maximum; minimum melting temperature was 60
◦C and 68
◦C maximum, minimum 
CG content was 20%, optimum at 50 60 % and 80% maximum. The designed primers were 
then sent to PAN facility in Stanford University, California, USA to be synthesized.  
        The primers for microsatellite markers were designed in a similar way. The sequence of 
the  markers  was  retrieved  from  the  NCBI  UniSTS  website 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=unists.  A  segment  of  the  sequence  which 
contained a few hundred base pair was selected from the sequence of the marker flanking 
the bi  or tri nucleoside repeating segment. This segment was pasted to the DNA duster on 
the  website  http://www.soe.ucsc.edu/~kent/dnaDust/dnadust.html  to  eliminate  unwanted 
strings or letters. This “dusted” sequence was then copied and pasted to the primer picking 
software on http://frodo.wi.mit.edu/cgi bin/primer3/primer3 to pick up primers. The criteria 
in picking up primers for the exons in gene sequencing were 18 base pair for minimum 
primer  size  and  20  bp  maximum;  minimum  melting  temperature  was  57
◦C  and  63
◦C 
maximum, minimum CG content was 20%, optimum at 50 60 % and 80% maximum.  
 
6.1.6.2 Candidate genes screening 
      When  a  possible  disease  locus  was  identified,  the  genes  within  the  locus  and  their 
functions  were  searched  from  the  websites  http://www.ensembl.org/  and 
http://www.genecards.org/index.shtml.  Both  known  genes  and  pseudo genes  within  the 
regions of interest were first identified through the ensemble website, and the functions of 
the known gene were looked up in the Gene Cards website. The Gene Cards website also 
provides web links that provide relevant of the gene functions that are not yet summarized 
in their website.  
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6.2 Saccadic Eye Movement Recording 
      The study “Eye movement and anti epileptic drugs” was approved by the Central Office 
for Research Ethic Committees (COREC, later as the National Research Ethic Service) and 
the Reference Number was 05/Q0505/119. The subjects in this project were recruited from 
the National Hospital for Neurology and Neurosurgery, Queen Square, London and the 
laboratory work were carried out in the Eye Movement Laboratory of the Institute of Child 
Health, Great Ormond Street Hospital, London.   
 
6.2.1 Subjects  
      In this pilot study, twelve healthy individuals who were not taking any medication and 
who did not have any visual fields defects or eye movement disorders were recruited as the 
control group. Their age were recorded at the time of recording. These healthy individuals 
were either staff or research fellows in the Institute of Neurology, Queen Square, London. 
      The  subjects  of the  case  group  were patients  with  epilepsy  who  were  taking  either 
phenytoin  or  carbamazepine  as  their  single  anti epileptics  drug  treatment.  They  were 
recruited from the out patient clinic of the NHNN. Information leaflets were given to each 
subject and consents were obtained before any eye movements were recorder and blood 
samples were taken. In this preliminary pilot investigation, five patients were recruited but 
only three subjects completed the whole recordings.       
 
6.2.2. Methodology  
6.2.2.1. Battery of eye movement recording 
      The stimulus for eye movements consisted of a row of 3 red LEDs which were spaced 
15 degrees apart [0°, −15° (left) and +15° (right)]. Each LED subtended 0.35° at the eye. 
The subject was asked to look at the illuminated LED with both eyes open. The stimulus 
sequence consisted of cycles in which first the LED in the primary position was illuminated 
(0°), followed by the LED at −15°, +15° and 0° again. The eye movements were recorded 
using an IRIS 6500 infrared limbal tracker (Skalar Medical, Delft, The Netherlands). The 
eye  movements  of  each  eye  were  recorded  simultaneously.  The  analogue  output  was 
filtered by a 100 Hz low pass filter, digitised to 12 bit resolution, and then sampled at 1 ms 
intervals. The system was linear over a range of ±25° (horizontal), with a resolution of  
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0.03°. Calibration was carried out using the 15° saccades (i.e. right and left), manually 
adjusting the graphs so that the foveating part of the waveform was set at approximately 0° 
and ±15°, respectively. 
      The eye movements was recoded when the head was stabilized in the primary position 
with a chin rest for one recording, and the whole battery of eye movement recording was 
repeated again without the chin rest used while the subject remain in the primary position. 
Such saccades recorded without chin rest is the “Eye head saccades”. 
 
6.2.2.2. The control group 
      Two sets of eye movement recording using the regime described above were carried out 
on the control group.  Their age at the time of recording were recorded. The time gap 
between the first and the second set of eye movement recording varied, from several hours 
to one week, depending on the availability of the control subjects. The purpose of having 
two  sets  of  recording  was  to  test  the  intra individual  reliability  of  the  saccadic  eye 
movement recording.  
 
6.2.2.3. The subject group 
      Two sets of recording using the same regime in the control group were carried out on 
the subject group.  The first set of recording was done before the subjects took the daily (or 
morning) dose of their antiepileptic drugs, and the second set recording was carried out 
several hours after they had taken their medication. The time gap between the first and the 
second set of eye movement recording varied, depending on the time needed in different 
AEDs to reach peak serum drug level. The serum drug levels were measured right before 
the  beginning  of their  eye  movement  recording.  If  subjects  also  consenting  for  genetic 
analysis,  another  10mls  of  blood  samples  would  be  taken.  They  could  drop  out  the 
recording at any stage if they felt any discomfort or inability to concentrate. The condition 
of  their  seizure  control,  anti epileptic  medication  in  use  during  the  eye  movement 
recording, and detail medical history were reviewed according to their medical notes.  
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6.2.3. Analysis 
      The recorded eye movements were exported to a 100 Hz low pass filter, digitised to 12 
bit resolution, and then sampled at 1 ms intervals before imported to Mathematica version 
5.0 for further analysis. 
      The eye movements of each eye were recorded simultaneously but analyzed separately. 
For each eye, the saccades generated when looking towards to right (+15°) and looking 
towards to left ( 15°) were analyzed separately. The peak velocity of each saccade was 
plotted against its amplitude, and the main sequence of each eye was obtained by fitting a 
curve that best fitted these dots plotted. The constant OCCURRED was then calculated 
according to the fitted curve. The main sequence was shown as “C * A ” (the square root 
equation model). As shown in Figure 6.1, each curve represents the main sequence of one 
eye looking to one direction; the curve at the right side represents the main sequence of the 
saccades generated when looking to right; and the left side curve side represents the main 
sequence of the saccades generated when looking to the left. These data were pooled later 
to obtained the average value of the main sequence in each eye. 
 
6.2.4 Statistics 
      The  statistics  used  in  this  project  were  Independent  T  test,  Paired  T  test,  Pearson 
regression  correlation, and Intraclass Correlation (ICC). To simplify the comparison,  A 
(amplitude)  was  assigned  of  the  same  value  in  each  subject,  thus  comparison  of  the 
constant OCCURRED was directly comparable to the comparison of the peak velocity of 
saccades  in  each  subject.  The  comparisons  of  the  constant  of  the  main  sequence  were 
analyzed by two tail paired T test using Microsoft Excel. The result was presented by P 
value. P1 represents the result of comparison between the first and the second set of eye 
movements recording in the same subject (Main Sequence obtained using chin rest in the 
first recording to main sequence obtained using chine rest in the second recording; and 
main sequence obtained without using chin rest in the first recording to Main Sequence 
obtained  without  using  chin  rest  in  the  second  recording).  P2  represents  the  result  of 
comparison of the main sequence obtained with chin rest to the recording obtained without 
using chin rest in the same individual. Thus P1 represented whether there were statistical 
differences between the 1
st and the 2
nd recording in each individual, while P2 represents  
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whether there were differences between the main sequence recorded with and without chin 
rest in the same individual.  
      Independent T test was carried out to compare the main sequence of the control group 
to subject group.  
      The test retest reliability calculation was carried out by Pearson regression correlation 
and  Intraclass  correlation  (ICC).  ICC  estimates  the  variability  arising  from  the  same 
individual during different testing. 
 
 
 
Figure 6.1 
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Figure 6.1, showing an example of fitting the curve to obtain the constant of the main sequence of 
saccades. The x axis is the amplitude and the y axis is the peak velocity calculated. Dots are plotted 
peak velocity against its amplitude in each saccade measured.  
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Results 
Section 7: Linkage analysis in familial mesial temporal 
lobe epilepsy  family B 
 
      Two  families  with  familial  medial  temporal  lobe  epilepsy  (fMTLE)  were  identified 
from the epilepsy out patient clinic: family B and family W. The clinical presentations of 
both families were similar, but the modes of inheritance were different.  
 
7.1 Pedigree  
     The pedigree of family B is shown in Figure 7.1.  Twenty four consenting subjects in 
this family took part in this study and all their DNA samples were available. Individuals 
who are marked green were those who did not have clinical symptoms suggesting epilepsy 
but were considered carriers because either their children or parents were affected. Such 
phenomenon  also  suggested  that  the  mode  of  inheritance  in  this  pedigree  could  be  an 
incomplete penetrance mode. 
 
7.1.1 Clinical presentation and investigation 
      The medical history and medical investigations (if available) of the affected individuals 
are presented in Table 7.1. Detailed medical histories of the first and second generations 
were  not  available.  I 1  was  labelled  as  a  carrier  in  the  parametric  analysis.  II 4  was 
epileptic according to the interview of her daughter (III 8) and granddaughter (IV 20). II 5 
and II 6 were not affected, but II 5 was marked as a possible carrier if the pain syndrome 
was  considered  a  phenotype  in  this  pedigree.  Their  spouses  II 30  and  II 31  were  not 
affected. There were another three unaffected individuals in the II generation, who were 
brothers and one sister of II 4 and II 5 but are not shown in the pedigree.     
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      In the third generation, III 8 had several episodes of fainting, described as fits according 
to her daughter, we accepted her as a case. However, no definite convulsions had been 
witnessed. One of her brothers, III 12 had typical mesial temporal lobe epilepsy, onset at 
the age of 5. His clinical presentations included absence seizures, complex partial seizures 
and simple partial seizures without history of febrile convulsion. III 10 and III 11 were 
unaffected. III 14 had an atypical pain syndrome since the age of 9. The symptoms began 
after he had recovered from rheumatic fever and was bed ridden for 2 years. The pain was 
always evoked by startle response, such as sudden movement of the lift or unexpected horn 
sounding while walking on the street. The episodes were brief, lasting for seconds only 
with spontaneous recovery and the pain was intense. It could be so severe that he might fall 
down to the ground before the pain subsided. The pain originated in his lower back and 
propagated rapidly to his occipital area before it subsided. Other diagnoses suggested in this 
subject included Crohn’s colitis and probable multiple sclerosis, both were made several 
years after the onset of such pain syndrome. His sister III 15 was unaffected. III 32 was 
unaffected.  
      In the fourth generation, IV 16 had late onset seizures. She had her first generalized 
seizure while she was in labour giving birth to her 4
th child. Several episodes of simple 
partial  seizure  were  noticed  after  this  generalized  seizure.  The  characteristics  of  these 
simple partial seizures included typical stomach rising sensation, pallor and dizziness  after 
the aura, and a feeling of fear at the same time occasionally. She was unable to respond 
during the episodes but remained conscious. Post ictally she would feel very tired and it 
might take up to half an hour for full recovery. She had 5 children and at the time of 
interview none of them had clinical syndromes suggesting seizures or epilepsy. IV 16 was 
also a Fragile X syndrome carrier (confirmed genetically) and she had 2 miscarriages. Her 
half sister IV 20 had intractable migraine, and the diagnosis of simple partial seizure was 
made after several EEG recordings and MRI scanning. She was also a Fragile X syndrome 
carrier. IV 22 was epileptic (confirmed by genetic testing). According to his mother, he had 
absence in his early childhood and several episodes of complex partial seizures with a 
similar pattern to his father’s. Other symptoms during the seizures included twitching of 
limbs,  especially  in  the  morning,  panic  sensation  and  an  inability  to  think.  Triggering 
factors  included  sleep  deprivation  and  rarely  very  bright  lights.  The  complex  partial  
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seizures subsided after the age of 20, but the other symptoms remained. His brother IV 23 
was unaffected. 
      In the fifth generation, V 25 had three episodes of generalized seizures, all occurred 
when he was drunk. No other symptoms related to temporal lobe epilepsy were reported in 
this individual. He was marked as a possible phenocopy of mesial temporal lobe epilepsy. 
V 28 had Fragile X syndrome (confirmed by genetic testing), intractable complex partial 
seizures with secondary generalization, and moderate learning disabilities. MRI did not 
reveal hippocampal sclerosis, the EEG suggested that the seizures were temporal lobe in 
origin. Her brother V 29 was epileptic, with an impression of temporal lobe epilepsy and 
fully was investigated, his MRI showed right hippocampal sclerosis and he underwent a 
temporal lobectomy. He was seizure free after surgery. Both V 28 and V 29 had febrile 
convulsions  and  several  episodes  of  status  epilepticus.  V 24,  V 26,  and  V 27  were 
unaffected.   
 
7.2 Linkage analysis 
7.2.1 Genotyping 
      The DNA samples were genotyped using a set of 546 microsatellite markers for an 8 
centi Morgan(cM) Whole Genome wide Scan.  
 
7.2.2 Mode of inheritance and analysis program 
      In this pedigree, there was male to male transmission, so the mode of inheritance (MOI) 
was not an X linked and or a mitochondrial inheritance. It was also not autosomal recessive 
because  there  were  affected  individuals  in  more  than  one  generation.  We  therefore 
considered the  MOI to be likely autosomal dominant and so therefore this pedigree was 
analyzed by parametric linkage analysis using MLINK. 
      In  this  pedigree,  III 8  was  not  epileptic,  but  her  daughter  IV 16  and  IV 20  were 
epileptic.  This  suggested  that  there  the  mode  of  inheritance  of  this  pedigree  could  be 
autosomal dominant (AD) with a reduced penetrance. This pedigree was analyzed both 
under the mode of AD with full penetrance and again under the mode of AD with reduced 
penetrance.  T
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7.2.3 Parameters in linkage analysis  
       The  disease  allele  gene  frequency  was  set  as  0.0001.  The  gene  frequencies  were 
provided by deCODE Genetics. The recombination increment was 0.1, started with 0.1 and 
the finishing value was 0.45. The LOD score was also calculated at θ= 0, 0.01, and 0.05. 
(θ= recombination fraction). When the mode of inheritance was set as AD with a reduced 
penetrance, the penetrance rate was set as 0.8. 
 
7.2.4 Results 
      This pedigree was analyzed in three different ways. First, this pedigree was analyzed 
assuming that migraine, pain and mesial temporal lobe epilepsy were caused by the same 
gene. The analysis result is presented in Table 7.2 showing the maximum LOD score (2.37) 
was  obtained at  θ  =  0.0 at marker  D6S1660,  at  6p22.3  –  6p21.33.  Multipoint analysis 
showed a much smaller LOD (0.773) which suggested that there was recombination event 
that was not picked up by two point parametric linkage analysis. Further fine mapping 
(Table 7.4) and haplotype analysis (Figure 7.2) confirmed that recombination had occurred. 
The  haplotype  analysis  showed  that  there  was  homozygosity  in  marker  D6S1660  in  4 
affected individuals; this uninformative marker could lead to a false positive LOD score. 
When this pedigree was analyzed under AD with a reduced penetrance mode, the maximum 
LOD score was 2.19 at θ = 0.0 at the same marker D6S1660 (Table 7.3).  
      
 
Table 7.2 LOD Scores in chromosome 6 (AD with a full penetrance) 
 
            θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D6S422   infini   4.62   1.80   0.66  0.22  0.43  0.30 
D6S1660  2.37  2.33  2.17  1.96  1.51  1.04  0.53 
D6S273   infini   2.47   1.04   0.45  0.03  0.18  0.15 
θ: recombination fraction 
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Table 7.3 Fine mapping of chromosome 6  
θ: recombination fraction  
 
 
Table 7.4 LOD Scores in chromosome 6(AD with a reduced penetrance) 
θ: recombination fraction 
      
 
     Fine mapping in this pedigree failed to fine a marker that showed a LOD greater than 3, 
but did help to narrow down the region of interest. However, there are only two genes in 
the region narrowed down: the prolactin gene and the HDGFL1 (hepatoma derived growth 
factor like 1) gene, but neither of them seems likely to be related in epileptogenesis so far. 
We therefore, excluded this region identified on chromosome 6 and the finding suggest that 
the migraine, pain syndrome and temporal lobe seizures were unlikely to be caused by the 
same gene. 
 
             θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D6S422   infini   4.62   1.80   0.66  0.22  0.43  0.30 
D6S1588   infini   2.59   1.28   0.76   0.28   0.06  0.02 
D6S1660  2.37  2.33  2.17  1.96  1.51  1.04  0.53 
D6S461   infini   1.92   0.53  0.02  0.40  0.43  0.27 
D6S299   infini   3.26     1.30     0.54     0.06     0.23     0.18 
D6S306   infini   2.10     0.69     0.15     0.22     0.25     0.15 
D6S276   infini   4.74     2.12     1.13     0.36      0.1     0.02 
D6S273   infini   2.47   1.04   0.45  0.03  0.18  0.15 
            θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D6S422   8.40     1.97     0.55     0.03     0.45     0.48     0.29 
D6S1660  2.19     2.15     2.00     1.80     1.39     0.95     0.48 
D6S273   3.66     0.91     0.21     0.08     0.29     0.29     0.19  
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      In the second parametric analysis; only subjects with seizures were marked as affected 
and individuals with the pain syndrome only were marked unaffected, i.e III 14 and II 5 
were marked unaffected in this pedigree. The maximum LOD score was 1.67 at θ = 0.1 at 
marker D4S1586 (Table 7.5) and no LOD scores were larger than 2 in this analysis. 
 
 
Table 7.5 LOD of chromosome 4 (seizures only, AD with a full penetrance) 
 
            θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D4S1575   infini      1.38        0.63     0.31     0.03     0.06     0.06  
D4S424   infini       2.60        0.52     0.26     0.76     0.75     0.47 
D4S1586       infini  1.04  1.59     1.67     1.49     1.12     0.62 
D4S2962   infini       5.24         1.95   0.73     0.19     0.42     0.32 
D4S3046   infini  0.14  0.82     1.05     1.08     0.88     0.52 
D4S1539  infini         7.39         3.38     1.81     0.52     0.04     0.07  
θ: recombination fraction 
 
      The second analysis was therefore inconclusive and did not support the hypothesis that 
all individuals with seizures in this pedigree shared a disease gene, V 25 and his father IV 
18 were further excluded as affected individuals in the third parametric analysis, based on 
the  clinical  presentations.  We  did  this  on  the  assumption  that  V 25  who  had  three 
generalized  seizures  all  evoked  by  alcohol  with  no  other  symptoms  suggesting  mesial 
temporal  lobe  epilepsy,  was  a  phenocopy.  His  father  IV 18  had  no  clinical  symptoms 
suggesting epilepsy but was marked as a carrier in the first and second parametric analysis. 
      The third parametric analysis showed a maximum LOD score of 2.35 at θ = 0.0 at 
marker D3S1266, at 3p23 3p24 (Table 7.6). The LOD score of multipoint analysis was 
2.72. Haplotype analysis (Figure 7.3) shows that there might be a disease locus in this 
region,  although  the  haplotype  analysis  in  the  individuals  of  the  second  and  third 
generations was hampered by the fact that their parents were not genotyped and the phase 
was  unknown.  It  was  also  possible  that  II 5,  III 10  and  III 11  might  share  the  same 
haplotype (2 2 3 3 7) with the affected individuals, thus there could be reduced penetrance. 
When analyzed under the mode of a reduced penetrance, the maximum LOD score was 
2.17 at θ = 0.0 at marker D3S1266 (Table 7.7), and there were another 2 LOD scores which 
were larger than 2: 2.15 at θ=0.0 at D5S674 (Table 7.8) and 2.15 at θ=0.0 at D7S672 (Table  
 
  141 
7.9). The haplotype analysis of chromosome 5 (Figure 7.4) and chromosome 7 (Figure 7.5) 
showed  that the  haplotypes  segregated  with  affected  individuals  both  in  the  regions  of 
5p13.3 5p 13.2  and  7q11.22 7q21.11,  although  the  haplotypes  of  the  individuals  in  the 
second and third generation could not be considered certain because their parents were not 
genotyped and the phase was unknown.  
      Because this pedigree had only 7 affected individuals, 2.35 (or 2.17 under AD with 
reduced penetrance mode) might be the largest LOD score this pedigree could have through 
parametric  linkage  analysis.  From  the  haplotype  analysis,  all  three  regions  identified 
appeared equally likely to be the candidate disease locus in this pedigree when analyzed 
under the mode of AD with a reduced mode. I therefore investigated the genes within these 
regions, and sequenced gene in the region identified on chromosome 3. 
.    
Table 7.6 LOD scores on chromosome 3 (phenocopy excluded, AD with a full 
penetrance) 
θ: recombination fraction 
 
Table 7.7 LOD scores on chromosome 3 (phenocopy excluded, AD with a reduced 
penetrance) 
          θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D3S1567   infini      1.45      0.81      0.57      0.33      0.17      0.07 
D3S2335  0.54      0.56      0.61      0.63      0.56      0.42      0.23 
D3S1266  2.35      2.31      2.14      1.94      1.51      1.07      0.57 
D3S3547  1.18      1.17      1.12      1.05      0.87      0.63      0.34 
D3S3521   infini      3.17      1.03      0.19     0.40      0.49      0.34 
          θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D3S1567   0.66      0.62      0.52      0.44      0.31      0.19      0.08 
D3S2335  0.43      0.44      0.48      0.49      0.46      0.36      0.20 
D3S1266  2.17      2.14      1.98      1.79      1.39      0.97      0.51 
D3S3547  1.08      1.07      1.02      0.96      0.79      0.57      0.31 
D3S3521   8.38      2.25      0.74      0.12     0.33      0.39      0.26  
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Table 7.8 LOD scores on chromosome 5 (phenocopy excluded, AD with a reduced 
penetrance) 
 
 
Table 7.9 LOD scores on chromosome 7 (phenocopy excluded, AD with a reduced 
penetrance) 
 
          θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D5S2081   8.74      2.89      1.53      1.01      0.56      0.34      0.16 
D5S2031   2.40     0.20      0.80      0.97      0.96      0.76      0.44 
D5S674  2.15      2.13      2.03      1.88      1.51      1.07      0.57   
D5S2021   3.61      0.92      0.25     0.00      0.18      0.20      0.14 
D5S628  0.09      0.08      0.07      0.05      0.03      0.01      0.00 
          θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D7S502   4.02      1.24      0.47      0.13     0.14      0.20      0.14 
D7S2500   5.37      2.00      1.10      0.62      0.13     0.07      0.11 
D7S672  2.15      2.13      2.06      1.92      1.55      1.07      0.54 
D7S2443  0.81      0.81      0.82      0.82      0.74      0.58      0.33   
D7S2485   3.21      0.52     0.14      0.38      0.52      0.47      0.29  
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7.3 Candidate genes on chromosome 3 and gene sequencing 
      Candidate genes were screened in this region (3p24.2 3p24.1), inclusion priorities are 
the ion channel genes and genes that express in the brain with no other criteria set. Seven 
genes were identified as candidates in this region. The function of these candidate genes are 
presented in Table 7.12.  
                  Five of the seven genes were sequenced on 5 individuals only (III 8, IV 20, IV 21, V 
28, and V 29) in this pedigree. The five genes sequenced were SLC4A7, LRRC3B, AZI2, 
NEK10, and ZCWPW2. No rare mutations or disease causing polymorphisms were found 
in the exons of these  genes. Table 7.13 summarized the polymorphisms found in  gene 
sequencing.  The  polymorphisms  found  in  the  sequencing  all  segregated  with  mesial 
temporal lobe epilepsy in this small sample. Several polymorphisms were found in the 
introns near the splicing sites (within a distance of 50 bp).   
       
7.4 Genes within 5p13.3 5p13.2  
      There  are  32  known  genes  and  pseudo genes  located  within  5p14.3 5p  13.2.  Their 
functions are summarized in Table 7.14. There are no ion channel genes included. None of 
the genes in this region were sequenced in this study.  
 
7.5 Genes within 7q11.22 7q21.11  
      There are 105 known genes and pseudo genes located within 7q11.22 7q21.11. Their 
functions are summarized in Table 7.15. None of the genes in this region were sequenced in 
this study. 
 
7.6 Summary 
      The  aim  of  this  study  was  to identify  the  genetic  basis  of  the  familial  epilepsy,  to 
determine the mode of inheritance in this family, to identify linked regions, and to sequence 
candidate genes within the linked regions. In summary, we found that the inheritance mode 
of this family was likely to be AD with a reduced penetrance. We identified three regions 
of interest in this pedigree, sequenced 5 candidate genes on one of the region identified 
(3p24.2 3p24.1) on five individuals, although no pathological mutations were found. There 
are another 2 regions of interest await further investigation.  
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Table 7.12 Candidate genes in 3p24.2 3p24.1 
 
(continued) 
 
 
 
 
 
Official 
Symbol  
Official  Full 
Name 
Function Summary  sequencing 
result 
EOMES  Eomesodermin 
homolog 
(Xenopus laevis) 
This  gene  encodes  a  member  of  a  conserved 
protein  family  that  shares  a  common  DNA 
binding domain, the T box. T box genes encode 
transcription factors involved in the regulation of 
developmental  processes.  A  occurred  gene 
disrupted in mice is shown to be essential during 
trophoblast development and gastrulation. 
Not 
successfully 
sequenced 
LRRC3B  Leucine  rich 
repeat  containing 
3B 
Also named LRP15, expression is extremely high 
in brain kidney and lung. Several reports showed 
that  it  functions  as  protein  interaction,  signal 
transduction, cell adherence, development, DNA 
repair,  gene  recombination  and  transcription 
according to its structure. Some reports showed 
that  it  might  have  relation  to  colon  cancer  and 
leukemia,  however  the  real  function  is 
unknown.(Tian et al.  2009). 
no  mutation 
found 
NEK10  NIMA  (never  in 
mitosis  gene  a)  
related kinase 10 
Unknown.  Possible  function  includes  ATP 
binding, kinase activity, magnesium ion binding, 
nucleotide  binding,  protein  serine/threonine 
kinase  activity,  protein  tyrosine  kinase  activity, 
and  transferase  activity.  No  related  human 
disease  has  been  reported  in  relation  to  this 
gene. 
No  mutation 
found 
AZI2  5 azacytidine 
induced 2 
AZI2,  or  NAP1,  contributes  to  the  activation  of 
NFKB  (see  MIM  164011) dependent  gene 
expression  by  activating  IKK related  kinases, 
such as NAK 
no  mutation 
found  
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Table 7.12 Candidate genes in 3p24.2 3p24.1 (continued) 
 
 
 
Table 7.13 Sequence result summary 
 
Gene  Position  polymorphism  Frequencies in 
Caucasian population 
Type of 
polymorphism 
SLC4A7  Exon 3  210A/G  A: 0.758, G:0.242  Synonymous 
SLC4A7  Exon 7  846T/C  A:0.720, G: 0.280  Synonymous 
SLC4A7  Exon 7  976G/A, Gly>Lys  A: 0.080, G:0.920,   Non  Synonymous 
SLC4A7  Exon 16  2319C/T  C: 0.750, T: 0.250  Synonymous 
SLC4A7  Exon 24  3499T/C  T: 0.092, C: 0.908  Synonymous 
LRRC3B  Exon 1  330A/T  N/A  Synonymous 
NEK10  Exon 20  1684A/G  A: 0.742, G: 0.259  Synonymous 
NEK10  Exon 24  2071C/G  C: 0.491, G: 0.508  Synonymous 
AZI2 
ZCWPW2 
no polymorphisms found in gene sequencing  
 
 
Official 
Symbol  
Official Full Name  Function Summary  sequencing 
result 
ZCWPW2  zinc  finger,  CW 
type  with  PWWP 
domain 2 
Function of this gene is not known yet. Possibly 
related to zinc ion binding or metal ion binding. 
No  mutation 
found 
RBMS3  RNA binding motif, 
single  stranded 
interacting protein 
The protein encoded by this gene is a member 
of a small family of proteins which bind single 
stranded DNA/RNA. The observation that this 
protein localizes mostly in the cytoplasm 
suggests that it may be involved in a 
cytoplasmic function such as controlling RNA 
metabolism, rather than transcription. Multiple 
alternatively spliced transcript variants encoding 
different isoforms have been found for this gene.  
The latest study showed that the depletion of 
this gene might be associated with 
neuroblastoma (Carén et al.  2008)  
not 
successfully 
sequenced 
SLC4A7  solute  carrier 
family  4,  sodium 
bicarbonate 
cotransporter, 
member 7 
Functions as Na/HCO3 cotransporter, which 
regulates intracellular pH and may play a role in 
bicarbonate salvage in secretory epithelia. May 
also have an associated sodium channel 
activity. 
No  mutation 
found  
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Table 7.14 Functions of the genes within 5p14.3 5p13.2 
 
GENE ID  FUNCTION 
CDH12  Cadherins are calcium dependent cell adhesion proteins. They preferentially interact 
with themselves in a homophilic manner in connecting cells; cadherins may thus 
contribute to the sorting of heterogeneous cell types. 
PMCHL1  Expressed in developing brain, found in fetal newborn and adult brain, function 
undetermined 
PRDM9  May be involved in transcriptional regulation 
CDH10  Cadherins are calcium dependent cell adhesion proteins. They preferentially interact 
with themselves in a homophilic manner in connecting cells; cadherins may thus 
contribute to the sorting of heterogeneous cell types. 
CDH9  Cadherins are calcium dependent cell adhesion proteins. They preferentially interact 
with themselves in a homophilic manner in connecting cells; cadherins may thus 
contribute to the sorting of heterogeneous cell types. 
CDH6  Cadherins are calcium dependent cell adhesion proteins. They preferentially interact 
with themselves in a homophilic manner in connecting cells; cadherins may thus 
contribute to the sorting of heterogeneous cell types. 
RNASEN  Executes the initial step of microRNA (miRNA) processing in the nucleus, that is 
cleavage of pri miRNA to release pre miRNA. Involved in pre rRNA processing. 
Cleaves double strand RNA and does not cleave single strand RNA. 
PDZD2  possibly be involved in intracellular signalling, this gene is upregulated in primary 
prostate tumours and may be involved in the early stages of prostate tumourigenesis.  
GOLPH3  The protein encoded by this gene is a peripheral membrane protein of the Golgi stack 
and may have a regulatory role in Golgi trafficking. 
MTMR12  Inactive phosphatase that plays a role as an adapter for the phosphatase myotubularin 
to regulate myotubularin intracellular location. 
ZFR  Involved in postimplantation and gastrulation stages of development. Involved in the 
nucleocytoplasmic shuttling of STAU2. Binds to DNA and RNA. 
SUB1  General coactivator that functions cooperatively with TAFs and mediates functional 
interactions between upstream activators and the general transcriptional machinery. 
May be involved in stabilizing the multiprotein transcription complex. Binds single 
stranded DNA. Also binds, in vitro, non specifically to double stranded DNA. 
(continued) 
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Table 7.14 Functions of the genes within 5p14.3 5p13.2 (continued) 
GENE ID  FUNCTION 
NPR3  Receptor for natriuretic peptide hormones. Has broad specificity and can bind 
several distinct natriuretic peptides, including atrial natriuretic peptide (NPPA) and 
brain natriuretic peptide (NPPB).  
TARS  A human gene that catalyze the aminoacylation of tRNA by their cognate amino acid. 
ADAMTS12  The enzyme encoded by this gene contains eight TS 1 motifs. It may play roles in 
pulmonary cells during fetal development or in tumor processes through its 
proteolytic activity or as a molecule potentially involved in regulation of cell adhesion. 
RXFP3  Receptor for relaxin 3. Binding of the ligand inhibit cAMP accumulation 
SLC45A2  Melanocyte differentiation antigen. May transport substances required for melanin 
biosynthesis (By similarity). 
C1QTNF3  Function undetermined. 
RAI14  Function undetermined. 
TTC23L  Function undetermined. 
BXDC2  Required for biogenesis of the 60S ribosomal subunit 
RAD1  Component of the 9 1 1 cell cycle checkpoint response complex that plays a major 
role in DNA repair. The 9 1 1 complex is recruited to DNA lesion upon damage by 
the RAD17 replication factor C (RFC) clamp loader complex.  
DNAJA1  Co chaperone of Hsc70. Seems to play a role in protein import into mitochondria. 
AGXT2  The protein encoded by this gene is a class III pyridoxal phosphate dependent 
mitochondrial aminotransferase. It catalyzes the conversion of glyoxylate to glycine 
using L alanine as the amino donor. 
RPLR  This is a receptor for the anterior pituitary hormone prolactin (PRL). Isoforms 4 and 6 
are unable to transduce prolactin signaling 
SPEF2  Required for correct axoneme development 
IL7R  The protein encoded by this gene is a receptor for interleukine 7 (IL7). The function 
of this receptor requires the interleukin 2 receptor, gamma chain (IL2RG), which is a 
common gamma chain shared by the receptors of various cytokines, including 
interleukine 2, 4, 7, 9, and 15. This protein has been shown to play a critical role in 
the V(D)J recombination during lymphocyte development. This protein is also found 
to control the accessibility of the TCR gamma locus by STAT5 and histone 
acetylation. 
(continued) 
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Table 7.14 Functions of the genes within 5p14.3 5p13.2 (continued) 
 
GENE ID  FUNCTION 
CAPSL  Function undetermined. 
UGT3A1  UDP glucuronosyltransferases catalyze phase II biotransformation reactions in which 
lipophilic substrates are conjugated with glucuronic acid to increase water solubility 
and enhance excretion. They are of major importance in the conjugation and 
subsequent elimination of potentially toxic xenobiotics and endogenous  compounds. 
UGT3A2  UDP glucuronosyltransferases catalyze phase II biotransformation reactions in which 
lipophilic substrates are conjugated with glucuronic acid to increase water solubility 
and enhance excretion. They are of major importance in the conjugation and 
subsequent elimination of potentially toxic xenobiotics and endogenous compounds. 
LMBRD2  Function undetermined. 
  Substrate recognition component of a SCF (SKP1 CUL1 F box protein) E3 ubiquitin 
protein ligase complex which mediates the ubiquitination and subsequent proteasomal 
degradation of target proteins involved in cell cycle progression, signal transduction 
and transcription. 
RANBP3L  Function undetermined. 
SLC1A3  Transports L glutamate and also L  and D aspartate. Essential for terminating the 
postsynaptic action of glutamate by rapidly removing released glutamate from the 
synaptic cleft. Acts as a symport by cotransporting sodium.  
NIPBL  Probably plays a structural role in chromatin. Involved in sister chromatid cohesion, 
possibly by interacting with the cohesin complex.  
WDR70  Function undetermined. 
GDNF  Neurotrophic factor that enhances survival and morphological differentiation of 
dopaminergic neurons and increases their high affinity dopamine uptake. 
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Table 7.15 Functions of the genes within 7q11.22 7q21.11 
 
GENE ID  FUNCTION 
AUTS2  Autism candidate gene, involved in neurodevelopment and neurotransmission. 
WBSCR17  May catalyze the initial reaction in O linked oligosaccharide biosynthesis, the Transfer 
of an N acetyl D galactosamine residue to a serine or threonine residue on the protein 
receptor. 
CALN1  May play a role in the physiology of neurons and is potentially important in memory 
and learning. 
POM121  Essential component of the nuclear pore complex (NPC). The repeat containing 
domain may be involved in anchoring components of the pore complex to the pore 
membrane. When overexpressed in cells induces the formation of cytoplasmic 
annulate lamellae. 
NSUN5C  May have S adenosyl L methionine dependent methyl transferase activity (Potential). 
TRIM74  Function undetermined 
NCF1B  May be required for activation of the latent NADPH oxidase (necessary for superoxide 
production) (By similarity)  
TRIM50  Function undetermined 
NSUN5  May have S adenosyl L methionine dependent methyl transferase activity (Potential). 
Gene is deleted in Williams syndrome, a multisystem  Developmental disorder caused 
by the deletion of contiguous genes at 7q11.23. 
FZD9  The FZD9 gene is located within the Williams syndrome common deletion region of 
chromosome 7, and heterozygous deletion of the FZD9 gene may contribute to the 
Williams syndrome phenotype. FZD9 is expressed predominantly in brain, testis, eye, 
skeletal muscle, and kidney. 
BAZ1B  Forms a chromatin ٛ evelopedٛ g complex that mobilizes nucleosomes and 
reconfigures irregular chromatin to a regular nucleosomal array structure. This gene 
is deleted in Williams Beuren syndrome 
BCL7B  May play a role in lung tumour development or progression 
TBL2  This gene encodes a member of the beta transducin protein family. Most proteins of 
the beta transducin family are involved in regulatory functions. This protein is possibly 
involved in some intracellular signaling pathway. This gene is deleted in Williams 
Beuren syndrome. 
(continued) 
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Table 7.15 Functions of the genes within 7q11.22 7q21.11 (continued) 
 
GENE ID  FUNCTION 
MLXIPL  This gene encodes a basic helix loop helix leucine zipper transcription factor of the 
Myc/Max/Mad superfamily. This protein forms a heterodimeric complex and binds and 
activates, in a glucose dependent manner, carbohydrate response element (ChoRE) 
motifs in the promoters of triglyceride synthesis genes. The gene is deleted in 
Williams Beuren syndrome. 
VPS37D  Component of the ESCRT I complex, a regulator of vesicular trafficking process. 
Required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies. 
May be involved in cell growth and differentiation. 
DNAJC30  This intronless gene encodes a member of the DNAJ molecular chaperone homology 
domain containing protein family. This gene is deleted in Williams syndrome. 
STX1A  Potentially involved in docking of synaptic vesicles at presynaptic active zones. May 
play a critical role in neurotransmitter exocytosis. 
WBSCR22  Methyltransferase that may act on DNA. 
ABHD11  This gene encodes a protein containing an alpha/beta hydrolase fold domain. This 
gene is deleted in Williams syndrome, a multisystem developmental disorder caused 
by the deletion of contiguous genes at 7q11.23. 
CLDN3  The protein encoded by this intronless gene, a member of the claudin family, is an 
integral membrane protein and a component of tight junction strands. 
CLDN4  This gene encodes an integral membrane protein, which belongs to the claudin family. 
The protein is a component of tight junction strands and may play a role in internal 
organ development and function during pre  and postnatal life.  
WBSCR27  This gene encodes a protein belonging to ubiE/COQ5 methyltransferase family. The 
gene is deleted in Williams syndrome. 
WBSCR28  Function undetermined 
ELN  Major structural protein of tissues such as aorta and nuchal ligament, which must 
expand rapidly and recover completely. Molecular determinant of the late arterial 
morphogenesis, stabilizing arterial structure by regulating proliferation and 
organization of vascular smooth muscle (By similarity). 
LIMK1  Protein kinase which regulates actin filament dynamics. Phosphorylates and 
inactivates the actin binding/ٛ  depolymerizing factor cofilin, thereby stabilizing the 
actin cytoskeleton. Isoform 3 has a dominant negative effect on actin cytoskeletal 
changes. May be involved in brain development. 
(continued) 
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Table 7.15 Functions of the genes within 7q11.22 7q21.11 (continued) 
 
GENE ID  FUNCTION 
WBSCR1  This gene encodes one of the translation initiation factors, which functions to 
stimulate the initiation of protein synthesis at the level of mRNA utilization. This gene 
is deleted in Williams syndrome. 
LAT2  Involved in FCER1 (high affinity immunoglobulin epsilon receptor) mediated 
signaling in mast cells. May also be involved in BCR (B cell antigen receptor) 
mediated ٛ evelopedٛ  in B cells and FCGR1 (high affinity immunoglobulin gamma 
Fc receptor I) mediated ٛ evelopedٛ  in myeloid cells. Couples activation of these 
receptors and their associated kinases with distal intracellular events through the 
recruitment of GRB2. 
CYLN2  Seems to link microtubules to dendritic lamellar body (DLB), a membranous 
organelle predominantly present in bulbous dendritic appendages of neurons linked 
by dendrodendritic gap junctions. May operates in the control of brain specific 
organelle translocations (By similarity). 
GTF2IRD1  May be a transcription regulator involved in cell cycle progression and skeletal 
muscle differentiation. May repress GTF2I transcriptional functions, by preventing its 
nuclear residency, or by inhibiting its transcriptional activation. May contribute to 
slow twitch fiber type specificity during myogenesis and in regenerating muscles.  
NCF1  May be required for activation of the latent NADPH oxidase (necessary for 
superoxide production) (By similarity). 
GTF2I  This gene encodes a multifunctional phosphoprotein with roles in transcription and 
signal transduction. It is deleted in Williams Beuren syndrome. 
GTF2IRD2  This gene is unusual in that its coding sequence is mostly derived from Charlie8 
repeat elements. However, there is mRNA and EST evidence to suggest that this 
gene is transcribed, and the encoded protein has a homolog in mouse, with which it 
shares 78% sequence identity. The exact function of this gene product is not known. 
GTF2IRD2B  This gene encodes a glycosylated phosphoprotein with a leucine zipper motif, two 
helix loop helix motifs (I repeats) that are similar to domains found in the TFII I family 
of transcription factors, one CHARLIE8 transposable element like sequence, and a 
BED zinc finger. 
WBSCR16  This gene encodes an RCC1 like G exchanging factor. It is deleted in Williams 
syndrome. 
(continued) 
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Table 7.15 Functions of the genes within 7q11.22 7q21.11 (continued) 
 
GENE ID  FUNCTION 
PMS2L2  Function undetermined 
TRIM73  Function undetermined 
NSUN5B  This gene shares high sequence similarity with the genes WBSCR20A and 
WBSCR20C; these three genes are the products of gene duplication during evolution. 
The protein encoded by this gene is smaller than the proteins encoded by WBSCR20A 
and WBSCR20C. This gene is deleted in Williams syndrome. 
POM121B  Putative component of the nuclear pore complex (NPC). The repeat containing domain 
may be involved in anchoring components of the pore complex to the pore membrane 
(By similarity). 
PMS2L3  Function undetermined 
HIP1  Plays a role in clathrin mediated endocytosis and trafficking. Involved in regulating 
AMPA receptor trafficking in the central nervous system in an NMDA dependent 
manner. Enhances androgen receptor (AR) mediated transcription. May act as a 
proapoptotic protein that induces cell death by acting through the intrinsic apoptosis 
pathway. Binds 3 phosphoinositides (via ENTH domain). May act through the ENTH 
domain to promote cell survival by stabilizing receptor tyrosine 
kinases following ligand induced endocytosis. May play a functional role in the cell 
filament networks. May be required for differentiation, proliferation, and/or survival of 
somatic and germline progenitors. 
CCL24  Chemotactic for resting T lymphocytes, and eosinophils. Has lower chemotactic 
activity for neutrophils but none for monocytes and activated lymphocytes. Is a strong 
suppressor of colony formation by a multipotential hematopoietic progenitor cell line. 
Binds to CCR3. 
CCL26  Chemotactic for eosinophils and basophils. Binds to CCR3. 
POR  This gene encodes an endoplasmic reticulum membrane oxidoreductase with an FAD 
binding domain and a flavodoxin like domain. The protein binds two cofactors, FAD 
and FMN, which allow it to donate electrons directly from NADPH to all microsomal 
P450 enzymes. Mutations in this gene have been associated with various diseases, 
including apparent combined P450C17 and P450C21 deficiency, amenorrhea and 
disordered steroidogenesis, congenital adrenal hyperplasia and Antley Bixler 
syndrome. 
(continued) 
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Table 7.15 Functions of the genes within 7q11.22 7q21.11 (continued) 
 
GENE ID  FUNCTION 
RHBDD2  Function undetermined 
TMEM120A  Function undetermined 
STYXL1  Probable pseudophosphatase. Contains a Ser residue instead of a conserved Cys 
residue in the dsPTPase catalytic loop which probably renders it catalytically inactive. 
. The binding pocket may be however sufficiently preserved to bind phosphorylated 
substrates, and maybe protect them from phosphatases. 
MDH2  Malate dehydrogenase catalyzes the reversible oxidation of malate to oxaloacetate, 
utilizing the NAD/NADH cofactor system in the citric acid cycle. The protein encoded 
by this gene is localized to the mitochondria and may play pivotal roles in the malate 
aspartate shuttle that operates in the metabolic coordination between cytosol and 
mitochondria. 
HSPB1  The protein encoded by this gene is induced by environmental stress and 
developmental changes. The encoded protein is involved in stress resistance and 
actin organization and translocates from the cytoplasm to the nucleus upon stress 
induction. Defects in this gene are a cause of Charcot Marie Tooth disease type 2F 
(CMT2F) and distal hereditary motor neuropathy (dHMN). 
YWHAG  Adapter protein implicated in the regulation of a large spectrum of both general and 
specialized ٛ evelopedٛ  pathway. Binds to a large number of partners, usually by 
recognition of a phosphoserine or phosphothreonine motif. Binding generally results 
in the modulation of the activity of the binding partner. 
SRCRB4D  The scavenger receptor cysteine rich (SRCR) superfamily is an ancient and highly 
conserved group of cell surface and/or secreted proteins, some of which are involved 
in the development of the immune system and the regulation of both innate and 
adaptive immune responses. Group B SRCR domains usually contain 8 regularly 
spaced cysteines that give rise to a well defined intradomain disulfide bond pattern.  
ZP3  The mammalian zona pellucida, which mediates species specific sperm binding, 
induction of the acrosome reaction and prevents post fertilization polyspermy, is 
composed of three to four glycoproteins, ZP1, ZP2, ZP3, and ZP4. ZP3 is essential 
for sperm binding and zona matrix formation. 
(continued) 
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Table 7.15 Functions of the genes within 7q11.22 7q21.11 (continued) 
GENE ID  FUNCTION 
DTX2  Regulator of Notch signalling, a signalling pathway involved in cell cell 
communications that regulates a broad spectrum of cell fate determinations. 
Probably acts both as a positive and negative regulator of Notch, depending on the 
developmental and cell context. Mediates the antineural activity of Notch, possibly by 
inhibiting the transcriptional activation mediated by MATCH1. Functions as an 
ubiquitin ligase protein in vitro, suggesting that it may regulate the 
Notch pathway via some ubiquitin ligase activity. 
UPK3B  Component of the asymmetric unit membrane (AUM); a highly specialized 
biomembrane elaborated by terminally differentiated urothelial cells. May play an 
important role in AUM cytoskeleton interaction in terminally differentiated urothelial 
cells. It also contributes to the formation of urothelial glycocalyx which may play an 
important role in preventing bacterial adherence (By similarity). 
POMZP3  This gene appears to have resulted from a fusion of DNA sequences derived from 2 
distinct loci, specifically through the duplication of two internal exons from the 
POM121 gene and four 3&apos; exons from the ZP3 gene. The 5&apos; end of this 
gene is similar to the 5` coding region of the POM121 gene which encodes an 
integral nuclear pore membrane protein. However, the protein encoded 
by this gene lacks the nuclear pore localization motif. The 3&apos; end of this gene 
is similar to the last 4 exons of the zona pellucida glycoprotein 3 (ZP3) gene and the 
encoded protein retains one zona pellucida domain. Multiple protein isoforms are 
encoded by transcript variants of this gene.  
CCDC146  Function undetermined 
FGL2  May play a role in physiologic lymphocyte functions at mucosal sites. 
PION  Function undetermined 
PTPN12  The protein encoded by this gene is a member of the protein tyrosine phosphotase 
(PTP) family. PTPs are signalling molecules that regulate a variety of cellular 
processes including cell growth, differentiation, mitotic cycle, and oncogenic 
transformation. This PTP contains a C terminal PEST motif, which serves as a 
protein protein interaction domain, and may regulate protein intracellular half life. 
This PTP was found to bind and dephosphorylate the product of the oncogene c ABL 
and thus may play a role in oncogenesis. This PTP was also shown to interact with, 
and dephosphorylate, various products related to cytoskeletal structure and cell 
adhesion, such as p130 (Cas), CAKbeta/PTK2B, PSTPIP1, and paxillin. This 
suggests it has a regulatory role in controlling cell shape and mobility. 
(continued)  
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Table 7.15 Functions of the genes within 7q11.22 7q21.11 (continued) 
 
GENE ID  FUNCTION 
RSBN1L  Function undetermined 
PHTF2  Function undetermined 
TMEM60  Function undetermined 
MAGI2  Seems to act as scaffold molecule at synaptic junctions by assembling 
neurotransmitter receptors and cell adhesion proteins. May play a role in regulating 
activin mediated signalling in neuronal cells. Enhances the ability of PTEN to 
suppress AKT1 activation. 
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Section 8: Linkage analysis in familial mesial 
temporal lobe epilepsy – family W  
 
8.1. Pedigree W 
        Family W was a large pedigree based in Swansea, South Wales. The complete family 
pedigree is shown in Appendix 1. A simplified pedigree showing the second, the third, and 
the fourth generation is presented in Figure 7.1. Twenty seven DNA samples were collected 
from this pedigree, and 20 of them were sent for genotyping.  
 
8.2 Clinical presentation and investigation 
      Of these 20 individuals, 9 had mesial temporal lobe epilepsy, five  were considered 
carriers and 6 were unaffected. Of the 9 individuals who had temporal lobe epilepsy, seven 
of them also had migraine, and 2 of these 7 subjects also had trigeminal neuralgia. The 
diagnosis  of  migraine  was  based  on  the  ICHD II  Diagnostic  Criteria  for  Migraine 
(OCCURRED,  2004).  The  clinical  presentation  and  the  medical  investigations  of  the 
affected individuals in this pedigree are summarized in Table 7.1.  
       Detail  medical  history  of  II 1  and  II 30  were  not  available,  both  were  epileptic 
according to family members interviewed and there were no medical records available to 
confirm this. Their spouses II 2 and II 29 were unaffected. In the third generation, III 3 and 
III 4 were both unaffected, they denied having any seizure or fainting related events but 
four out of their four children were epileptic. IV 15 had cerebral palsy, whether this was 
related to her epilepsy could not be clarified because she did not agree to participate in this 
study  and  refused  to  be  interviewed.  IV 16  died  at  the  age  of  3,  with  a  diagnosis  of 
intractable seizures and severe learning disability. No further description or diagnosis of his 
epilepsy syndrome was available. IV 17 had typical manifestations of mesial temporal lobe 
epilepsy. She had  febrile convulsions at the age of 8  months  and her  first tonic clonic 
generalized epilepsy at the age of 31 months. There was a seizure free period for a few 
years in her childhood until she was 10 years old when generalized seizures relapsed. She 
became seizure free when she was 12 years old under the control of valproate until she was 
15. She remained seizure free and was not on medication until the age of 18 when seizures  
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relapsed again with complex partial seizures, generalized tonic clonic seizures, and several 
episodes  of  status  epilepticus.  Her  paralytic  migraine  started  around  at  this  time.  Her 
complex  partial  seizures  started  with  unpleasant  smells  or  tastes,  followed  with  talking 
rubbish,  flushed  face  and  altered  consciousness.  Other  symptoms  were  oro facial 
automatism,  and  jerky  limbs  movement  which  was  usually  confined  to  right  side.  The 
duration of her complex partial seizures was within 30 seconds to a few minutes. Postictally 
she was often exhausted with severe headache. From the age of 18 to 26, anti epileptic 
drugs including lamotrigine, gabapentin and vigabatrin were described but failed to control 
the seizures. Her MRI scan showed left hippocampal sclerosis and the EEG showed left 
temporal epileptiform discharge. She had left temporal lobectomy at the age of 26 and 
remained seizure free since. Left side trigeminal neuralgia was found after surgery. She had 
one  son  who  had  intractable  epilepsy  and  severe  learning  disability  (not  shown  in  the 
pedigree)  but  the  father  of  her  child  was  unaffected.  Her  brother  IV 18  had  febrile 
convulsion, complex partial seizures and generalized seizures. His first seizure was a febrile 
convulsion when he was 3 months old. He denied frequent seizures but his partner had 
witnessed at least 1 episode and was aware of the existence of 4 other episodes of seizures 
during approximately one year time (2007). According to his partner who witnessed one 
episode of seizures, he  fell down suddenly  with no obvious warning,  with whole body 
shaking,  jerky  limbs  and  wet  himself.    Confusion  with  slow recovery  was  noticed.  He 
claimed that his seizure frequencies were low and had not had any medical investigation. 
He had two daughters who had not had any seizures by the time of the interview. His 
partner was unaffected. 
      III 5 was epileptic according to his wife. He had one generalized seizure after they were 
married and although a brain CT was done, the report was not available. Whether he was 
epileptic and what epilepsy syndrome he had could not be certain. III 6 was not epileptic, 
but four out of her five children with III 5 were affected and three of them had migraine, 
only one was free of symptoms of seizures or migraine. IV 19 had simple partial seizures, 
symptoms including becoming pale for a few seconds, accompanied by mumbling. When it 
happened, although he knew what he was going to say but could not avoid mumbling. No 
loss  of  consciousness  had  been  noticed.  IV 20  had  generalized  seizures,  déjà  vu,  and 
hemiplegic migraine. Her seizure onset was at the age of 12 years old. According to her  
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description, she would suddenly fall to the ground without having any warning usually with 
arms outstretched accompanied with unidentifiable vocal sound. These were followed with 
shaking of the whole body with the eyes widely open, with or without tongue biting and 
loss of consciousness. She noticed that she often injured her right thumb during seizures. 
Stiffness of one side of the body was recalled sometimes during seizures but she could not 
be sure which side. She had déjà vu and the frequency was 1 2 per week, often with a 
strong feeling that she had been to some places familiar and was doing some familiar tasks. 
The onset of migraine was at the age of 15, the frequency of migraine was around 1 2 per 
week, often started with bright light and spots followed with darkened right side visual field 
and her right side body would become numb, eventually becoming right hemiplegic. Other 
less frequent symptoms were pain, and a sensation of needles over her head after the aura, 
severe pulsating headache at right side, feeling nauseous and vomiting. The duration of 
migraine  could  last  6  hours.  Trigger  factors  including  stress,  bright  light  and  sleep 
deprivation. IV 21 had simple partial seizures with déjà vu but was not certain about the 
frequency. Her déjà vu usually were feelings that she was in a place she actually had not 
been to or was at the middle of doing something but in the reality she was not. She also had 
migraine without aura, starting with right pulsating periorbital pain and gradually spreading 
to right head with nauseous sensation which could last for hours. Trigger factors were lack 
of sleep and tiredness. The other medical history of IV 21 included several episodes of pre 
syncope or near fainting which usually relieved after chocolate intake, and 4 5 episodes of 
what have been taken to be sleep paralysis. IV 22 had simple partial seizures and migraine 
without  aura.  Her  seizure  onset  was  at  the  age  of  12  when  she  started  to  have  rising 
sensation  of a  stomach  followed by  giddiness  lasting  for  seconds  to  minutes, and then 
tiredness.  There  was  no  vomiting,  or  symptoms  suggesting  abdominal  diseases.  The 
frequency ranged from 2 times per week to 2 times per month. She also had frequent déjà 
vu, around 4 times a week, with the feeling that she was suddenly in a familiar place. Her 
migraine was evoked by having cheese or seeing bright light. The pain was unilateral and 
throbbing in character and started with mild headache which gradually worsened. There 
was no aura. IV 23 was the only child of III 5 and III 6 and was free from any symptoms of 
seizures and migraine.  
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      III 7  and  III 8  denied  any  symptoms  of  epilepsy  or  migraine,  despite  careful 
interviewing. Two of their three children were epileptic.  IV 24 was the only unaffected 
child. IV 25 was epileptic and his seizures onset was at the age of 4 with no history of 
febrile convulsion. His seizures included complex partial seizures and generalized tonic 
clonic seizures. The complex partial seizures started with a sensation of an unpleasant smell 
and taste which lasted for several minutes, followed with head turning to one side (could 
not recall which side) and convulsions. He had déjà vu which started at the age of 8 years 
old that he might recall a scene suddenly which he was sure he had not been to. He was on 
Epilim and had been seizure free from the age of 13. He also had migraine without aura, 
but was infrequent. His migraine was throbbing or stabbing in character, located at right 
frontotemperal area, with no nauseous feeling. III 26 had complex partial seizures. The 
seizures onset was at the age of 4 years. As far as his parents could recall his first seizures 
clustered and were not febrile seizures. He denied having further seizures until the age of 
22, when he developed complex partial seizures started with a funny and unpleasant taste 
and  smell,  followed  by  stiffness.  The  duration  was  about  1  minute.  He  was  not  on 
medication and refused to give blood sample because of needle phobia.  
     III 11, III 12 and III 13 were not epileptic. III 12 had a severe head injury falling from a 
pile of cargo placed on a truck, and was comatose for 3 week in the hospital. Prior to the 
accident she did not have history of seizures or migraine. After the accident, she recovered 
well but had chronic daily headache, impaired visual acuity (damaged optic nerve), and a 
damaged lacrimal gland as the consequence of the accident. Her relatives noticed also that a 
marked personality change with prominent indifference. She denied having seizures or déjà 
vu. According to the interview of III 12, her partner III 11 and III 13 had no symptoms 
suggesting epilepsy. Her daughters IV 27 and IV 28 were half sisters. IV 27 had déjà vu, 
migraine, and trigeminal neuralgia on the right side. Her déjà vu was quite frequent with 
the feeling as that she was in a place she actually had not been to, or felt certain in some 
circumstances  about  what  was  happening  as  if  she had witnessed  or  experienced  them 
before.  She  had  several  episodes  of  pre syncope,  starting  with  blurred  vision,  severe 
dizziness  and  sometimes  mixed  with  a  rising  sensation  in  the  stomach.  No  loss  of 
consciousness or convulsion had occurred. Her migraine started with blurred vision and a 
right sided shooting headache, with occasionally light spots and bright lights seen before  
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the headache. The light was not “zig zag” in shape. She usually also felt nauseous. The 
trigeminal neuralgia was located at right side. IV 28 had infrequent déjà vu about twice a 
year, experienced as if she was in a familiar place, or with a strong feeling that she had 
witnessed something happening before. The déjà vu episodes could happen at any time 
without any warning.  
       In the third generation, III 9, III 10 and III 14 were unaffected. Their children were not 
interviewed and they were not affected according to the parents.  
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8.3 Phenotyping and the mode of inheritance 
      In this pedigree, some affected individuals did not have detailed medical investigation. 
In most individuals, the seizure frequencies were not high and the severity of seizures was 
mild. A few of them had stereotyped déjà vu only as the main clinical presentation. 
      My interpretation of the inheritance pattern in this pedigree was likely to be admixture 
effect that the susceptibility genes of epilepsy were brought in by unrelated founders: from 
individual II 1, II 30, and III 5. It was not possible to know whether these genes were the 
same or different. Assuming these genes were the same and individual III 3, III 4, III 6, III 
8,  and  III 12  were  carriers,  the  inheritance  mode  of  this  pedigree  could  be  autosomal 
dominant  (AD)  with  a  incomplete  penetrance.  Male  to  male  transmission  and  the 
occurrence of affected individuals were in more than one  generation and no history of 
consanguity  excluded  X  linked  disease,  mitochondrial disease,  and  autosomal  recessive 
inheritance.  This  is  considered  to  be  an  incomplete  penetrance  because  in  the  third 
generation  there  were  only  carriers  but  no  affected  individuals.  This  hypothesis  could 
explain why there were many affected individuals in the fourth generation. 
     However the probability of three unrelated individuals carrying the same susceptibility 
gene and brought it into the same pedigree is low.  If the genes these founders carried were 
different, this pedigree would exhibit polygenic and this could explain the different seizure 
patterns, severities, and frequencies observed from the affected individuals in this pedigree. 
This seems to be likely that the possibility that the three founders were not carrying the 
same susceptible gene. 
      If  the  founders  II 1  and  II 30 were  not considered  epileptic  because  of  the  lack  of 
evidence, and III 5 might not be epileptic because he had only one late onset seizure, III 3, 
III 4, III 6, III 8, and III 12 would less likely to be carriers. Under this assumption, to 
explain  the  cause  of  epilepsy  in  this  pedigree  entirely  by  genetics  appeared  difficult, 
because it would be very unlikely that the four (five) couples of the third generation (III 3 
and III 4, III 5 and III 6, III 7and III 8, III 11, III 12, and III 13) were carrying the same 
susceptible gene to make the pedigree autosomal recessive (AR). Even though this family 
was based in a small valley of Swansea and inbreeding was possible, they seemed unlikely.  
     Another possible mode of inheritance is to consider II 1, II 30 and III 5 as unaffected 
individuals  in  which  case  the  pedigree  could  be  interpreted  as  showing  a  maternal  
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transmission pattern suggesting mitochondrial inheritance. Until now, there is no report that 
mesial temporal lobe epilepsy has been caused by mitochondrial disease, but mitochondrial 
functional impairment has been found in temporal lobe of those who have mesial temporal 
lobe epilepsy (Vielhaber et al.  2008).  
     Environmental factors might be part of the cause of mesial temporal lobe epilepsy in this 
pedigree,  however  no  such  factors  shared  between  the  affected  individuals  were  found 
based on the information gathered from interviews. 
      In summary, the mode of inheritance of this pedigree is not certain. Several situations 
are  considered  but  each  had  its  uncertainty.  Parametric  analysis  would  not  be  suitable 
because the MOI could not be defined in the analysis, so Non parametric linkage analysis 
was the choice in this pedigree. Two programs (MERLIN and SimWalk2) were chosen to 
do this analysis. 
 
8.4 NPL analysis 
8.4.1 MERLIN 
      Because this pedigree was too large for MERLIN, so II 29, II 30, IV 15, IV 16, and IV 
26 (these individuals were not genotyped), III 14 (unaffected individuals, parents were not 
genotyped) and IV 23 (unaffected individuals, but one of their parents was not genotyped) 
and IV 24 (unaffected individual whose parents were fully genotyped) were trimmed off to 
suit  the  NPL  analysis  by  using  MERLIN.  Trimming  off  unaffected  individuals  whose 
parents were fully genotyped would not affect the NPL analysis. However, in this pedigree, 
only IV 24 fulfilled these criteria.  
       
8.4.1.2 Input files, parameters setting and error detection 
      The input files for MERLIN NPL were prepared by Mega2 using standard protocol. 
The  allele  frequencies  were  provided  by  deCODE  Genetics.  The  affection  states  were 
assigned  according  to  the  pedigree  shown  in  Figure8.1.  Genotyping  error  was  checked 
when preparing and converting the input files by Mega2. If genotyping errors were found 
they were adjusted by setting the incompatible genotype data to unknown. The formatted 
input  files  were  checked  again  by  PEDSTATS  (part  of  the  MERLIN  package)  before  
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starting the NPL analysis. Any file preparation errors and incompatible genotype data were 
corrected accordingly. 
       
8.4.1.3 LOD scores obtained by MERLIN 
      The LOD score obtained by MERLIN is the King and Cox LOD score,  (see Section 4). 
The  maximum  King  and  Cox  LOD  score  obtained  by  MERLIN  was  1.001  at  marker 
D22S420 at  chromosome 22 (P  value = 0.01588) (Table 8.2). The expected  maximum 
K&C LOD score was 2.006 in this pedigree. The LOD score distribution of chromosome 
22 is shown in Figure 8.2. The result did indicate linkage. 
 
 
Table 8.2 LOD scores obtained by MERLIN 
 
Chr. 22  Position 
(Haldane, in 
cM) 
Makers  Z 
score 
Delta 
(δ) 
LOD 
score 
(King and 
Cox LOD) 
P 
value 
22  3.048  D22S420  1.279  7.602  1.001  0.01588 
22  6.002  D22S427    0.003    0.018  0  0.504 
22  15.820  D22S539    0.091    0.018    0.001  0.5227 
22  20.026  D22S1174    0.113    0.018    0.001  0.5253 
22  23.911  D22S315    0.123    0.018    0.001  0.5263 
22  25.726  D22S1154    0.125    0.018    0.001  0.5266 
22  36.195  D22S531    0.126    0.018    0.001  0.5267 
22  40.834  D22S1265    0.127    0.018    0.001  0.5268 
22  51.211  D22S276    0.027    0.018  0  0.5125 
22  59.393  D22S928  0.060  7.602  0.154  0.1996 
22  68.417  D22S1170  0.062  7.602  0.159  0.1964 
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Figure 8.2 King &Cox LOD scores distribution obtained in MERLIN 
3.048 6.002 15.820 20.026 23.911 25.726 36.195 40.834 51.211 59.393 68.417
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8.4.2 Simwalk2 
      This pedigree was re analyzed by SimWalk2 NPL, using the same parameter setting as 
used in MERLIN without trimming off any individual. The advantage of SimWalk2 is that 
it can analyze large pedigrees but the time needed for analysis using SimWalk2 NPL was 
much longer than the time needed for MERLIN NPL.  
 
8.4.2.1 Parameters settings and error detection for Simwalk2  
      The input files were constructed from data stored in Linkage format files by Mega2. 
The  allele  frequencies  were  provided  by  deCODE  Genetics.  Genotyping  errors  were 
checked by Simwalk2 by the “setup” option before entering any specified linkage analysis. 
Genotyping errors were adjusted by setting the incompatible data to unknown.  
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8.4.2.2 Location scores by SimWalk2 
      In Simwalk2, the location score is calculated from the equation: 
        ) ( log10 value p− − .  
      A p value of 0.5 (i.e a location score of 0.3010 [ ) 5 . 0 ( log10 − ]) indicates equal evidence 
for and against linkage. The maximum p value was set as 1.0, the smaller the p value is, the 
higher the significance. In this SimWalk2 analysis, the default minimum p value was set as 
0.0001, with a maximum location score of 4. Under Simwalk2 NPL analysis, there are 5 
statistics  methods  available.  The  BLOCKS  statistic  is  the  number  of  founder alleles 
contributing alleles to the affected individuals. This statistic was designed for traits best 
modelled  by  recessive  inheritance.  The  MAX TREE  statistic  is  the  largest  number  of 
affected subjects inheriting an allele from one founder allele. This statistic was designed for 
traits best modelled by dominant inheritance. The ENTROPY statistic is a measure of the 
entropy of the alleles among the affected individuals. The NPLpair statistic is roughly the 
sum of conditional kinship coefficients for all affected pairs. This statistic was designed for 
traits best modelled by ADDITIVE inheritance. The NPLall statistic is a measure of whether 
a  few  founder alleles  are  overly  represented  in  affected  individuals.  This  statistic  was 
designed for traits best modelled by ADDITIVE inheritance.  
      The largest location score obtained by SimWalk2 NPL analysis was 1.733 in NPLpair, at 
the position 90.7876 cM on chromosome 13, the nearest marker was D13S1241 (Table 
8.3). Another location score larger than 1 was on chromosome 22, with a location score of 
1.235 by NPL pair analysis and 1.343 by NPLall. However, in none of the location scores 
obtained via Simwalk2 NPL did the analysis exceed the significant threshold.  
      The reason that SimWalk2 showed a maximum location score at marker D13S1241 but 
not D22S420 could be that several genotyped individuals were trimmed off in MERLIN 
NPL analysis, but the entire pedigree shown in Figure 8.1 was included in the SimWalk2 
NPL analysis, including those who were not genotyped.  
 
 8.5 Summary 
      In this analysis,  we  aimed to identify the  genetic basis of this  familial epilepsy, to 
determine  the  mode  of  inheritance  in  this  family,  to  identify  linked  regions,  and  to  to  
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determine whether there was a similar genetic cause as in the other pedigree (pedigree B) 
However,  the mode of inheritance of this pedigree could not be determined, and the NPL 
analysis by MERLIN and SimWalk2 were both inconclusive; the maximum K&C LOD 
was 1.001 at marker D22S420, and the maximum location score by SimWalk2 NPL pair was 
1.733 at marker D13S1241. In pedigree B, the mode of inheritance was AD with a reduced 
penetrance, and three regions of interest were identified. Thus the underlying genetics in 
this pedigree and pedigree B is likely to be different.  
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Table 8.3 Location scores on chromosome 13 (Simwalk2 NPL) 
 
Chromosome  Position 
(Haldane, 
in cM) 
Marker  Block  Max 
Tree 
Entropy  NPL 
(pair) 
NPL 
(all) 
13  53.9549  D13S272  0.402  0.738    1.207   1.168   1.138 
13  65.4734  D13S279  0.501  0.827    1.831    1.626   1.510 
13  79.9789  D13S271  0.503  0.822   1.792    1.617   1.513 
13  90.9876  D13S1241  0.507  0.992   1.844    1.733   1.652 
13  100.3041  D13S1256  0.282  0.948   0.844    0.925   1.000 
13  107.2660  D13S1809  0.280  0.945   0.858   0.942     1.014 
 
Figure 8.3 Distribution of the location score on chromosome 13 
(SimWalk2NPL)
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Table 8.4 Location scores on chromosome 22 (Simwalk2 NPL) 
 
Chromosome  Position 
(Haldane, 
in cM) 
Marker  Block  Max 
Tree 
Entropy  NPL 
(pair) 
NPL 
(all) 
22  0.0000  D22S420  0.250  1.268   1.046    1.235   1.343 
22  2.9535    D22S427  0.222   0.538    0.699   0.694  0.705 
22  12.7713    D22S539  0.151   0.337   0.466   0.456   0.476 
22  16.9774    D22s1174  0.130   0.279   0.406   0.393   0.407 
 
Figure 8.4 Distribution of the location scores on chromosome 22(SimWalk2 NPL) 
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Section 9:  Linkage Analysis in Photosensitive Epilepsy 
 
 
9.0 Overview 
       The DNA samples of this pedigree were collected approximately 15 years ago, the 
access of the DNA samples was made through collaborating with Professor Nick Wood, 
Head of the Department of Molecular neuroscience, Institute of Neurology, Queen Square, 
London.  Electroencephalography  (EEG)  was  used  as  a  phenotyping  tool  in  this  study. 
Some of the EEGs of the individuals were repeated 8 to 17 years after their first EEGs 
using the same protocol. The EEGs were reported by Professor Graham F.A. Harding and 
reviewed by Professor Peter M Jeavons.  
 
9.1 Family pedigree 
      The  pedigree  of  this  family  is  shown  in  Figure  9.1.  Nineteen  DNA  samples  were 
available from this family. Of these 19 individuals, 10 had a photoparoxysmal response 
(PPR) based on their EEG investigation with intermittent photic stimulation (IPS) by using 
Grass PS 22. The intensity was set at 2, with and without grid testing.  
 
9.2 Clinical presentation and investigation 
      The  medical  records  of  this  pedigree  are  summarized  in  Table  9.1.  In  the  first 
generation, the DNA sample of I 2 was not available. Her EEG investigation was carried 
out at the age of 48 and 65. The first EEG showed a clear PPR at 35 and 40Hz photic 
stimulation. In the second EEG, whole body myoclonic jerks were induced during the IPS 
at 50 60 Hz. I 1 was unaffected. His DNA sample was not available.  
      In the second generation, II 3 was not affected. II 4 had 2 seizures. The first one was 
evoked by watching TV and the last seizure was at the age of 18. He had one EEG at the 
age of 35 which showed marked occipital spiking with anterior involvement at 35, 38, 40, 
and 45 Hz photic stimulation. He was seizure free after the age of 18 and was not on 
medication. II 5 was not affected. II 6 had seizures, but his EEG report and medical history 
were not available; whether he had photosensitivity was unknown.  II 7 had 2 seizures 
which were both induced by watching TV. She was seizure free after the age of 16. She had 
2 EEG recordings, the first one was carried out at the age of 19 and an inconstant PPR were  
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recorded at 20, 50 Hz photic stimulation as well as occipital spikes induced at 30 40 Hz 
photic  stimulation.  The  second  EEG  was  carried  out  at  the  age  of  31  which  showed 
occipital spiking and a degraded PPR. II 8 had no seizures, but bright sun light bothered her 
with dizziness. She had one EEG at the age of 15, showing a definite PPR at 20 and 50 Hz 
photic stimulation.  II 8 was unaffected. II 9 had no seizures and his EEG showed, on 
photic stimulation, occipital spikes at 50 Hz stimulation. II 10 and II 11 were not affected.  
II 12  did  not have  seizures,  but  responded  to  bright  light  with  “jumping”.  She  had  no 
problem in watching TV and had no jerky limb movements in the morning. On her EEG 
record at the age of 28, when the PPR were induced at 40 Hz photic stimulation, she felt 
“funny”. II 13 was not affected. II 14 had photosensitive seizures, with an onset at the age 
of 11 and was always induced by watching TV. He was on phenytoin and was seizure free 
after the age of 16. He had 1 EEG at the age of 15 years old and 10 months, which showed 
a PPR at 16, 18, 24, 25, 40, and 52 Hz photic stimulation. His follow up EEG was at the 
age of 27, which did not show a typical PPR but did show some abnormality (sharp waves) 
at the occipital lobe with anterior spread at 40, 45 Hz stimulation, suggesting that his PPR 
had deteriorated or degraded. II 15 was not affected. II 16 did not have seizures, on her 
EEG a PPR was recorded at 14 25 Hz photic stimulation with her eye closed or at 9 25 Hz 
stimulation on eye  closure. EEG was not tested on  II 13, who did not have history  of 
seizures.  
      In the third generation, III 17 was not affected. III  18 did not have seizures. On her 
EEG at the age of 15, a definite PPR were recorded at 20 and 50 Hz photic stimulation. III 
19 had epilepsy, but his EEG did not show any PPR. III 20 and III 21 was not affected. III 
22 had no seizures, and no symptoms suggesting photosensitivity but a degraded PPR was 
found on his EEG, mainly confined to the occipital area. On 1 or 2 occasions, there was a 
slight anterior involvement. III 22 also had asthma. III 23 had seizures with mild learning 
disability, with an onset at the age of 7. His seizures were evoked by watching TV and 
flashing  lights. There  were  also  nocturnal  seizures  usually  preceded by seeing flashing 
lights, particularly in the right visual field. With the onset of the sparkling light, he would 
say “I cannot see” and this would be followed by left side jerky limb movements and mild 
left side Todd’s paralysis. The partial seizures  could evolve to  generalized tonic clonic 
seizures. He was on Epilim 2000 mg per day. The imaging study of brain was normal. He  
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had 2 EEGs, the first EEG was carried out at the age of 12 and showed a PPR at 35 and 40 
Hz photic stimulation. His second EEG was carried out at the age of 18 and showed PPR at 
50 Hz photic stimulation and at the same time he reported seeing flashing light. A focal 
seizure  was  evoked  on  pattern  testing  at  200  Hz.  III 24  had no  seizures.  On  her  EEG 
examination, PPR were recorded at 15, 17, 18, 19, 35, 36, 37, 40, 42, Hz photic stimulation. 
No special sensation was reported by this individual when a PPR were recorded.   
      The  clinical  presentations  of  the  affected  individuals  are  summarized  in  Table  9.1. 
Except for individual I 2, II 3, II 9, and II 12 in whom the first EEGs were conducted after 
the age of 20 years, the rest of the subjects had EEGs recorded between the age of 10 and 
20  years.  A  degraded  PPR  (Doose  Type  1)  were  found  on  the  follow up  EEG  of  I 2 
(68y/o), II 7 (31 y/o), and on the first EEG recording of II 4 (35 y/o), II 9 (36 y/o), and II 
22 (15y/o).   
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9.3 Linkage analysis         
9.3.1 Phenotyping and mode of inheritance 
      This pedigree was divided into 4 groups based on both their clinical presentation and 
EEG reports:  
Group 1: Unaffected individuals; who had no history of seizures and in whom there were 
no PPRs evoked on EEG during IPS. There were 11 individuals in this group and 8 DNA 
samples were available from this group. 
Group 2: Individuals showing PPR on EEG recording during IPS; but who clinically did 
not have history of epilepsy and had no seizures were induced during IPS. There were 6 
individuals in this group. All of their DNA samples were available. 
Group 3: Individuals with photosensitive epilepsy; and in whom PPRs were induced and 
recorded on EEG during IPS. There were 5 individuals in this group and 4 DNA samples 
were available from this group. 
Group 4: Individuals with epilepsy but whose seizures were not related to photosensitivity, 
and  whose  epilepsy  was  not  visually  sensitive  (no  PPRs  and  no  seizures  induced  by 
photosensitivity). There were 2 individuals in this group and 1 DNA sample was available. 
     The  different  definition  of  phenotype  in  the  family  inducted  different  mode  of 
inheritance. If PPR is the single factor considered in determining the case status (group2 
and group3), there was male to male transmissions indicating this was not an X linked or 
an  mitochondrial  inheritance,  and  affected  individuals  were  seen  in  three  generations, 
indicating that this was not autosomal recessive inheritance. The inheritance mode would 
thus  likely  to  be  autosomal  dominant.  In  this  analysis,  the  phenotype  was  defined  as 
positive PPRs on EEG, which included both group 2 and group 3.  
 
9.3.2 Parameters for MILNK analysis  
     Parametric linkage analysis was carried out by MLINK. The mode of inheritance was 
set as autosomal dominant with full penetrance. Other parameters such as allele frequencies 
were  set  according  to  the  data  provided  by  deCODE  Genetics,  the  increment  of 
recombination fraction was set at 0.1, starting from 0 and ended at 0.45. The LOD scores 
were also calculated when the recombination fraction was at 0.01 and 0.05. The program  
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UNKNOWN was used to check genotyping errors. Such errors were corrected by changing 
the wrongly genotyped data as “unknown”.  
      Clinically, statistics has suggested that photosensitivity is an age related phenomenon 
with maximum prevalence in the age group between 5 20 years old. A degraded PPR is 
common when patients exceed 20 years old. Most of the degraded PPRs (Doose Type 1, 2, 
and  3)  are  confined  to  occipital  area,  parietal area,  or  frontal lobe without  generalized 
spreading. Female are more likely to be affected than male with the ratio of 2 2.5:1. In this 
pedigree,  with  the  exception  of  4  individuals,  the  EEG  investigations  were  carried  out 
between the ages of 10 20 years, in this way, the influence of age was minimized. 
 
9.4 LOD scores by MLINK 
     The  maximum  LOD  score  was  1.14  at  marker  D1S2865  at  θ  =  0.1,  with  another 
comparable LOD score was 1.06 at marker D1S495 at θ = 0.2. The LOD scores distribution 
is presented in Table 5.2. Multipoint linkage analysis at this locus the LOD score was 1.57. 
      The haplotype analysis of this region is shown in Figure 9.2. If the genotype data is 
missing it is shown as “?”. If the haplotype is not certain because the phase of meiosis was 
unknown,  it  is  marked  with  an  “?”  beside  the  haplotype.  The  haplotype  analysis  of 
chromosome  1  did  not  support  the  existence  of  a  disease  locus  at  this  region,  and 
demonstrated that any disease locus was not adjacent to the markers used. No haplotype 
segregated with the affected individuals. 
 
Table 9.2 LOD score of chromosome 1 
 
            θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D1S2766   infini     5.54     2.26     1.03     0.13     0.11     0.08 
D1S2865        infini     0.53     1.06     1.14     0.95     0.58     0.18  
D1S2627   infini     0.25     0.34     0.50     0.51     0.37     0.16 
D1S435   infini     3.35   1.37     0.63     0.07     0.07     0.04 
D1S206  0.35     0.34     0.29     0.24     0.17     0.13     0.06 
D1S495         infini     1.55     0.30     0.87     1.06     0.79     0.31 
D1S2688   infini     0.84     0.21     0.00     0.11     0.08     0.03  
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      The phenotyping of this pedigree is based as it was on the existence of a PPR, which 
was interpreted by 2 experts in photosensitivity, and false phenotyping was unlikely. The  
MOI in the pedigree suggested a single gene disease which was autosomal dominant with 
full penetrance. However parametric analysis by MLINK failed to find a disease linkage, 
because  of  this,  the  pedigree  was  re analyzed  using  NPL  by  SimWalk2  to  test  the 
hypothesis that photosensitivity in this pedigree was polygenic with a dominant gene. 
 
9.5 NPL by SimWalk2  
      The input files for Simwalk2 were constructed by Mega2 using Linkage format files. 
The input files were checked by selecting the “option” of SimWalk2. Genotyping errors (if 
there were any) were adjusted by setting the data as “unknown”. The parameters used were 
the same as used in MLINK, and the map file was based on the Decode genetic map. 
      The NPL analysis by Simwalk2 showed that the location score [–Log10 (p value)] of 
NPL pair at marker D16S2621 was 2.231, the corresponding P value was 0.0059, and the 
location score of NPLall was 1.629 at the same location, the corresponding pointwise P 
value  was  0.0235.  Part  of  the  NPL  location  score  distributions  by  SimWalk2  on 
chromosome 16 is presented in Table 9.3 and Figure 9.4. The haplotype analysis showed 
that recombination was found on III 18 and III 24; these 2 affected individuals did not 
share the haplotype with the other affected individuals. 
      If photosensitivity is a single gene disease, the NPL analysis as well as the parametric 
analysis by MILNK failed to identify the disease locus. If photosensitivity is a polygenic 
disease with a dominant gene (susceptibility gene that is shared by the majority of affected 
individuals),  the  region  identified  by  SimWalk2  NPL  analysis  showed  that  a  single 
haplotype was shared by most of the affected individuals except III 18 and III 24, whose 
photosensitivity could be caused either by non dominant genes or non genetic factor. 
      The region identified via NPL analysis was located at 16q24.1 16q24.3, and is around 
6.1 Mb in length. There are around 90 known genes and pseudo genes in this area, but no 
ion channel gene is found within this region. One ion channel gene, KCNG4 (the potassium 
voltage gated channel gene, subfamily G, member 4), was adjacent to this region. But, 
there is no evidence that this gene expresses in the brain and its function has not been 
determined. The functions of the known genes in this region are summarized in Table 9.4.   
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 9.6 Summary 
      In this photosensitive epilepsy pedigree, we aimed to identify the genetic basis of the 
Photoparoxysmal  response  (PPR)  in  a  large  family  with  photosensitive  epilepsy,  to 
determine the mode of inheritance, and to identify linkage. 
      In  summary,  the  NPL  analysis  of  Simwalk2  suggested  a  region  of  interest  on 
chromosome16 in which a haplotype was shared by the majority of affected individuals. 
This pedigree could be thus explained by a polygenic inheritance in which involving a 
dominant gene.   
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(continued) 
Gene ID  Function 
USP10  This gene encodes a member of the ubiquitin specific protease family of cysteine 
proteases, may be associated with poor survival of glioblastoma multiform. 
CRISPLD2  Candidate gene for Non syndromic cleft lip with or without cleft palate. 
ZDHHC7  Palmitoyltransferase with broad specificity. Palmitoylates SNAP25 and DLG4/PSD95. 
May palmitoylate GABA receptors on their gamma subunit (GABRG1, GABRG2 and 
GABRG3) and regulate their synaptic clustering and/or cell surface stability. 
KIAA0513  a novel signaling molecule that interacts with modulators of neuroplasticity, apoptosis, 
and the cytoskeleton. 
FAM92B  candidate gene of Crohn Disease. 
TMEM148  function unknown 
KIAA0182  function unknown 
GINS2  The GINS complex plays an essential role in the initiation of DNA replication, and 
progression of DNA replication forks. GINS complex seems to bind preferentially to 
single stranded DNA. 
C16orf74  function unknown 
COX4NB  function unknown 
COX4I1  This gene encodes the nuclear encoded subunit IV ٛ soforms 1 of the human 
mitochondrial respiratory chain enzyme. 
IRF8  Interferon regulatory factor 8 The IRF family proteins bind to the IFN stimulated 
response element (ISRE) and regulate expression of genes stimulated by type I IFNs, 
namely IFN alpha and IFN beta. IRF family proteins also control expression of IFN 
alpha and IFN beta regulated genes that are induced by viral infection. 
MTHFSD  function unknown 
FOXF1  This gene belongs to the forkhead family of transcription factors which is 
characterized by a distinct forkhead domain. The specific function of this gene has not 
yet been determined; however, it may play a role in the regulation of pulmonary genes 
as well as embryonic development. 
FOXL1  Candidate gene of primary lymphedema. 
FOXC2  This gene belongs to the forkhead family of transcription factors which is 
characterized by a distinct DNA binding forkhead domain. The specific function of this 
gene has not yet been determined; however, it may play a role in the development of 
mesenchymal tissues. 
Table 9.4 Genes within 16q24.1 16q24.3  
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Gene ID  Function 
FBXO31  Probably recognizes and binds to some phosphorylated proteins and promotes their 
ubiquitination and degradation. May act as a breast tumour suppressor.  
MAP1LC3B  Probably involved in formation of autophagosomal vacuoles (autophagosomes). 
ZCCHC14  function unknown 
JPH3  Contributes to the stabilization of the junctional membrane complexes, which are 
common to excitable cells and mediate cross talk between cell surface and 
intracellular ion channels. Probably acts by anchoring the plasma membrane and 
endoplasmic reticulum. May play an active role in certain neurons involved in motor 
coordination. Had been reported as a candidate gene for Huntington disease. 
KLHDC4  function unknown 
SLC7A5  Sodium independent, high affinity transport of large neutral amino acids such as 
phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with 
SLC3A2/4F2hc. Involved in cellular amino acid uptake. Acts as an amino acid 
exchanger. Involved in the transport of L DOPA across the blood brain barrier, and 
that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell 
membrane in tissues such as placenta. Plays a role in neuronal cell proliferation 
(neurogenesis) in brain. Involved in the uptake of methylmercury (MeHg) when 
administered as the L cysteine or D,L homocysteine complexes, and hence plays a 
role in metal ion homeostasis and toxicity. Involved in the cellular activity of small 
molecular weight nitrosothiols, via the stereoselective transport of L nitrosocysteine 
(L CNSO) across the transmembrane. May play an important role in high grade 
gliomas. Mediates blood to retina L leucine transport across the inner blood retinal 
barrier which in turn may play a key role in maintaining large neutral amino acids as 
well as neurotransmitters in the neural retina. Acts as the major transporter of 
tyrosine in fibroblasts   
CA5A  Reversible hydration of carbon dioxide 
BANP  Controls V(D)J recombination during T cell development by repressing T cell receptor 
(TCR) beta enhancer function. Binds to scaffold/matrix attachment region beta 
(S/MARbeta), an ATC rich DNA sequence located upstream of the TCR beta 
enhancer. Represses cyclin D1 transcription by recruiting HDAC1 to its promoter, 
thereby diminishing H3K9ac, H3S10ph and H4K8ac levels. Promotes TP53 'Ser 15' 
phosphorylation and nuclear accumulation, which causes cell cycle arrest. 
(continue) 
Table 9.4 Genes within 16q24.1 16q24.3 (continue)  
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Gene ID  Function 
ZFPM1  Transcription regulator that plays an essential role in erythroid and megakaryocytic cell 
differentiation. Essential cofactor that acts via the formation of a heterodimer with 
transcription factors of the GATA family GATA1, GATA2 and GATA3. Such heterodimer 
can both activate or repress transcriptional activity, depending on the cell and promoter 
context. The heterodimer formed with GATA proteins is essential to activate expression 
of genes such as NFE2, ITGA2B, alpha  and beta globin, while it represses expression 
of KLF1. May be involved in regulation of some genes in gonads. May also be involved 
in cardiac development, in a non redundant way with ZFPM2/FOG2. 
ZC3H18  function unknown 
IL17C  Stimulates the release of tumour necrosis factor alpha and IL 1 beta from the monocytic 
cell line THP 1. 
CYBA  Critical component of the membrane bound oxidase of phagocytes that generates 
superoxide. Associates with NOX3 to form a functional NADPH oxidase constitutively 
generating superoxide.  
MVD  Performs the first committed step in the biosynthesis of isoprenes 
SNAI3  Seems to inhibit myoblast differentiation. Transcriptional repressor of E box dependent 
transactivation of downstream myogenic bHLHs genes. Binds preferentially to the 
canonical E box sequences 5' CAGGTG 3' and 5' CACCTG 3'. 
FAM38A  Expressed in numerous tissues. In normal brain, expressed exclusively in neurons, not 
in astrocytes. In Alzheimer disease brains, expressed in about half of the activated 
astrocytes located around classical senile plaques. In Parkinson disease substantia 
nigra, not detected in melanin containing neurons nor in activated astrocytes. 
RNF166  Function unknown 
APRT  Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less 
costly than de novo synthesis. 
GALNS  This gene encodes N acetylgalactosamine 6 sulfatase which is a lysosomal 
exohydrolase required for the degradation of the glycosaminoglycans, keratan sulfate, 
and chondroitin 6 sulfate. Sequence alterations including point, missense and nonsense 
mutations, as well as those that affect splicing, result in a deficiency of this enzyme. 
Deficiencies of this enzyme lead to Morquio A syndrome, a  lysosomal storage disorder. 
(continue) 
 
 
Table 9.4 Genes within 16q24.1 16q24.3 (continue)  
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Gene ID  Function 
CBFA2T3  Functions as a transcriptional repressor. Regulates the proliferation and the 
differentiation of erythroid progenitors by repressing the expression of TAL1 target 
genes. Plays a role in granulocyte differentiation. Isoform 2 functions as an A kinase 
anchoring protein. 
TRAPPC2L  Function undetermined 
ACSF3  Acyl CoA synthases catalyze the initial reaction in fatty acid metabolism, by forming a 
thioester with CoA. May have some preference toward very long chain substrates. 
ZNF778  May be involved in transcriptional regulation 
CDH15  Cadherins are calcium dependent cell adhesion proteins. They preferentially interact 
with themselves in a homophilic manner in connecting cells; cadherins may thus 
contribute to the sorting of heterogeneous cell types. M cadherin is part of the 
myogenic program and may provide a trigger for terminal muscle differentiation. 
ANKRD11  May recruit HDACs to the p160 coactivators/nuclear receptor complex to inhibit 
ligand dependent transactivation. 
SPG7  This gene encodes a nuclear encoded mitochondrial metalloprotease protein that is a 
member of the AAA (ATPases associated with a variety of cellular activities) protein 
family. Members of this protein family share an ATPase domain and have roles in 
diverse cellular processes including membrane trafficking, intracellular motility, 
organelle biogenesis, protein folding, and proteolysis. Two transcript variants 
encoding distinct isoforms have been identified for this gene. Mutations associated 
with this gene cause Autosomal recessive spastic paraplegia 7. 
RPL13  This gene encodes a ribosomal protein that is a component of the 60S subunit of 
ribosome. This gene is expressed at significantly higher levels in benign breast 
lesions than in breast carcinomas. 
CPNE7  May function in membrane trafficking. Exhibits calcium dependent phospholipid 
binding properties. 
DPEP1  Hydrolyzes a wide range of dipeptides. Implicated in the renal metabolism of 
glutathione and its conjugates. Converts leukotriene D4 to leukotriene E4; it may play 
an important role in the regulation of leukotriene activity. 
CHMP1A  This gene encodes a member of the CHMP/Chmp family of proteins which are 
involved in multivesicular body sorting of proteins to the interiors of lysosomes. 
ZNF276  May be involved in transcriptional regulation 
(continued) 
Table 9.4 Genes within 16q24.1 16q24.3 (continue)  
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Gene ID  Function 
CDK10  The protein encoded by this gene belongs to the CDK subfamily of the Ser/Thr protein 
kinase family.The CDK subfamily members are highly similar to the gene products of S. 
cerevisiae cdc28, and S. pombe cdc2, and are known to be essential for cell cycle 
progression. 
FANCA  Mutations in this gene are the most common cause of Fanconi anemia. 
SPIRE2  Acts as a actin nucleation factor, remains associated with the slow growing pointed end 
of the new filament. Involved in vesicle transport processes providing a novel link 
between actin organization and intracellular transport. 
TCF25  TCF25 is a member of the basic helix loop helix (bHLH) family of transcription factors 
that are important in embryonic development. 
AFG3L1  Possible candidate gene of human spastic paraplegia 
TUBB3  Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an 
exchangeable site on the beta chain and one at a non exchangeable site on the alpha 
chain. Over expression of this gene may be a maker of poor clinical outcome of 
advanced ovarian cancer patients. 
DEF8  Function unknown 
PRDM7  The protein encoded by this gene is a transcription factor of the PR domain protein 
family. It contains a PR domain and multiple zinc finger motifs. Transcription factors of 
the PR domain family are known to be involved in cell differentiation and tumorigenesis. 
DBNDD1  Function undetermined 
GAS8  This gene includes 11 exons spanning 25 kb and maps to a region of chromosome 16 
that is sometimes deleted in breast and prostrate cancer. The second intron contains an 
apparently intronless gene, C16orf3, which is transcribed in the opposite orientation. 
This gene is a putative tumour suppressor gene. 
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Section 10: Linkage Analysis in Kohlschütter Tönz 
Syndrome 
 
10.0 Overview  
      Five small families were identified with Kohlschütter Tönz Syndrome. These families 
were identified and diagnosed in several different countries, including Italy (2 families), 
Germany (1 family), United Kingdom (1 family) and Australia (1 family). All of the DNA 
samples were obtained from consenting individuals of these families. The detail clinical 
presentations  and  medical  history,  pedigrees  of  these  families  have  been  published 
(Christodoulou et al.  1988; Guazzi et al.  1994; Donnai et al  2005; Musumeci et al.  1995; 
Petermöller et al.  1993).  
 
10.1 The Kohlschütter Tönz Pedigrees 
      Pedigree 1, 3, and 5 are shown in Figure 10.1, pedigree 2 is shown in Figure 10.2, and 
pedigree 4 in Figure 10.3. All the families except pedigree 4 showed a typical autosomal 
recessive inheritance. There was consanguinity in pedigree 2 and in pedigree 4; the parents 
were first cousins. In pedigree 4, there were four phenotypes and the mode of inheritance 
was complicated, depending on the phenotypes defined.  
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10.1.1 Clinical presentation 
     The clinical presentation and some of their clinical investigations of these 5 pedigrees 
are summarized in Table 10.1.  
     Pedigree 1 was a UK family reported by Donnai (Donnai et al.  2005). The parents were 
healthy  unrelated  individuals  who  had  no  family  history  of  dental  abnormality  or 
neurological disorders. II 3 had a seizure onset at the age of 5 weeks, and the EEG at four 
months showed hypsarrhythmia. His CT scan at the same time showed enlargement of the 
lateral and third ventricles as well as abnormality of the cortical sulci particularly over the 
surface  of  the  left  hemisphere.  His  teeth  appeared  to  have  essentially  normal  dentine 
structure and morphology but the enamel was poorly formed with an irregular rod structure 
and  prominent  hypoplasia,  which  was  consistent  with  the  diagnosis  of  amelogenesis 
imperfecta (AI). His psychomotor development was severely impaired and he could not 
talk or walk at the age of 13 and only smiled to a lot of attention. II 4 was sister of II 3. At 
the  age  of  nine  weeks  she  appeared  hypotonic  and  had  feeding  problems  with  lactose 
intolerance.  At  the  age  of  11  weeks  she  had  the  first  episode  of  partial  seizures 
accompanied by myoclonic jerks of the left arm which lasted 45 minutes. Despite combined 
anticonvulsant therapy she continues to have 5 to 10 seizures per day and subtle signs of 
seizure activity such as twitches and unusual eye and lip movements. The EEG at this time 
showed an abnormal pattern with loss of normal rhythmic activities and frequent multi 
focal discharges. The MRI scan showed incomplete myelination and enlargement of the 
lateral  ventricles,  possibly  consistent  with  cerebral  atrophy.  She  demonstrated  more 
awareness of her surroundings than her brother and was able to communicate with her 
mother by eye movements. Other symptoms shared by the siblings included facial flushing 
and the passage of sediment in the urine every few weeks. The crystals have been analyzed 
and were 75% calcium phosphate and 25% magnesium ammonium phosphate. The mode of 
inheritance was autosomal recessive in this pedigree.  
      Pedigree 2 was an Italian family with consanguity reported by Musumeci (Musumeci et 
al.  1995). The parents (III 7 and III 8) were first cousins. There were family members 
reported to have epilepsy or mental retardation in this pedigree, but were not specified 
which  side  these  family  members  were  from  (paternal  or  maternal)  and  the  detailed 
symptoms and signs were not available. History and DNA of I 1, I 2, II 3, II 4, II 5 and II  
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6 were not available. IV 10 was found to have psychomotor development delay at the age 
of 2 months when his first seizure occurred.  They seizures were characterized by cyanosis, 
staring spell and loss of muscular tone which lasting a few seconds. During the following 
months more seizures were observed, sometimes with head turning to the left and intense 
cyanosis of the lips. Other types of seizures included left unilateral tonic clonic seizures 
with  a  prolonged  Todd's  paralysis  and  generalized  tonic clonic  seizures,  mostly  during 
sleep. On physical examination, spastic hypertonia of the 4 limbs was found together with 
bilateral Babinski sign, severe mental retardation with no verbal language, yellow teeth, 
and  broad  thumbs  and  toes.  The  interictal  EEG  during  awake  and  sleep  showed  high 
voltage diffuse continuous theta and delta waves with multifocal spikes over the frontal 
regions, asynchronously occurring over the two hemispheres and over the right temporo 
occipital  areas.  Brain  CT  scans  and  MRI  showed  hypoplasia  of  the  cerebellar  vermis, 
asymmetric dilation of the lateral ventricles, the subarachnoid spaces and cisternae. IV 9 
was  sister  of  IV 10,  she had delayed  neuromotor  development  noticed  at  the  age  of  4 
months. Her seizures onset was at the age of 10 months and was a febrile convulsion with 
loss  of  consciousness.  Most  of  her  seizures  were  correlated  with  sleep  onset  and  were 
characterized by rigidity of the 4 limbs, rotation of the head to the right and occasionally 
the left, eyelid  and facial myoclonus, and oro facial automatisms. These episodes were 
short  and  consciousness  was  promptly  recovered.  These  episodes  were  rare  in  the 
beginning  but  showed  a  progressive  increase  in  frequency  which  was  not  modified  by 
valproate or carbamazepine. The interictal EEG showed high voltage diffuse slow wave 
activity at 3 4 c/s. Intermittent photic stimulation did not show any abnormal effects. Brain 
MRI  showed  only  an  enlargement  of  the  lateral  ventricles.  In  both  patients,  seizure 
frequencies were greatly reduced by clobazam. In both case, biochemistry or metabolic 
screening tests were normal. 
      Pedigree 3 was a German family reported by Petermöller (Petermöller et al.  1993). The 
parents  were  healthy  unrelated  individuals  who  had  no  remarkable  family  history  of 
abnormal enamel or neurological disorders. II 3 had delayed psychomotor development 
noticed as early as 5 months old. For the first five months he was very restless but became 
very quiet thereafter, showed no interests to toys, became extremely  reluctant to being 
touched and made very few movements. The seizures (febrile seizure) started at the age of  
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8.5 months and were very difficult to control. The seizure pattern changed to generalized 
seizures with left preponderance later, and was resistance to most of anti epileptic drugs. 
The  teeth  were  noticed  to  be  yellow  and  crumble  from  the  start  of  dentition.  All 
biochemistry tests were normal and the MRI showed only slight ventricular enlargement. 
II 4 had normal development milestones for the first year. At the age of 8 months, however, 
she  had  her  first  febrile  convulsion  which  was  a  generalized  seizure  with  a  left  sided 
preponderance.  Frequent seizures started at the age of 13 months and were resistant to 
phenytoin and carbamazepine. Psychomotor development regressed from the age of two. 
Her teeth were yellowish and prone to crumble at the start of dentition. The EEG showed 
generalized slow activity with discrete focal sharp waves. The mode of inheritance of this 
pedigree appeared to be autosomal recessive. III 5 was unaffected. 
      Pedigree  4  was  an  Italian  family,  which  was  investigated  by  Guazzi (Guazzi  et  al.  
1994). The first generation I 1 and I 2 were both unaffected. In the second generation, there 
were 7 siblings, II 7 had amelogenesis imperfecta but not neurological disorders. His sister 
II 9, on the contrary, had psychomotor delay only but not amelogenesis imperfecta. In the 
third generation, III 12 was affected with both amelogenesis imperfecta and seizures. He 
had absence seizures during childhood and later tonic clonic generalized epilepsy, but was 
well controlled by anti epileptic drugs. He had no learning disability. He married his first 
cousin III 13, who was unaffected. In the fourth generation, IV 14 had a normal birth but 
early psychomotor development was delayed. Other later neurological symptoms included 
ataxia,  dysarthria,  hyperactive  lower  limb  deep  tendon  reflexes,  and  bilateral  positive 
Babinski sign. Neuropsychologic examination showed difficulty in maintaining attention, 
slowness, slight reduction of recent memory, and infantilism. EEG showed normal alpha 
activity in the posterior regions with bursts of theta waves, but clinically there was no 
record  of  seizures.  IV 15  had  psychomotor  deterioration  after  the  age  of  2,  and 
amelogenesis  imperfecta  was  diagnosed  at  the  age  of  9.  Other  abnormalities  included 
kyphoscoliosis  of  the  dorsal  spine.    From  the  age  of  10,  episodes  of  partial  loss  of 
consciousness appeared. At the same age the child once became comatose for 36 hours and 
during hospitalization, spasticity of all limbs was described. The EEG was characterized by 
the presence of widespread theta and delta waves in all records. He died suddenly at the age 
of 12 years in 1979. III 16 had amelogenesis imperfecta only and no other abnormality  
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such as psychomotor delay or neurological disorders. III 17 was cyanotic at birth, but did 
not  need  any  therapy  or  intensive  care  and  his  psychomotor  development  was  slightly 
delayed. From the age of 10, he developed a ataxic gait and complained of cramps in the 
legs. Neurological examination showed only brisk tendon reflexes in the lower limbs. The 
EEG  showed  alpha  activity  (8  c/sec)  in  the  posterior  regions  interrupted  by  2  brief 
generalized bursts of sharp waves. MRI of the brain showed slight periventricular gliosis 
and hypoplasia of the corpus callosum. The patient did not have enamel hypoplasia of the 
teeth.  Whether  these  symptoms  were  related  to  the  hypoxia  during  birth  was  not 
determined.  
      The mode of inheritance of pedigree 4 was more complicated than the other 4 pedigrees 
as  there  were  four  different  phenotypes:  amelogenesis  imperfecta  only;  delayed 
psychomotor developments; ataxia and abnormal EEG; neurological disorders or seizures 
and amelogenesis imperfecta. Guazzi in his report concluded that this was an autosomal 
dominant  pedigree  with  amelogenesis  imperfecta  as  the  main  phenotype  but  with  
additional variable manifestations, including seizures, ataxia, and psychomotor retardation. 
However,  this  pedigree  could  be  autosomal  recessive  if  amelogenesis  imperfecta  and 
neurological disorders was the defined phenotype. Under such a phenotype definition, II 7 
was unaffected, only III 12, IV 14 and IV 15 were affected. Because of consanguity, III 13 
could be a carrier, with a 50% chance that offspring would be affected. 
      Pedigree 5 was an Australian family. This family was investigated by Christodoulou 
(Christodoulou et al.  1988). There were 6 affected individuals in this pedigree, three of 
them had expired and  DNA samples were only  available from the other three affected 
individuals, one unaffected individual, and one of the parents (mother). Both parents were 
unaffected with no remarkable dental or neurological disorders. There were four maternal 
relatives which had mental retardation of unknown cause. The affected individuals in the 
second generation all had the same phenotype, including amelogenesis imperfecta, seizures, 
and delayed neuromotor development. The seizure onset of II 3 was at 7 months and the 
diagnosis  of  Kolhschütter Tönz  syndromes  was  confirmed  at  the  age  1.5  years.  No 
investigation details of this individual were available. II 4 was sister of II 3, her seizure 
onset  was  at  22  months  old  and  the  clinical  presentation  included  delayed  neuomotor 
development and amelogenesis imperfecta. II 5 was one of the twins survived. His seizure  
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onset was at the age of 18 months, with regression of neuromotor development as well as 
amelogenesis imperfecta. His biochemistry tests were all normal, which included normal 
pyruvate dehydrogenase, cytochrome c oxidase, succinatecytochrome c reductase, NADH 
cytochrome  c  reductase,  El  ATPase,  serum  uric  acid,  blood  porphyrin  screen,  blood 
ammonia,  CSF  lactate,  pyruvate,  and  amino  acids.  His  G  banded  karyotype  was  also 
normal.  II 6  had  seizures  began  at  the  age  of  22  months,  with  delayed  neuromotor 
development.  II 7 was the only unaffected individual in this generation. II 8 was normal 
until the age of 11 months when he was brought to hospital in status epilepticus. He had 
severe learning disability and intractable epilepsy, died at the age of 10 and ½ years old of 
pneumonia  and  emaciation.  II 9  had  seizures  began  at  the  age  of  11  months  with 
amelogenesis imperfecta and delayed neuromotor development. She died at the age of 1.5 
years old. The mode of inheritance in pedigree 5 was autosomal recessive.  
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10.2 Linkage Analysis 
10.2.1 Mode of inheritance and choosing linkage analysis program 
      The mode of inheritance of these 5 pedigrees was considered as autosomal recessive. 
The analysis was done by parametric linkage analysis with MLINK.  
 
10.2.2 Setting parameter files 
      The parameter files were prepared by PREPLINK. The mode of inheritance was set as 
autosomal recessive with full penetrance. Liability class was set at 1, the gene frequencies 
were  provided  by  deCODE  Genetics.  Because  there  were  consanguity  in  two  of  the 
pedigrees, a loop data file indicating where to break the loop was made when converting 
the pedigree files to pedfiles to facilitate the speed in analysis.  
  
10.2.3 Genotyping errors 
     The genotype data and compatibility were checked by UNKNOWN. Genotyping errors 
(if there is any) were adjusted by setting the genotypes in question as “unknown”. 
 
10.2.4 LOD scores 
     The maximum LOD score obtained from MLINK was 3.05, at θ =0 at D16S423. The 
LOD scores is presented in Table 10.2.The haplotype analysis is shown in Figure 10.4 to 
Figure 10.8. 3.05 is considred significant linkage. The haplotype analysis further suggested 
that there was a disease locus between 16p13.3 13.2. There are approximately 30 known 
genes  and  pseudo  genes  within  this  region,  and  the  functions  of  the  known  genes  are 
summarized in Table 10.3 There are no known ion channel genes in this area, nor are there 
any ion channel regulating genes. Possible candidate genes are marked red in this table.  
 
Table 10.2 LOD score on chromosome 16  
            θ 
Marker 
0.0  0.01  0.05  0.1  0.2  0.3  0.4 
D16S521   infini     5.59     2.35     1.17     0.31     0.04     0.02 
D16S3065   infini      0.57     0.56     0.82     0.75     0.47     0.18 
D16S423  3.05     2.97     2.64     2.23     1.44     0.74    0.22 
D16S418   infini     0.58     0.57     0.85     0.81     0.53     0.23 
D16S3062    infini     3.92     1.40     0.54     0.00     0.09     0.06 
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10.3 Microarray Analysis  
      In order to seek further evidence to support our result, 4 DNA samples were sent for 
Microarray analysis for SNPs detection. Two of the DNA samples (one affected and one 
control) failed on Microarray analysis. The other 2 DNA samples successfully analyzed 
showed a region of homozygosity  from the location 37354 bp of chromosome 16 (snp 
rs8466) to the location 6005359 bp (snp rs955905) on the affected individual while the 
same locus showed heterozygosity in the unaffected individuals. This locus shown on the 
microarray chip analysis was larger than the disease locus identified through linkage (which 
started approximately from 3762270 bp to 7579883 bp on chromosome 16) but there was 
an obvious overlap. The flanking SNP that showed homozygosity in the chip analysis were 
rs8466 and rs955905, located at 37354 bp and 6005359bp on chromosome 16, respectively. 
This  finding  provided  supporting  evidence  that  there  could  be  a  disease  locus  on 
chromosome 16p13.3 16p13.2. If only the region overlap in two analyses was taken into 
consideration,  the  microarray  analysis  results  was  able  to  narrow  down  the  region  in 
interest by 1574524 bp. 
 
10.4 Summary 
      The aim of this analysis was to identify the genetic basis (linkage) of this rare syndrome 
(in five families), to determine the mode of inheritance, to identify linkage, to define the 
clinical phenotype associated with the linked area, and to if possible identify the causative 
gene. We confirmed a disease linkage on chromosome 16 through both linkage analysis and 
microarray chip analysis. There are 30 known genes within this area however there are no 
ion channel genes. More investigation is necessary both in identifying candidate genes as 
well as in establishing the pathogenesis once the gene is identified. 
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 Table 10.3 Summary of the genes within 16p13.3 16p13.2 
 
Gene ID  Function 
CREBBP  Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates 
non histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated 
CREB and enhances its transcriptional activity toward cAMP responsive genes. 
ADCY9  May play a fundamental role in situations where fine interplay between intracellular 
calcium and cAMP determines the cellular function. May be a physiologically relevant 
docking site for calcineurin. 
SRL  Function undetermined 
TFAP4  Transcription factor that activates both viral and cellular genes by binding to the 
symmetrical DNA sequence 5' CAGCTG 3'. 
GLIS2  Members of the Kruppel like zinc finger protein family, such as GLIS2, function as 
activators and/or repressors of gene transcription. 
CORO7  May play a role in the maintenance of the Golgi apparatus morphology and in the 
protein export from the Golgi. 
VASN  May act as an inhibitor of TGF beta signaling 
DNAJA3  Modulates apoptotic signal transduction or effector structures within the mitochondrial 
matrix. Affect cytochrome C release from the mitochondria and caspase 3 activation, 
but not caspase 8 activation. Isoform 1 increases apoptosis triggered by both TNF 
and the DNA damaging agent mytomycin C; in sharp contrast, isoform 2 suppresses 
apoptosis. Can modulate IFN gamma mediated transcriptional activity. 
NMRAL1  Function undetermined 
HMOX2  Heme oxygenase cleaves the heme ring at the alpha methene bridge to form 
biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. 
Under physiological conditions, the activity of heme oxygenase is highest in the 
spleen, where senescent erythrocytes are sequestrated and destroyed. Heme 
oxygenase 2 could be implicated in the production of carbon monoxide in brain where 
it could act as a neurotransmitter. 
MGRN1  Probable E3 ubiquitin protein ligase. 
ZNF500  May be involved in transcriptional regulation 
FAM100A  Function undetermined 
NUDT16L1  Probable adapter protein, which may link syndecan 4 (SDC4) and paxilin (TGFB1I1 
and PXN) receptors. 
(continued) 
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Table 10.3 Summary of the genes within 16p13.3 16p13.2 (continued) 
 
Gene ID  Function 
ANKS3  Function unknown 
SEPT12  Septins, such as SEPT12, are conserved GTP binding proteins that function as 
dynamic, regulatable scaffolds for the recruitment of other proteins. They are involved 
in membrane dynamics, vesicle trafficking, apoptosis, and cytoskeleton remodeling, as 
well as infection, neurodegeneration, and neoplasia. 
ROGDI  May act as a positive regulator of cell proliferation. 
UBN1  May be required for replication independent chromatin assembly. 
PPL  The protein encoded by this gene is a component of desmosomes and of the epidermal 
cornified envelope in keratinocytes. Component of the cornified envelope of 
keratinocytes. May link the cornified envelope to desmosomes and intermediate 
filaments. May act as a localization signal in PKB/AKT mediated signaling. 
SEC14L5  Function undetermined 
NAGPA  Catalyzes the second step in the formation of the mannose 6 phosphate targeting 
signal on lysosomal enzyme oligosaccharides by removing GlcNAc residues from 
GlcNAc alpha P mannose moieties, which are formed in the first step. 
ALG1  Participates in the formation of the lipid linked precursor oligosaccharide for N 
glycosylation. Involved in assembling the dolichol pyrophosphate GlcNAc(2) Man(5) 
intermediate on the cytoplasmic surface of the ER. 
FAM86A  Function unknown 
A2BP1  RNA binding protein that regulates alternative splicing events by binding to 5' 
UGCAUGU 3' elements. Regulates alternative splicing of tissue specific exons and of 
differentially spliced exons during erythropoiesis. 
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Section 11: Saccadic eye movement experiments 
 
11.1 Control Group (n=12) 
      The  main  sequence  of  saccades  recorded  from each  subject  in  the  control  group  is 
presented in Table 12.1 in the form of square root model (Main Sequence = C * A ). “A” 
represents the amplitude the eye ball had travelled in each saccadic eye movement, “C” 
represents the constant and was calculated after fitting the line to the dots which plotted the 
peak velocity of each saccade against the amplitude after data conversion and analysis. 
Paired T test was carried out to compare the main sequence recorded between the first and 
second recording (data recorded with chin rest in the first recording compared to the second 
recording  with  chin  rest,  and  without  chin  rest  to  without  chin  rest)  as  well  as  main 
sequence recorded by chin rest and without chin rest within 1 individual in the same set of 
recording. P1 values represented the results of the comparison in each individual between 
the 1
st and the 2
nd recording, and P2 values represented the results of comparison in each 
individual with and without chin rest. 
      Twelve healthy subjects were recruited in the control group. The recording of one of the 
healthy subjects was not available because of technical error during recording. Case 7 was 
able to repeat the eye movement battery both with and without chin rest during the second 
set of recording twice, and Case 8 was able to repeat the battery three times in both sets of 
recording with and without chin rest. The chin rest free saccadic eye movement recording 
was  not  done  in  case  1, 2,  3,  and  4.  In the  recordings of  case  8,  sufficient  data  were 
available to calculate the mean and 95% CI of the main sequence in this subject. 
      From Table 11.1, it shows that most of the 1
st set and 2
nd
 set recording from the same 
individual did not show any significant statistical difference when analyzed with paired T 
test, except case 3, case 4 and case 9 ((P1=0.036, 0.0013,and 0.041, respectively). In other 
words,  81%  (9/11)  of  cases  showed  no  significant  difference  in  their  main  sequence 
recorded  at  different  time  when  using  chin  rest,  and  85.7%  (6/7)  of  cases  showed  no 
significant difference in their main sequence recorded at different times while chin rest was 
not used.  
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       In the comparison between main sequence obtained using chin rest and without chin 
rest, only case 10 showed that there was a significant difference of the main sequences 
between using chin rest and without using chin rest (P2=0.005).  
       The test retest reliability in the control group was calculated with Pearson regression 
correlation, and Intraclass Correlation Coefficient (ICC). The 95% confidence interval of 
ICC  value  and  typical  error  is  presented  in  Table  12.2.  The  results  showed  that  both 
Pearson Correlations Coefficient (r) and ICC was 0.433, (95% CI 0.014 0.723) when chin 
rest was used. Pearson Correlations Coefficient (r) was 0.615 and ICC was 0.588 (95% CI 
0.083 0.852) when the chin rest was not used. In general r values are within 0.7  0.9 for 
adequate reliability and correlation, and > 0.9 if of very good reliability.  The test retest 
reliability in the control group was below these values and thus the reliability has to be 
considered poor.  
      Figure A and B are graphs with data of the second recording plotted against the first 
recording, with data form the left eye plotted to left eye and right eye to right eye. Figure C 
and  D  are  graphs  with  the  subtraction  of  recording  2  to  recording  1  plotted  against 
recording 1, with data from the left eye plotted against to left eye and right eye against to 
right eye. The graphs showed that the correlation was slightly better in the main sequence 
recorded when chin rest was not used.  
     To sum up, the analysis of the results of the main sequence measurements in the control 
group did not show good test retest correlation, although paired T test did not suggest that 
the measurement of the first recording are statistically different from the second recording 
except in three cases. The reliability was thought to be such that the identification of small 
differences due to drug actions in the subject group would not be able to be detected. 
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11.2 Subject group (n=3) 
      The main sequence measurements changes in the subject group and the results of the 
analysis are presented in Table 12.3. None of the case showed significant change in main 
sequence measurements before and after medication (all P values > 0.05). The serum drug 
levels at the time of eye movement recording are also listed. 
      The eye movement of Case 1 and Case 3 were recorded before and once again after 
they took their daily carbamazepine (CBZ) medication, and the two set of testing were 
completed in the same day with a time interval of three hours and 4 hours respectively. The 
first  recording  of  case  2  was  done  when  the  case  was  experiencing  phenytoin  (PHT) 
intoxication. Her serum drug level was 84 umol/l and was higher than standard therapeutic 
level  and  symptoms  and  signs  of  intoxication  were  also  found  at  the  time  of  the  first 
recording. The second set of recordings was done 1 week after the first recording while the 
serum drug level had returned to the normal range 62 umol/l.. Case 3 declined to have 
serum  drug  level  tested  again  for  the  second  set  of  recording.  All  cases  had  their  eye 
movements recorded with and without chin rest.  
      Case 1 had intractable seizures and did not show any optimal drug response to either 
old or new generation anti epileptic drugs, carbamazepine was the only drug that she had 
showed partial responses and she was considered a non respondent. Case 2 had reasonable 
seizure control, with a seizure frequency around 1 2 times annually, usually with apparent 
triggering factors such as sleep deprivation. Case 3 had optimal seizure control and at the 
time of recording she had been seizure free for approximately one year. We expected that 
there would be saccadic eye movement parameter changes seen in these 2 cases. 
      We  hypothesized  that  the  main  sequence  of  case  1  would  not  show  mark  changes 
between the 2 sets of eye  movements  recordings of the paramters we used.  In case 2, 
however,  the  subject  did  not  show  the  expected  significant  change  of  main  sequence 
parameter between the 2 recordings, despite the fact that she had fairly good seizure control 
and a considerable change of the phenytoin serum drug level was observed between the two 
sets of eye movements recordings. In case 3, again we expected there to be changes of the 
main sequence parameter, but no significant changes were observed between the 2 sets of 
recordings.   
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11.3 The comparison between the control group and the subject group 
      The comparison of the main sequence between the control group and the subject group 
is presented in Table 12.4. The comparison was made case by case to the control group, 
because in each case their serum drug levels and the medication they took were different.  
      The P values presented in Table 12.4 show that only the main sequence of case 1 was 
statistically different from the control group. The main sequence of case 2 and case 3 did 
not  differ  from  the  control  group,  even  though  they  were  either  on  carbamazepine  or 
phenytoin therapy. The main sequence of case 1 obtained without using chin rest before 
and after taking carbamazepine, as well as the main sequence obtained with chin rest after 
taking medication (carbamazepine) showed significant difference from the control group.              
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Table 11.4 comparison between control group and subject group  
 
11.4 Summary 
     In this  pilot (or scoping) phase we aimed to: 
1. to devise a clinically applicable method for measuring saccadic main sequence and peak 
saccadic velocity.  
2. to carry out measurements in a suitable control group, to identify mean values and the 
range of normality. 
3. to carry out a pilot study in patients with epilepsy, to determine whether changes in 
blood  levels  were  reflected  by  measurable  changes  in  saccadic  velocity  in  a  reliable 
fashion, and to determine the extent of this effect 
4. In a preliminary manner, to whether the there is an association between the magnitude of 
the effect of saccadic variation and clinical effects (side effects/efficacy).  
 
       In  summary  of  the  results,  the  Pearson  regression  and  correlation  coefficient  and 
Intraclass coefficient did not suggest that there was a high correlation and a good reliability 
of main sequence (peak saccadic velocity). Thus it was not possible to obtaine a reliable 
normative  data  of  the  main  sequence.  The  analysis  results  from  the  three  cases  in  the 
subject  group  were  inconclusive.  None  of  the  cases  in  this  group  showed  significant 
changes  of  their  main  sequence  recorded  before  and  after  taking  their  AEDs.  When 
comparing their main sequence to the control group, only case 1 had a peak velocity of 
saccades which were slower than the mean of the control group. 
  with chin rest, 1
st  with chin rest 2
nd   without chin rest 1
st  without chin rest 2
nd 
Case 1  P=0.09  P=0.00039<0.05  P=0.0147<0.05  0.000678<0.05 
Case 2  P=0.18  P=0.49  P=0.21  P=0.26 
Case 3  P=0.21  P=0.22  P=0.56  P=0.99  
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Discussion 
Section 12: The Linkage Studies 
 
12.0 Hypothesis 
      The hypothesis underpinning the genetic linkage analyses in this thesis is that the cause 
of  these  familial  epilepsy  syndromes  (mesial  temporal  lobe  epilepsy,  photosensitive 
epilepsy,  and  Kohlschütter Tönz  syndromes)  is  genetic  in  origin,  and  genetic  linkage 
analysis could detect a disease locus for each epilepsy syndrome.  
      In this body of work, I studied 8 families within epilepsy syndromes (familial temporal 
lobe  epilepsy,  photosensitive  epilepsy,  Kohlschütter Tonz  syndrome)  and  collected 
appropriate clinical phenotypic data (from clinical examination, note review and hospital 
inquiry) to carry out the laboratory genetic analysis of the DNA from individuals in this 
families  (preparation,  genotyping  and  sequencing).  I  devised  and  conducted  the 
computerised linkage analysis using various linkage programmes.  
The aims of the study were: 
i.  Familial  temporal  lobe  epilepsy  (two  families).  To  identify  the  genetic  basis  of  the 
familial  epilepsy,  to  determine  whether  there  was  a  similar  genetic  cause  in  the  two 
families, to determine the mode of inheritance in the families, to identify linked regions, to 
sequence candidate genes within the linked regions and to determine the clinical phenotype 
associated with any linkage discovered. 
ii.  Photosensitive  epilepsy  (one  large  family):  To  identify  the  genetic  basis  of  the 
Photoparoxysmal  response  (PPR)  in  a  large  family  with  photosensitive  epilepsy,  to 
determine the mode of inheritance, and to identify linkage. 
iii.  Kohlschütter Tonz  Syndrome:  To  identify  the  genetic  basis  (linkage)  of  this  rare 
syndrome (in five families), to determine the mode of inheritance, to identify linkage, to 
define the clinical phenotype associated with the linked area, and to if possible identify the 
causative gene.  
      The linkage analyses confirmed a disease linkage in the five small families with the 
Kohlschütter Tönz syndrome, and a less confirmed linkage with three regions of interest in  
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pedigree B with mesial temporal lobe epilepsy. The genetics underlying the photosensitive 
family was likely to be polygenic, and a region of interest was identified through NPL. In 
the pedigree W with mesial temporal lobe epilepsy, the mode of inheritance could not be 
determined, and the analysis was negative. In this discussion, I will speculate on these 
results and the reasons for these positive and negative findings. 
 
12.1 The fMTLE pedigrees 
12.1.1 Pedigree B 
      The B pedigree was a middle size pedigree with 8 affected individuals, including a 
person who was a possible phenocopy and who was excluded as an affected individual in 
the third parametric analysis. The first parametric analysis in which both pain and seizures 
were the defined phenotypes showed a maximum LOD score of 2.37 at chromosome 6, but 
multipoint analysis, fine mapping, and haplotype analysis excluded this region. The second 
parametric analysis in which seizures only was the defined phenotype did not show any 
LOD  scores  larger  than  2.  In  the  third  parametric  analysis,  a  possible  phenocopy  was 
further excluded and the result showed that there might be a disease locus on chromosome 
3 with a LOD score 2.35, however the haplotype analysis showed that there could be a 
reduced penetrance. The same pedigree was re analyzed assuming an AD with a reduced 
penetrance inheritance and showed that were three regions of interest on chromosome 3 
(3p24.1 3p24.2, LOD 2.17), chromosome 5 (5p13.3 5p13.2, LOD 2.15) and chromosome 7 
(7q11.22 7q21.11, LOD 2.15). Five genes within 3p24.1 3p24.2 were sequenced, including 
SLC4A7, LRRC3B, AZI2, NEK10, and ZCWPW2 genes.  
      The SLC4A7 gene functions as a Na
+/HCO
  co transporter and has been found in the 
dendrite and soma of neurons in the hippocampus especially. Recent research showed that 
this gene might increase the cytotoxicity in magnesium depletion, as found in the primary 
cultures of hippocampal neurons in rat (Cooper et al.  2009). However it is not known 
whether this upregulation effect on cytotoxicity might contribute to hippocampal sclerosis 
or epileptogenesis. I did not find any rare mutations on this gene but did discover a few 
polymorphisms that are considered to be normal variations in Caucasian population (Table 
12.1). I therefore do not consider these polymorphisms to be pathogenic.  Most of the 
polymorphisms are synonymous, which means they do not alter the amino acid coded to  
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that  region  and  they  do  not  change  the  peptide  products.    There  is  only  one  non 
Synonymous polymorphism, which is considered non pathogenic.  
 
Table 12.1 Polymorphisms on SLC4A7 gene and LRRC3B gene 
 
Gene  Position  polymorphism  Frequencies in 
Caucasian population 
Type of 
polymorphism 
SLC4A7  Exon 3  210A/G  A: 0.758, G:0.242  Synonymous 
SLC4A7  Exon  7  846T/C  A:0.720, G: 0.280  Synonymous 
SLC4A7  Exon 7  976G/A, Gly>Lys  A: 0.080, G:0.920   Non  
Synonymous 
SLC4A7  Exon 16  2319C/T  C: 0.750, T: 0.250  Synonymous 
SLC4A7  Exon 24  3499T/C  T: 0.092, C: 0.908  Synonymous 
LRRC3B  Exon 1  330A/T  N/A  Synonymous 
NEK10  Exon 20  1684A/G  A: 0.742, G: 0.259  Synonymous 
NEK10  Exon 24  2071C/G  C: 0.491, G: 0.508  Synonymous 
AZI2 
ZCWPW2 
no polymorphisms found in gene sequencing  
 
 
      The LRRC3B gene belongs to the Leucine rich gene family, as does the LGI1 gene. 
This  gene  is  usually  considered  to  be  a  tumour  suppressor  gene,  and  some  researches 
suggested  that  it  might  be  related  to  leukaemia  and  colon  cancer.  Its  expression  is 
extremely high in brain, but its function in brain is unknown, for instance, whether it is 
involved in the regulation of ion channel in the primate brain or what its function is likely 
to be in the CNS system (Kim et al.  2008; Tian et al.  2009). 
      The AZI2  gene, also known  as NAP1,  was identified as an activator
 of I B kinase 
[(IKK) related  kinases]  in  a  recent  study  (Fujita  et  al.    2003).  IKK  contributes  to  the 
activation of NF  B dependent gene expression, and the transcription factor NF  B plays a 
central role in inducing the
 expression of many genes that contribute to diverse biological
 
functions,  including  cell  proliferation,  cell  survival,  oncogenesis,
    inflammatory  and 
immune  responses  (Baeuerle.  &  Baltimore.  1996;  Ghosh  et  al.    1998;  Silverman  and 
Maniatis, 2001). It is not known whether such biological functions of the AZI2 gene might  
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indirectly contribute to epileptogenesis via activation of other genes. No mutations or rare 
polymorphism were found in the exons of this gene.  
      The functions of the other two genes, NEK10 and ZCWPW2, are even less clear. Most 
of the reported functions of these two genes have been predicted by the structure of their 
protein transcription. Although the expression of these genes is also found in the brain, 
there are yet no reports available as to what influences or functions they have in the CNS 
system. No rare mutation or polymorphisms were found on the exons of these two genes, 
either. There are 7 transcripts (variation) of NEK10 but only one of them was sequenced. 
The first two exons of ZCWPW2 gene were not sequenced, because they appeared to be 
non expression exons.  
      There are several possible reasons which might explain why no disease gene has been 
identified through linkage analysis in the B pedigree. First, the sample size of this pedigree 
was not large enough. There were only 7 affected individuals in this pedigree and 2.1 was 
as  large  a  LOD  score  can  be  with  a  sample  size  of  7  (Table  12.2)  It  is  not  however 
appropriate to interpret this result as a genuinely strong linkage. Second, there were three 
regions  of  interest  identified, but  only  5  genes  within  3p24.1 3p24.2  were  successfully 
sequenced  on  5  individuals  in  this  pedigree,  and  the  other  2  regions  have  not  been 
investigated. Third there were several polymorphisms identified in the introns adjacent to 
the  spicing  site  of  exons  which  did  segregate  with  the  affected  individuals  sequenced. 
Although unlikely, the polymorphisms in the introns adjacent to exons might cause splicing 
errors and contribute to epileptogenesis in this pedigree; however this could not be proved 
in this study. In general, polymorphisms or mutations in the intron rarely are pathological, 
however, in recent genetic association studies, some of the hotspot ( or hitSNPs) identified 
were either in the non coding areas or “gene desert”, where there were no adjacent genes 
and is an example in the study of Crohn disease (Libioulle et al.  2007; The Wellcome 
Trust  Case  Control  Consortium,  2007).  Such  phenomenon  suggested  that  regulatory 
regions or element of a gene can be located far from the gene itself and yet still be able to 
affect  expression  and  function  of  the  gene,  as  found  in  the  ENCODE  Project  (The 
ENCODE  Project  Consortium,  2007).  The  exploration  of  such  phenomenon  remains  a 
challenge,  as  biological  studies  such  as  functional  determination  and  the  transcript  
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regulation of the protein transcript are difficult, and to explore the functional role of SNPs 
located in non coding areas or gene deserts is going to be challenging.  
     Finally, it is also possible in this family that Fragile X syndrome is partially involved in 
the epileptogenesis in this pedigree, even though the mode of inheritance did not suggest an 
X linked disease pattern. Fragile X syndrome is the most common inherited form of mental 
retardation, with a prevalence of about 1 in 4000 males and 1 in 8000 females (Turner et al.  
1996).  The  mental  retardation  results  from  a  triplet  repeat  (CGG)  expansion  mutation 
(Verkerk et al.  1991) which inactivates the FMR1 gene (fragile X mental retardation 1 
gene), resulting in loss of expression of the FMR1 gene product, known as fragile X mental 
retardation protein FMRP(Devys et al.  1993; Pieretti et al.  1991). Another milder form of 
Fragile X syndrome has been identified as Fragile XE syndrome, FRAXE (Orr and Zoghbi, 
2007). FRAXE is caused by the expansion of a CCG repeat in the 5′ UTR of the fragile X 
mental retardation 2 gene (FMR2). When the CCG repeat expands beyond 200, the CpG 
island upstream of the FMR2 gene is hypermethylated causing transcriptional silencing of 
FMR2 and leads to loss of protein function. Patients with Fragile XE syndrome (FRAXE) 
present with mild mental retardation, learning deficits, and developmental delay (Mulley et 
al.  1995). Epilepsy can also be present. 
      Berry Kravis  (Berry Kravis,  2002)  investigated the  seizure  patterns  in 16  Fragile  X 
syndromes patients, twelve of them had complex partial seizure and  four of them had 
generalized  tonic–clonic  seizures.  In  the  abnormal  EEG  recording  of  these  patients,  6 
showed  centro temporal  spikes.  Most  of  the  EEG  patterns  were  similar  to  the  EEG  in 
Benign  Focal  Epilepsy  of  Childhood,  however,  clinically  it  might  be  difficult  to 
differentiate the seizures of Fragile X syndrome from temporal lobe epilepsy.  
      No  study  has  reported  a  structural  anomaly  of  either  the  temporal  lobe  or  the 
hippocampus in the patients with Fragile X syndrome or the carriers. One study using high 
resolution fMRI did not find any volume change of the temporal lobe or the hippocampus 
in mice with Fragile X syndrome (Kooy et al.  1999). Another study which investigated the 
hippocampal volume, the neuropsychological performances, and the CGG repeat number in 
full mutation Fragile X syndrome subjects (those which the CGG repeat was larger than 
200  with  hypermethylation  of  the  CpG  island  and  who  were  mentally  retarded)  and 
premutation Fragile X syndrome subjects (those which the CGG repeat was within 60 to  
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200,  no  hypermethylation  of  the  CpG  island,  with  normal  or  nearly  normal  phenotype 
without  severe  learning  disability)  suggested  that  there  were  only  minor  structural 
anomalies of the temporal lobes  in patients with full mutation Fragile X Syndrome (Jäkälä 
et al.  1997).  Whether such a subtle anomaly could contribute to temporal lobe epilepsy 
has not been further clarified.  
      Both  FMRP  and  FMR2  protein  have  been  trafficked  in  hippocampus  (Antar  et  al.  
2005; Miller et al.  2000). It was believed that lack of expression of these proteins may 
contribute to the memory impairment, learning disability or mental retardation in Fragile X 
syndromes.  Whether  the  lack  of  these  protein  expressions  in  the  hippocampus  also 
contributes  to  mesial  temporal  lobe  epilepsy  or  hippocampal  sclerosis  has  not  been 
investigated.       
      In this pedigree, there were 2 Fragile X carriers (IV 16, and IV 20) who had a normal 
phenotype without memory impairment or severe learning disability  and one Fragile X 
syndrome  victims  with  moderate  mental  retardation,  learning  disability  and  poorly 
controlled epilepsy (V 28). It was possible that Fragile X syndrome might have influenced 
the epileptogenesis at least in some of the members in this pedigree, and this may have 
complicated the analysis of inheritance in this pedigree. 
 
12.1.2 Pedigree W 
     The linkage analysis of pedigree W was negative. No single K&C LOD scores using 
MERLIN or single location score using SimWalk2 was larger than 2. There are several 
possible explanations.  
       First,  it  was  possible  that  there  were  false  phenotyping  in  this  pedigree.  Accurate 
phenotyping was particularly important in parametric linkage analysis. A phenocopy not 
carrying the disease locus shared by other genuine affected individual (is considered as 
having  recombination  in  the  linkage  analysis)  will significantly  reduce  the  LOD  score, 
especially when the sample sizes are small (Table 12.2). Some of the subjects who were 
classified  as  affected  in  this  pedigree  did  not  have  detailed  medical  investigations  (for 
instance MRI), particularly those who had very mild symptoms and infrequent seizures. 
Under such circumstances, a phenotyping error is possible. Even after detailed medical 
investigation, a phenotyping error cannot be totally avoided as epilepsy is essentially a  
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clinical diagnosis and a negative EEG or MRI cannot definitively exclude a diagnosis of 
MTLE. 
 
Table 12.2 Influences of sample size and number of recombinants on LOD score  
Number of recombinants￿ ￿ ￿ ￿ 
  0  1  2  3  4  5  6  7 
2  0.6021  0  0  0  0  0  0  0 
3  0.9031  0.0738  0  0  0  0  0  0 
4  1.2041  0.2272  0  0  0  0  0  0 
5  1.5051  0.4185  0.0437  0  0  0  0  0 
6  1.8062  0.6321  0.1476  0  0  0  0  0 
7  2.1072  0.8604  0.2884  0.0311  0  0  0  0 
8  2.4082  1.0992  0.4545  0.1097  0  0  0  0 
9  2.7093  1.3458  0.6388  0.2213  0.0242  0  0  0 
10  3.0102  1.5985  0.8371  0.3574  0.0874  0  0  0 
11  3.3113  1.856  1.0463  0.5121  0.1799  0.02  0  0 
12  3.6124  2.1175  1.2642  0.6817  0.2951  0.073  0  0 
13  3.9134  2.3823  1.4895  0.8635  0.4285  0.152  0.0167  0 
14  4.2144  2.6499  1.7209  1.0553  0.5769  0.252  0.0623  0 
15  4.5154  2.9199  1.9574  1.2556  0.7376  0.369  0.1312  0.0145 
20  6.0206  4.2963  3.197  2.349  1.6742  1.136  0.7147  0.3969 
25  7.5257  5.7023  4.4991  3.5419  2.7521  2.093  1.5425  1.0878 
       
      Second,  the  inheritance  pattern  in  this  pedigree  could  be  a  quantitative  trait.  The 
severity of the clinical presentation of the affected individuals in this pedigree varied from 
one  to  another,  which  is  a  characteristic  of  quantitative  trait  or  polygenic  diseases.  In 
pedigrees with polygenic disease, a dominant gene could be shared by the majority of the 
affected individuals and it would be possible to detect a linkage if the pedigree was large 
enough. However, this was not the situation in this pedigree. It appeared that no dominant 
gene  was shared by the  majority  of the  affected  individuals;  therefore  linkage  analysis 
would not be able to map the disease locus successfully.  
      Third, is the possibility of a founders’ effect. Some of the un related founders (II 30 and 
II 1) in this pedigree were said to be epileptic although no medical records are available to 
prove the diagnosis. However, this may well be the case,  as those founders’ unaffected and 
unrelated offspring were married to each other (III 3 and III 4) and all of their offspring 
appeared  to  have  epilepsy  (IV 15,  IV 16,  IV 17,  and  IV 18).  The  possibility  of  an 
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autosomal recessive inheritance pattern can not be excluded, but it seems more likely that 
two susceptibility genes, coming from two different founders, influenced each other and 
contributed to the epileptogenesis in this situation. Hence, the possibility and the effect of 
epistasis  (gene  to  gene  interaction)  cannot  be  overlooked  in  this  pedigree.  Neither 
parametric  nor  non parametric  linkage  analysis  can easily  identify  interactions  between 
genes. Moreover, the phenomenon that one whole generation (the III generation) was free 
from  symptom  of  epilepsy  while  their  next  generation  (the  IV  generation)  was  greatly 
affected by epilepsy cannot be easily explained by genetics alone.  
      Finally, it has long been realised that a disease gene does not always cause the expected 
disease and environmental factors may be necessary to induce its expression. Although we 
failed to identify any possible environmental factors from the interviews and investigations, 
Swansea is one of the areas in the UK that has a high incidence and prevalence of epilepsy 
and this might suggest that some environmental influences cannot be overlooked in this 
pedigree (Figure 12.1). 
      In summary, non parametric linkage analysis did not successfully identify the disease 
locus  in  this  pedigree.  Uncertainties  in  the  founder  states,  phenocopies,  polygenic 
inheritance, epistasis, and the gene environment interactions might have contributed to the 
negative findings. 
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Figure 12.1 Epilepsy prevalence across the UK  
(Information from General Medical Service, UK) 
 
 
12.2 The linkage analysis in fMTLE 
12.2.1 A comparison 
      In this study, genetic linkage analysis was carried out in two families diagnosed with 
familial mesial temporal lobe epilepsy to map the disease locus. Both families had more 
than two members that were diagnosed to have mesial temporal lobe epilepsy and both  
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fully fulfilled the criteria of familial mesial temporal epilepsy. There was one individual in 
each family who had hippocampal sclerosis and both were seizure free after surgery. There 
were  two  individuals  in  each  family  who  had  history  of  febrile  convulsion,  and  status 
epilepticus were found in severely affected individuals in both families. A considerable 
variation of disease severities and seizure frequencies between affected individuals were 
observed in both families. There were several individuals in family W who had stereotyped 
déjà vu as the only symptom of MTLE but such clinical presentation was not found in 
family B. In family B, the mode of inheritance (MOI) was likely to be autosomal dominant, 
or a single gene inheritance, but the MOI could not be clearly defined in family W. Such 
phenomenon suggested that the underlying genetics of MTLE in these two families might 
well be different.  
      In comparison to other linkage analyses of familial MTLE, Claes et al (Claes et al.  
2004) mapped the disease locus to 12q22 q23.3 in their linkage analysis of a family with 
FTLE associated with FS based on a 2 point LOD score of 6.9 and a multipoint LOD score 
of 7.8 at the same marker. The sample size of this study was larger than ours (5 generation, 
53 participants and 22 affected individuals). 10 cM whole genome scan was done in this 
pedigree  and  MLINK  was used  for  the  linkage analysis.  Hedera  (Hedera et  al.    2007) 
identified a disease locus at 4q13.2 q21.3 with a LOD score of 4. The samples size in 
Hereda’s  was  smaller  than  Claes  but  larger  than  ours,  with  12  affected  individuals 
distributed in 3 generations. 8 cM whole genome scan was carried out and the linkage 
analysis was done by MLINK using the ‘affected only’ method. In both studies, the mode 
of inheritance was autosomal dominant. No disease gene has been mapped in these two 
loci, and the results have not yet been replicated. In contrast to these studies, the sample 
size in B family was much smaller, the mode of inheritance appeared to be AD with a 
reduced penetrance, and three regions of interest were identified. As was also the result in 
the two studies mentioned, no susceptibility genes have been mapped despite the fact that I 
sequenced five candidate genes in one of the regions identified. The mode of inheritance of 
W  family  could  not  be  defined,  non parametric  linkage  analysis  failed  to  identify  any 
disease locus, and this pedigree was unlikely to have a single  gene disease inheritance 
pattern.  
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      Current  meta analysis  of  the  association  studies  in  mesial  temporal  lobe  epilepsy 
showed  that  Interleukin  –β  gene  might  be  one  of  the  susceptibility  genes  of  MTLE 
(Kauffman et al.  2008b). The linkage analysis in the two families did not show that this 
gene  was  related  to  either  pedigree.  Other  candidate  genes  that  had  been  reported  in 
association study of MTLE include APOE4, PRNP (M129V), GABBR1, PDYN residue 
171, and 5 HTTVNTR (Briellmann et al.  2000; Gambardella et al 2003; Labate et al.  
2007; Manna et al.  2007; Walz et al.  2003). Except the Interleukin –β gene, none of the 
results of these candidate gene association studies have been replicated, and these genes are 
not in the loci identified in the B family.  
      In summary, we did not replicate any of the studies results either in association or in 
genetic  linkage  studies  of  mesial  temporal  lobe  epilepsy.    We  provided  evidences  that 
familial mesial temporal lobe epilepsy can be polygenic, and complicated epistasis or gene 
environmental  interaction  may  exist  and  both  involved  in  the  development  of  mesial 
temporal lobe epilepsy. Conventional genetic linkage analysis may not be suitable in these 
circumstances to map the disease locus in familial mesial temporal lobe epilepsy, without 
enhancement in analytical methods on larger samples. 
 
12.2.2 The future of fMTLE gene mapping 
       Despite  the  fact  that  we  did  not  successfully  map  the  disease  gene  from  the  two 
pedigrees, they form potentially good material for future genetic studies of fMTLE, and 
future detailed within in family investigation.  
      In the B family, the pedigree size was not large enough to have a LOD score larger than 
3 (2.1  might  be  the  largest  LOD  score  that  could be  obtained through  MLINK  in  this 
pedigree). It will be worthwhile sequencing more candidate genes on the other 2 regions 
identified  on  chromosome  5  (5p13.3 5p13.2)  and  chromosome  7  (7q11.22 7q21.11).  It 
would also be worthwhile attempting to collect more subjects from the 6
th generation of this 
pedigree to enlarge the sample size ; however there is no guaranteed that there will be more 
cases available. It may also be worthwhile sequencing the FRM1 gene and/or FRM2 gene 
in all subjects that had seizures in this pedigree. A study of the numbers of CGG repeat in 
relation to the clinical presentation of epilepsy might be worthwhile in understanding the 
impact of these genes on epileptogenesis, which is a polygenic setting.  
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      In family W, conventional linkage analysis did not prove adequate to map the disease 
locus.  More  advanced  mapping  methods  might  be  more  successful,  for  instance  using 
quantitative trait mapping techniques. Such mapping methods became available in 1972 
(Haseman and Elston, 1972), but their implementation remain challenging even if advanced 
computing facilities are available nowadays (Forabosco et al.  2005). The current pedigrees 
we have alone was not large enough to carry out such analysis. To do quantitative trait 
mapping in mesial temporal lobe epilepsy, more information would be needed to define the 
model of quantitative trait, to evaluate the magnitude of the gene gene interaction and the 
gene environmental  interaction,  or  to  define  different  endophenotypes  within  mesial 
temporal lobe epilepsy. In quantitative trait mapping, a good disease model is as important 
as an accurate MOI in parametric linkage analysis. Whole genome assessment using dense 
tagging SNPs across the whole genome for linkage analysis is another choice in the future. 
Such technology is available and the cost has been largely reduced recently (Maresso and 
Broeckel, 2008). I will seek to further this work in the future.  
        The susceptibility  genes  underlying  both  pedigrees  could  be  different,  because  the 
MOI were clearly different and the LOD scores which were larger than 1.5 in each pedigree 
did not show any regional overlap. We therefore considered that pooling the data of the two 
pedigrees  for linkage analysis was not likely to be helpful, but if  more pedigrees with 
similar  clinical  presentations  could  be  collected  in  the  future,  quantitative  trait  locus 
mapping or family based whole genome linkage/association study might be possible on the 
combined material. 
      Finally, I would recommend that further refinement is carried out in relation to the 
criteria for phenotyping mesial temporal lobe epilepsy. If such phenotyping methods lead to 
a more homogeneous study sample population, the power of the linkage analysis would be 
higher. A good example is the association studies in patients with hippocampal sclerosis 
which led to the association of Interleukin –β gene with mesial temporal lobe epilepsy. In 
our study, the phenotype in fMTLE was decided mainly according to clinical symptoms 
and we did not restrict our analysis to those with hippocampal sclerosis on MRI or those 
who had epileptiform discharge on EEG suggesting MTLE. It is possible that subcategories 
of MTLE exist, with specific inheritance patterns and a specific analysis for each would be 
helpful.  
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      To sum up, the future work for mapping disease locus in fMTLE includes developing 
more  specific  phenotyping,  and  the  development  of  advanced  analysis  programmes  for 
linkage  analysis,  especially  when  whole  genome  assessment  using  SNPs  has  become 
available for linkage analysis. In this situation, more powerful statistic tools will be needed 
to accommodate the massive amount of data accumulated. 
 
12.3 The photosensitive epilepsy pedigree 
      The  linkage  analysis  of  the  photosensitive  epilepsy  pedigree  turned  out  to  be 
inconclusive in this study. The pedigree size was large enough for linkage analysis and 
genetics seem to play a major role in the pathogenesis of photosensitivity in this pedigree, 
but the analysis did not successfully identify the disease locus. In the MLINK parametric 
analysis, the maximum LOD score was 1.14 on chromosome 1 and the haplotype analysis 
did not support a disease linkage. The largest location score was 2.231 on chromosome 16 
in  NPLpair  using  SimWalk2.  In  some  circumstances,  such  location  score  may  have  its 
significance, however  the haplotype  analysis  at  this  region  on  chromosome  16  showed  
recombination  in  2  affected  individuals,  which  suggested  that  the  locus  identified  was 
unlikely  a  disease  locus  if  photosensitivity  is  a  single  gene  disease.  There  are  several 
possible explanations. 
       First, photosensitivity itself could be a quantitative trait or a polygenic disease. The 
phenotype defined in this pedigree was based on photoparoxysmal response (PPR) proved 
by EEG, and the subjects with seizures only were excluded. The phenotype appeared to be 
well defined and the study population appeared homogeneous. However, it could be argued 
that the affected individuals were not as homogeneous as they appeared to be, and that 
some of the affected individuals did not have seizures evoked by photosensitivity. Whether 
these two groups (photosensitivity with or without seizures) were of the same genotype has 
been  widely  discussed  without  definite  conclusion  (Stephani  et  al.    2004).  Our  results 
suggested either situation was possible. This was supported by the haplotype analysis on 
chromosome 16 showing that 2 individuals (III 18 and III 24) who had photosensitivity 
without seizures did not have the haplotype shared by those who had both photosensitivity 
and seizures. Instead, they inherited the other haplotype that was not shared by all the other 
affected individuals. Such a phenomenon could be explained if more than one gene could  
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cause  photosensitivity.  Another  simple  explanation  of  this  analysis  was  that  these  two 
groups were of the same genotype and these two subjects who had different haplotype were 
phenocopies and that the photosensitivity was caused by other nongenetic factors. However 
it is generally rare to find 2 phenocopies in one pedigree. In summary, the analytic result of 
this study did not provide a definite answer as to whether the two phenotypes (PPR with 
seizure and PPR without seizure) have the same genotype. 
      Second, in polygenic gene disease, two or more genes could have equal potential in 
causing photosensitivity and possessing any of them is sufficient for a subject to express 
photosensitivity. It was possible that most of the affected individuals in this pedigree might 
share a dominant gene but a few of them did not. If the pedigree was large enough, linkage 
analysis  might  be  able  to  identify  the  locus  where  the  dominant  gene  was  linked  to. 
However, this would prove difficult in small pedigrees.  
     Third,  it  might  not  be  entirely  appropriate  to  phenotype  this  pedigree  based  on  the 
existence of PPR on EEG only. Doose and Waltz (Waltz  et al.  1992) categorized the PPRs 
on EEG into 4 different types:  Spike within the occipital rhythm (type 1), Parietal occipital 
spikes with biphasic slow waves (type 2), Parieto occipital spikes with biphasic slow waves 
and spread to the frontal region (type 3), and Generalized spike and waves or polyspikes 
(type 4). In our analysis, PPR were not subcategorized.  The age dependency of the patterns 
is a particular issue. Deterioration of the generalized spike and wave (type 4) into occipital 
spike (type 1) was observed on the same subject in the follow up EEG years after the first 
recording in this pedigree, indicating that different types of PPR might arise from the same 
genotype but regulated by different factors. Similar findings were made in the  previous 
investigation by Waltz and Dose (Waltz  et al.  1992). In their study, it was  concluded that 
“the  phenotypical  expression  of  the  PPR  is  age related  and  modified  by  other  factors 
predisposing to generalized epilepsy, and the varied patterns of the PPR only represents 
different levels of expression of the same genetically determined trait”. Furthermore, PPR 
often totally disappears after the third decade and this renders the use of EEG in adults of 
doubtful validity. To assign all individuals who failed to show a PPR on EEG recording as 
unaffected individuals risks inaccuracy.  Age is not the only influence and gender is also 
important as females are more likely to be photosensitive than males. Drug treatment can 
greatly  affect  the  PPR.  Moreover,  multiple,  successive  examinations  with  varying  time  
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intervals in EEG recordings tend to show considerable variation in the PPR, which further 
indicates that a number of other unknown factors are in play and many of them have not 
been fully identified (Stephani et al.  2004).  
      Fourth, a PPR are seen in other epilepsy syndromes, such as idiopathic generalized, 
idiopathic  partial,  cryptogenic,  and  symptomatic  epilepsies,  not  just  in  idiopathic 
photosensitive occipital lobe epilepsy (IPOLE). The susceptibility genes of some of these 
epilepsy syndromes have been identified, such as GABRA1 gene in Juvenile Myoclonic 
Epilepsy (JME) (Cossette et al.  2002), but these susceptibility genes have not been shown 
to be responsible in causing photosensitivity (Stephani et al.  2004). These might suggest 
that complicated gene to gene interactions could be a part of the mechanisms leading to 
photosensitive  epilepsies,  and  may  further  complicate  gene  mapping  in  photosensitive 
epilepsies.  
       In  conclusion,  photosensitivity  is  likely  to  be  a  quantitative  trait  or  a  polygenetic 
disease. EEG although accurate and sensitive in detecting the PPR might not be reliable in 
detecting individuals whose photosensitivity has been fully suppressed because of various 
regulating factors. The locus identified on chromosome 16 near marker D16S2621 could be 
a region of interest, but more supportive evidence should be gathered before going on the 
next step of investigation. 
 
12.3.1 Comparison with other research 
      As reviewed in the introduction, no susceptibility genes for the PPR or photosensitivity 
have  been  conclusively  mapped.  Pinto  (Pinto  et  al.    2005)    in  a  family  based  linkage 
analysis  mapped  two  susceptibility  loci  for  epilepsy related  photosensitivity  (PPR)  at 
regions 7q32 (PPR type 1, HLOD=3.47 with α = 1, P value  (NPL) =3.39 3 10
 5 at whole 
genome wide level) and 16p13 (PPR type 2, HLOD = 2.44 with α = 1, P value (NPL) = 7.91 
3 10
 5 at whole genome wide level). The subjects were families with a PPR and prominent 
myoclonic seizures (MS related PPR). In a later study, the same research group reanalyzed 
the data using two locus linkage analysis to evaluate whether certain degree of interaction 
(epistasis) exist between the two loci identified. They suggested that the two loci may have 
similar  functions  or  act  in  the  same  biochemical  pathway.  No  definite  gene  has  been 
mapped from these two loci so far.   
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      Our study population differed from theirs. We did not subclassify the PPR into different 
liability  classes  in  the  analysis.  The analysis  program used in  their  study  was  Allegro, 
whereas  we  used  Simwalk2.  The  largest  NPLall  location  score  was  2.231  at  16q24 
(D16S2621) with a pointwise P value 0.0059 in our study. Pinto suggested that the two loci 
they  identified  could  have  similar  biological  functions;  while  our  parametric  linkage 
analysis  suggested  that  photosensitivity  is  unlikely  to  be  a  single  gene  disease,  and 
polygenic inheritance is likely. Another familial linkage study mapped a disease locus on 
chromosome 6 (6p21.2) and chromosome13 (13q31.3) (Tauer et al.  2005). No significant 
location score was obtained either on chromosome 6 or on chromosome 13 in our pedigree. 
      Compared with the results of the association studies in photosensitivity and JME which 
suggested an association with BRD2 gene (Cavalleri et al.  2007; Lorenz et al.  2006b), 
there was no evidence that the disease gene in this pedigree was linked to the BRD2 gene.  
      In summary, we did not replicate any of the results reported in other genetic studies of 
photosensitive epilepsies. No definite susceptibility locus or gene was mapped in our study, 
but  we  provide  some  evidence  that  photosensitivity  (PPR)  is  likely  to  have  polygenic 
inheritance.  
 
12.3.2 Future work 
      To  map  the  susceptibility  genes  of  photosensitive  epilepsies  is  one  of  the  major 
challenges of epilepsy genetic research. Little is known about the role of genetics in its 
pathogenesis. Several reported pedigrees had shown that the mode of inheritance (MOI) 
was likely to be AD with an age dependent incomplete penetrance. The inheritance pattern 
in our pedigree resembled an AD pattern however the parametric analysis using MLINK 
did not demonstrate linkage. This study did not successfully map any disease locus, but 
provided evidence that photosensitivity is unlikely to be a single gene disease. The non 
parametric analysis further suggested that there might be a locus of interest on chromosome 
16 but more investigation is necessary. 
      Accurate  phenotyping  is  mandatory  in  any  kind  of  genetic  analysis.  It  may  be 
worthwhile, in my opinion, combining EEG with other diagnostic tools such as MEG, VEP 
or  SPECT  which  have  shown  potential  in  refining  the  diagnosis  of  the  PPR  to  detect 
photosensitivity. As discussed above, EEG alone cannot be reliable in detecting affected  
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individuals. It would be very helpful if an alternative biomarker for photosensitivity was 
available, and the identification of such a biomarker would potentially rapidly move this 
field forward. 
      More attention to the clinical epidemiology of photosensitive epilepsy syndromes might 
also be profitable, and contribute to genetic studies. For example, current studies showed 
that photosensitivity is both gender and age dependent, and it is also associated with many 
epilepsy syndromes. More epidemiological figures will help in the study design of genetic 
studies.  For  example,  different  disease  traits  might  be  further  stratified  to  provide  a 
homogeneous study population, such as PPR + JME, or PPR + IGE, and pure PPR, etc. 
Such information will also be useful in quantitative trait locus mapping by providing a 
better defined quantitative trait models.  
      Whole genome association studies are another approach to mapping the genes causing 
photosensitivity. However, it will be very difficult to recruit a large enough sample size, 
since  pure  photosensitive  epilepsy  is  rare.  Even  though  broader defined  photosensitive 
epilepsies may be helpful in obtaining a large sample size, as photosensitivity co exists 
with disparate epilepsy syndromes, it is quite possible that the underlying genotype of each 
photosensitive epilepsy syndrome will differ, and in such situation a large sample size will 
not improve the power of study (in fact, the reverse). An association study will still face the 
same phenotyping issues which confound the linkage analysis such as age, gender, and the 
difficulties in finding affected individuals whose photosensitivity has been fully delineated. 
Furthermore, assessing the complexity of epistasis remains difficult and challenging.  
      In summary, the gene mapping and genetics in photosensitivity remain challenging. 
Existing gene mapping methods and phenotyping tools have not yet satisfactorily overcome 
the difficulties in mapping genes arising from the complexity of photosensitivity.  
       
12.4 The Kohlschütter Tönz pedigree 
      The  Kohlschütter Tönz  syndrome  is  comprised  of  early  onset  seizures,  mental 
retardation  or  deterioration,  spasticity,  ataxia,  and  amelogenesis  imperfecta  (abnormal 
enamel  formation).  Patients  often  die  before  the  third  decade  of  their  life  because  of 
complications arising from severe handicap. Currently there is no cure. The syndrome is 
quite rare but mapping the gene and understanding its expression may provide a tool for  
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understanding the pathogenesis of the condition and of its epileptogenesis, which in turn 
will contribute to the development of treatment. An example of the potential value of gene 
identification is that of the identification of the ion channel genes such as SCN1A and 2A 
in Idiopathic Generalized Epilepsies (IGEs) which have had an enormous impact on the 
understanding of these forms of epilepsy and in facilitating ongoing development of new 
AEDs. 
      The  linkage  analysis  of  the  5  small  families  with  Kohlschütter Tönz  syndrome 
suggested significant linkage of a disease locus on chromosome 16. The maximum LOD 
score was 3.05 in parametric linkage analysis at 16p13. The haplotype analysis and the 
preliminary microarray chip analysis provided convincing confirmatory evidence. There 
were two main reasons for the successfully mapping of the disease locus by MLINK, one 
was  because  it clearly  showed  that the  inheritance mode  was  autosomal recessive,  and 
second  because  there  was  consanguity  reported  in  two  of  the  families.  Both  factors 
contributed to the power of this study to detect linkage.  
      To date, the genetic basis of Kohlschütter Tönz syndrome is still unknown. There are 
around 24 known genes located in the region identified in this study. Clearly, the next stage 
is to identify candidate genes in this region to find the disease mutations, to explore the 
gene  expression  through  functional  studies,  and  to  establish  the  pathogenesis  of  this 
syndrome.  However,  in  this  case  the  identification  of  candidate  genes  is  not 
straightforward. There are no known ion channel genes in this location, and little is known 
about  the  genes  that  play  a  role  in  regulating  ion  channels  or  ion  channel  genes. 
Furthermore, very little is known about the genetics of abnormal enamel formation. To 
sequence all known genes within this locus is possible, but is probably not considered cost 
effective.  Fine mapping would be an ideal way to narrow the region of interest before 
choosing  candidate  genes  for  sequencing.  I  attempted  this  in  this  study  but  no  ideal 
microsatellite marker was available. Preliminary  microarray chip analysis provided was 
somewhat  helpful  in  narrowing  the  region  in  interest.  As  the  cost  of  microarray  chip 
analysis has been reduced rapidly, whole genome assessment with SNPs in linkage analysis 
is now available (John et al.  2004; Middleton et al.  2004), and could be considered in the 
near future. An alternative approach might be a whole genome association study, but these 
are  not  generally  recommended  for  such  “rare  disease,  rare  variant”  traits,  as  a  large  
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sample,  mandatory  in  these  studies,  is  not  possible  and  such  studies  will  inevitably  
underpowered and fail to map rare disease variants.   
       
12.5 Discussion of the Linkage analysis:  
12.5.1 Overview 
      In this study, 8 families with different epilepsy syndromes were genotyped by an 8 cM 
whole genome scan using a set of microsatellite markers. Three potential disease loci were 
identified in one of the families with fMTLE, but no disease mutations were found on five 
of the candidate genes that were sequenced. No disease locus was identified in the other 
fMTLE pedigree which the MOI was more complicated. The parametric linkage analysis 
by  MLINK  did  not  identify  any  disease  locus  under  the  inheritance  mode  AD  in  the 
photosensitive  pedigree,  but  the  NPL  analysis  showed  that  there  might  be  a  region  of 
interest, if photosensitivity is a polygenic disease with a dominant gene. In the five small 
pedigrees  with  Kohlschütter Tönz  syndrome,  a  disease  locus  was  identified  with 
approximately 24 known genes in this region. No disease mutation genes have yet been 
identified.  
      According to the linkage analysis of the fMTLE pedigrees, it seemed that although the 
clinical presentation of the two pedigrees was similar, the MOI and the susceptibility genes 
underlying  each  pedigree  might be  different.  This  suggests that  fMTLE  is  likely  to be 
polygenic, that family based studies in gene mapping of fMTLE will be difficult, unless 
large samples can be collected. 
      The parametric linkage analysis on the pedigree with photosensitive epilepsy showed 
that photosensitivity was unlikely to be a single gene disease. The NPL analysis helped to 
locate  a  region  of  interest  on  chromosome  16,  however,  more  supporting  evidence  is 
needed.  Another  problem  in  this  pedigree  is  that  we  could  not  be  certain  whether  the 
unaffected individuals defined by negative PPR on EEG were truly unaffected, because 
EEG can not identified subjects whose PPR were completely suppressed or has resolved . 
      The  linkage  analysis  in  the  Kohlschütter Tönz  families  was  promising,  with  the 
convincing  evidence  gathered  from  microarray  chip  analysis  and  haplotype  analysis.  
Future work would be to identify the mutation genes and the work on gene expression to 
establish the pathogenesis of this syndrome.  
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12.5.2 Gene mapping methods  
      More and more emerging evidence suggests that most epilepsy syndromes are unlikely 
to be single gene diseases but to have polygenic causation. Conventional linkage analysis is 
therefore unlikely to be the only method of value in identifying causal genes. In the past, 
candidate gene association studies had been the main method of mapping disease genes but 
little  has  been  achieved.  As the  advances  in  technology  and  the  completion  of  Human 
Genome Project, whole genome assessment association studies using different microarray 
platforms have become the major tool in genetic mapping. However, although such studies 
were able to demonstrate rigorously the association between certain common diseases and 
disease variants, so far they have only explained a small fraction of the underlying genetics 
of most of the common diseases, and have not been able to detect rare disease variants but 
with considerable effect size (effect size is a function of what a variant dose) (Goldstein, 
2009). In contrast to association studies, many rare disease variants have been identified 
through linkage analysis but such studies often fail to map common disease variants.  
        Various modifications to linkage analysis programs have been made. Quantitative trait 
mapping has been introduced in 1972, and at least three types of quantitative trait mapping 
are available now (Table 12.3). Their reliability and validity have not been well established 
yet, and it has been a main challenge to implement the algorithm to computation, despite 
the advanced computing facilities are available. Besides using microsatellite markers for 
genotyping  in  the  linkage  analysis,  genotyping using  Single Nucleotide  Polymorphisms 
(SNPs) are now available and will provide more information (John et al.  2004; Maresso 
and  Broeckel,  2008)  (Table  12.4).  The  major  challenge  in  applying  SNPs  in  linkage 
analysis is that powerful statistical tools are mandatory to accommodate huge amount of 
data.  
      Genetic  association  studies  had  been  considered  to  be  more  powerful  than  linkage 
analyses  in  gene  mapping,  and  were  originally  designed  to  solve  the  disadvantages  of 
linkage analysis in mapping complex traits.  However, to date not much progress has been 
made by association studies in the gene mapping of epilepsy syndromes. Most such studies 
were candidate gene based, and many were underpowered by utilising too small a sample 
size. In contrast, genetic linkage studies have mapped many disease genes, and indeed are  
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still responsible for most of the successful gene finding investigations in epilepsy as well as 
other diseases. There has been a fierce debate about whether association study or linkage 
studies are the most suitable choice for gene mapping, and a comparison of the linkage and 
association study is appropriate here to clarify some of the issues.  
 
12.5.3 Comparison between different gene mapping methods 
      The comparison of quantitative trait mapping, genetic association study and  genetic 
linkage study is presented in Table12.3, which provides an outline of the advantages and 
disadvantages in each type of gene mapping method. 
      Parametric linkage analysis has been very successful in mapping Mendelian traits in the 
past  two  decades.  However  its  value  is  greatly  reduced  in  mapping  genes  in  complex 
disease  trait  or  quantitative  traits.  Most  linkage  analysis  has  taken  the  form  of  non 
parametric linkage analysis because most pedigrees of interest are not single gene diseases. 
However,  non parametric  linkage  analysis  is  less  powerful  in  detecting  linkage  in  a 
Mendelian  trait  disorder  and  often  ignores  available  genotype  data  from  unaffected 
individuals,  lessening  its  power  in  detecting  linkage.  Quantitative  trait  mapping  was 
another  method  developed  to  solve  this  disadvantage.  However,  the  quantitative  trait 
mapping required several steps and can be laborious and complicated in comparison to 
conventional linkage analysis. To perform quantitative trait mapping, segregation analysis, 
establishing  model  definitions,  and  relevant  epidemiological  information  are  often 
necessary.   
      The design of association study is essentially different from linkage analysis. It aims at 
finding  common  disease  variations  with  moderate  gene  strength  shared  by  a  large 
population, based on the hypothesis “common disease, common variation”. In other words, 
it seeks genes that express moderately by majority rather than genes that expressed strongly 
but only by minority, such as in a Mendelian trait pedigree. There are several different 
forms of association study. Based on the study design, these can be roughly classified into 
three types: candidate gene based, linkage disequilibrium (LD), family based, or population 
based. Each has its advantages and disadvantages in mapping disease genes (Table 12.3). 
      Despite the fact that there have been many debates and disagreements about whether 
linkage or association is the better way to find causation genes, it might be reasonable to  
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conclude that these two methods complement rather than compete with each other. Both 
have  a  place.  For  example,  although  whole  genome  assessment  has  been  applied  to 
association studies using different platforms of tagging SNPs, most of the new associations 
do  not  explain  previous  genetic  linkage  results,  suggesting  that  even  whole  genome 
association studies cannot replace linkage analysis in mapping rare disease variants (Mullen 
et  al.    2009).  On  the  other  hand,  genetic  linkage  analysis  is  much  less  powerful  in 
identifying  common  variants  than  the  association  studies.  Ideal  study  design  varies 
according  to  the  characteristic  of  the  study  population,  and  carefully  selecting  suitable 
mapping methods remains a vital ingredient in gene mapping. 
      Recently,  Goldstein  (Goldstein,  2009)  estimated  that  to  explain  80%  of  a  common 
variation, such as human height, as much as 93,000 SNPs are needed based on the data 
reported by Manolio (Manolio et al 2008) and the formula by Risch and Merikangas (Risch 
et al  1996). He also suggested that the associations with several common diseases (such as 
type II diabetes) that have been reported through genome wide association studies might be 
those that have the strongest effect size, however the majority are the SNPs of weak effect 
size which might not be able to be further identified through GWAS with a mass number of 
study population. Thus, it is unlikely that such variations identified through genome wide 
association studies can be ideally applied to clinical practice, either in gene screening or in 
developing  therapy,  because  these  variants  only  account  for  a  small  fraction  of  these 
common diseases. Therefore, it seems reasonable that in clinical practice, seeking genes 
with larger effect size would be more clinically applicable and cost effective. This further 
point out that linkage analysis has its place and cannot be replaced by GWAS.  
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  250 
12.5.4 SNPs vs microsatellite markers in linkage analysis  
      Single Nucleotide Polymorphisms (SNPs) has been replacing microsatellite markers in 
genotyping after the completion of Human Genome Project and now the ongoing HapMap 
project.  The  application of  dense  SNPs  sets for  whole  genome  linkage  scans  has  been 
reported (John et al.  2004; Middleton et al.  2004) and showed that using the Affymetrix 
Mapping 10 K array offers significantly higher information content (IC) across the whole 
genome when compared to standard 300 400 10 cM spaced microsatellite markers scan. 
Further more, the LOD scores obtained using SNPs were more precisely defined and the 
loci  identified  were  narrower  compared  with  microsatellite  markers  scans  (John  et  al.  
2004). Although SNPs are less polymorphic than microsatellite markers, local clusters or 
haplotypes of SNPs can result in more genetic information being extracted from a particular 
genomic region than microsatellite markers (Schaid et al.  2004). 
      However,  using  SNPs  as  a  whole  genome  scan  in  linkage  analysis  is  not  without 
disadvantages. For example, while linkage disequilibrium (LD) is a substantial benefit in 
association study, its impact on linkage analysis can be negative leading, for instance, to an 
upward bias in identical by descent (IBD) estimates though underestimation of haplotype 
frequencies. However, the overall impact of LD on linkage analysis requires further study 
as  not  enough  data  have  been  accumulated.  Table  12.4  is  a  brief  comparison  of  the 
advantages  and disadvantages using  SNPs  and  microsatellite markers for  genotyping in 
linkage analysis.  
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12.5.5 Whole genome wide assessment and  genome wide association studies (GWAS) 
      Dense SNP maps are now widely available through the human genome mapping and 
the HapMap studies (International HapMap Consortium, 2005), which cataloged SNPs that 
could  be  used  to  capture  the  majority  of  human  variability.  There  are  approximately 
500,000  SNPs  whose  genetic  analysis  can  be  used  to  assess  about  95%  of  genetic 
variability (Hardy and Singleton, 2008).  With the advances in microarray chip analysis 
technology along with dense informative tagging SNPs, whole genome assessment to map 
disease  gene  has  become  a  feasible  option  in  non Mendelian  trait  diseases,  and  has 
facilitated  the  genome  wide  association  studies  (GWAS)  of  many  common  diseases, 
especially after the cost in microarray chip analysis has been rapidly reduced. Genome wide 
association studies (GWAS) have been successful in mapping genes of several complex 
disease, such as breast cancer and prostate cancer (Easton et al.  2007; Yeager et al.  2007). 
       Two types of  microarray  chips are now available, one is the Affymetrix Genechip 
platform, which randomly selects SNPs available across the whole genomes for microarray 
analysis.  The  other  is  the  Illumina  BeadChip  platform,  which  employs  an  LD based 
selection strategy, that different specific tagging SNPs can be selected according to the 
population  in  interest.  The  Affymetrix  Genechip  seeks  event  spacing  of  the  SNPs 
distribution across the whole genome, while the density of the SNPs platform on Illumina 
varies  according  to  LD,  so  different  SNPs  in  strong  LD  (genetically  identical  SNPs, 
giSNPs, or redundant markers) are not selected as they tend to give the same result in 
association  study.  The  coverage  of  the  Snips  across  the  genome  directly  affects  the 
information content (IC) and the results of GWAS. Newer platforms also include the ability 
to  detect  copy  number  variation,  as  this  may  play  a  major  role  in  contributing  to  the 
complex relationship between phenotype and genotype (Mares so and Broeckel, 2008). 
      Several factors affect the results of genome wide association study. First, a large sample 
size is necessary to provide adequate statistical powers. An underpowered association study 
is  likely  to  fail.  It  was  estimated  that  for  an  adequate  association  study,  at  least  2500 
subjects are necessary (Altshuler and Daly, 2007), although these figure may be more or 
less adjusted according to disease prevalence and incidence (Mullen et al.  2009). Such 
large  sample  sizes  often  make  the  replication  of  association  studies  difficult.  Careful 
selection of tagging SNPs for a good coverage across the genome is another variable that  
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contributes to success of an association study. The magnitude (potency) of the alleles in 
causing disease and the allele frequency are also determining factors, however neither is 
likely to be known prior to study (Maresso and Broeckel, 2008). Finally, because a large 
number  of  SNPs  are  genotyped  in  a  GWAS,  P  values  of  10
 6   10
 7  after  Bonferroni 
correction are currently accepted as the significance threshold to confirm an association in 
GWAS.  Such  stringent  P  values  threshold  may  have  excluded  many  true  association 
results, and such a threshold is only reasonable when the sample size in genome wide scan 
is  large  enough  and  the  statistical  power  is  adequate  enough.  Carefully  choosing  the 
significance threshold is therefore another determining factor of successful GWAS.  
      The strengths of GWAS are that it is hypothesis free and is able to comprehensively 
interrogate the entire human genome, which enables investigators to identify novel loci or 
genes for various diseases. It is especially good in complex diseases or quantitative trait, 
powerful  in  detecting  alleles  that  are  common  but  with  minor  or  moderate  effects  on 
disease  phenotypes.  These  are  great  advantages  over  conventional  linkage  analysis. 
However, there are also limitations in GWAS (Goldstein, 2009). The major limitation is 
that a large sample size is mandatory. Genotyping more SNPs does not compensate for a 
lack  of  power  to  detect  real  effects  if  the  sample  size  is  not  large  enough.  Hence, 
collaboration is almost mandatory and a universal approach is important in pooling data. 
Second, GWAS is largely based on the principals of LD, therefore the markers identified 
through association studies are unlikely to be the disease variants. Extensive re sequencing 
and fine mapping are required to discern the disease variants. Re sequencing will enable 
investigators to uncover novel and uncommon variants, and biological studies of the genes 
are  required.  This  has  been  a  great  challenge  since  LD  does  not  further  help  in  fine 
mapping  once  a  SNP  or  marker  is  identified,  because  the  genetically  identical  SNPs 
(giSNPs) in LD with the identified SNP nearby offer the same information as the identified 
SNP,  and  the  functional  studies  are  limited  in  regions  that  are  not  well  characterized 
(Kruglyak,  2008;  Seng  and Seng,  2008).  Currently,  it  remains  difficult  to  establish  the 
functional role of the disease variants as well as the transcription regulation. Moreover, 
since GWAS offers massive  genetic data output, it is hypothesis generating rather than 
hypothesis testing, therefore replication is paramount to confirm the results. Unbiased and 
rigorous replication is essential for all kinds of association discoveries as this validates the  
 
  254 
study results, and offers a wider evidence base with which to try to make inferences about 
the validity and biases (Ioannidis, 2008). Replication is not always possible in such large 
scale studies, especially with disease that have low prevalence rate.  
 
12.6 GWAS in epilepsy syndromes  
      GWAS  has  not  generally  been  a  tremendous  success  in  elucidating  the  cause  of 
neurological  disorders.  Associations  have  been  reported  in  Restless  Leg  Syndrome, 
Multiple  Sclerosis,    and  Periodic  Limb  Movements  in  Sleep  and  these  have  been  
considered  the  most  successful  GWAS  in  neurological  disorders  (Simón Sánchez  and 
Singleton, 2008; Stefansson et al.  2007; Winkelmann et al.  2007). Most of GWAS in 
neurological disorders have been small in scope and designed to detect moderate to large 
effect sizes (examples are the GWAS in Parkinson disease, Amyotrophic lateral Sclerosis 
and Ischemic Stroke)(Cronin et al.  2008; Fung et al.  2006; Matarin et al.  2007; Schymick 
et  al.    2007).  In  Amytrophic  Lateral  Sclerosis,  although  several  disease  loci  identified 
through GWAS have been published, none has been replicated, suggesting that the genetics 
of ALS is more heterogeneous that previous thought (Chio et al.  2009; Valdmanis et al.  
2009) In the GWAS of Parkinson disease, none of the disease loci have been replicated and 
one of the studies did not identify any associations in the SNPs genotyped in 276 patients 
and 276 controls (Fung et al.  2006). In the GWAS of ischemic stroke, a recent study 
reported that a genetic locus on chromosome 12p13 is associated with an increased risk of 
stroke, in a sample size of 1544 incidence of stroke among 19602 persons. This result has 
not been replicated (Ikram et al.  2009). In the Alzheimer Disease GWAS, several disease 
associated loci (including APO E gene) have been reported, but with limited replication to 
support the findings except the APOE gene (Waring and Rosenberg, 2008).       
      The  GWAS  in  epilepsy  syndromes  are  on  going  in  several  research  centres,  and 
preliminary reports are yet available. In comparison to other common disease, there are 
additional  challenges  in  GWAS  in  epilepsy  syndromes.  The  difficulties  of  performing 
GWAS in Idiopathic Generalized epilepsy can be taken as an example. 
      Idiopathic Generalized Epilepsy syndromes (IGEs) have a cumulative incidence around 
0.25%  with  several  sub syndromes,  which  are  usually  diagnosed  using  clinical  and 
electrographic  criteria.    These  syndromes  have  been  proved  to  have  a  strong  genetic  
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predisposition and several ion channel gene mutations have been identified in rare families 
with  single  gene  disorders    (Kjeldsen  et  al.    2003;  Meisler  and  Kearney,  2005).  Such 
findings have facilitated many candidate gene based association studies in the last 20 years 
but all have failed to provide convincing reproducible results. Although GWAS may offer a 
new hope in mapping genes for IGE, there are several challenges. The first challenge is the 
difficulties in phenotyping. Symptoms may overlap in some of the IGE syndromes. For 
example, Juvenile Myoclonic Syndrome is characterized with myoclonic seizures, with or 
without generalized tonic clonic seizures; and Juvenile Absence Epilepsy is characterized 
with absence with or without myoclonic seizures. The overlap of seizure types in these 
IGEs has made the phenotyping and population stratification difficult. Secondly, to include 
all  types  of  IGEs  in  GWAS  might  fail  as  distinct  genetic  determinants  may  underlie 
different  sub syndromes.  Phenotyping  based  on  different  IGE  syndromes  faces  the 
difficulty  of  setting  clear  boundaries  for  population  stratification.  However,  the  small 
sample size in sub syndrome carries the risk of rendering a GWAS underpowered (Mullen 
et al.  2009). Such a situation may also apply if seizure types are used as the basis of 
phenotyping  in  GWAS.  The  phenotyping  difficulties  and  the  dilemma  in  population 
stratification also apply to studies of familial temporal lobe epilepsy, which consists of a 
wide  variety  of  seizure  types  and  symptoms.  Furthermore,  complicated  epistasis  and 
environmental factors may have their roles in epileptogenesis, and a GWAS is less likely to 
be able to take these factors into account (Kruglyak, 2008). 
 
12.7 Biomarker and phenotype 
      In both GWAS and in genetic linkage analysis, phenotyping is a substantial factor in 
determining successful gene mapping. In linkage analysis, there are two common situations 
that hamper the power of gene mapping. First, when an allele has only a minor or moderate 
effect on a phenotype, some relatives might be affected because of other causes and may 
not carry the risk allele. Second, when an allele is common, it can enter the family through 
multiple founders, erasing a clear inheritance pattern. An association study is influenced by 
the first phenomenon as much as in the linkage analysis. Such an effect might not be easily 
compensated for even if a large number of cases are involved. Moreover, as discussed 
above, a homogenous population will enhance the success rate in either types of study. It is  
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therefore  necessary  to  develop  sensitive  and  unique  biomarkers  for  common  diseases, 
especially in those in which clinical phenotyping is complicated and a major impediment to 
gene mapping. Many studies to identify markers are on going and many hypotheses are 
being developed and tested, but in epilepsy syndromes, no reliable biomarkers have yet 
been identified. 
      The advantages of developing sensitive and unique biomarkers will assist in other ways. 
Biomarkers can also be used to predict the therapy outcome and in turn contribute to further 
adjustment of therapies. In comparison to expensive gene screening, biomarkers can be 
cost effective in the practice of Public Health.   
 
12.8 Conclusion 
      The gene mapping in familial epilepsy syndromes remain challenging. We concluded 
that  familial  mesial  temporal  lobe  epilepsy  might  be  either  a  single  gene  disease  or 
polygenic  disease,  while  photosensitive  epilepsy  is  probably  polygenic.  Whole  genome 
association study may provide new hopes in mapping the disease genes of mesial temporal 
lobe epilepsy. However, the susceptibility genes of the two epilepsy syndromes (familial 
mesial temporal lobe epilepsy and photosensitive epilepsy) in the pedigrees collected in this 
study are likely to be rare disease variants with moderate to strong effects, and it remains 
questionable whether GWAS is suitable to map the susceptibility genes in such a situation. 
Gene mapping in familial epilepsy syndromes can be improved in several ways: adequate 
epidemiological information, precise phenotyping via unique biomarkers, advanced linkage 
analysis software, and genotyping with dense SNPs across the whole genomes.   
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Section 13: Saccadic eye movement Studies 
 
13.0 Hypothesis 
      Saccadic eye movements are influenced by anti epileptic drugs, especially those act on 
ion  channels  or  receptors  to  exert  the  anti epileptic  effects,  such  as  benzodiazepine, 
phenytoin, and carbamazepine. The most common effects of these AEDs on saccades are 
slowing of the peak velocities, and prolongation of the latencies.  
      In this body of work, we aimed to conduct a pilot study as part of a programme to 
investigate  the  potential  of  saccadic  eye  movement  parameters  (main  sequence,  peak 
saccadic velocity) to act as a biomarker of value in pharmacogenomic studies of epilepsy.  
      The long term aim of this work is to determine whether saccadic eye movements were 
useful as a measure of the pharmacological effects of antiepileptic drugs – in other words to 
determine whether they would prove a useful pharmacogenomic biomarker. The specific 
objective is to determine whether large effects on saccadic velocity due to drugs correlated 
with large drug effects on epilepsy in terms of side effects or efficacy.  If the AED effects 
on  saccades  did  indeed  correlate  with  clinical  AED  effects,  a  second  phase  of  the 
programme was planned to identify whether polymorphic variation in SCN1A (or other 
candidate  genes)  could  be  identified  as  underpinning  the  saccadic  variation  –  thus 
potentially leading eventually to the use of saccadic eye movements as a biomarker, and 
identification  of  genotypes  which  correlate  to  clinical  response.  The  first  phase  of  the 
project  reported  in  this  thesis,  the  pilot  (or  scoping)  phase,  which  had  the  following 
narrower aims: 
1. to devise a clinically applicable method for measuring saccadic main sequence and peak 
saccadic velocity.  
2. to carry out measurements in a suitable control group, to identify mean values and the 
range of normality. 
3. to carry out a pilot study in patients with epilepsy, to determine whether changes in 
blood levels were reflected by measurable changes in saccadic velocity in a reliable 
fashion, and to determine the extent of this effect 
4. In a preliminary manner, to whether the there is an association between the magnitude of 
the effect of saccadic variation and clinical effects (side effects/efficacy).   
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13.1 Findings of the study 
      There  were  significant  variations  on  test retest  comparisons  in  the  control  group. 
Although  many  differences  were  not  significant,  due  to  small  sample  numbers,  we 
concluded that small differences due to drug action will be lost within the noise. In the test 
retest  reliability  calculation,  the  Pearson  regression  correlation  and  the  Intraclass 
correlation  coefficient  (ICC),  we  showed  that  the  peak  saccadic  velocity  did  not  have 
adequate reliability, with RPearson = 0.433 (same as in RICC) when chin rest was used and 
RICC = 0.588 (RPearson = 0.615) when chin rest was not used. The analysis of the subject 
group showed that the main sequence measured before and after the subjects took their 
medication, did not show any significant changes. The comparison of the main sequence of 
the subject group to the control group showed that only the peak saccadic velocity in case 1 
was significantly lower than the control group. The other 2 subjects did not differ from the 
control group even when one of them was experiencing phenytoin intoxication. Although 
only three cases were tested in the subject group, the results would seem such that  the peak 
saccadic velocity was neither reliable nor sensitive enough in reflecting the changes of 
serum drug level on saccadic eye movements.   
 
13.2 Possible explanations 
      There are several reasons for the failure to achieve good test retest reliability, which 
was the main reason for our decision not to proceed beyond the pilot stage of this study. 
 
13.2.1 The natural variability of saccades: 
      The variability of saccades was noticed as early as 1978 by Boghen (Boghen et al.  
1974) using electro oculogram to record and analyze the characteristics of the velocity of 
saccadic eye movements. He found that there was a considerable intra subject variability in 
the peak velocity of saccades, and in one of his subject tested, the two sets of recording 
which was carried out in a time interval of several  months showed significant statistic 
difference. This finding was similar to the results in our control group. A subsequent study 
done by Bollen (Bollen et al.  1993) that used an infrared tracking device to analyze the 
main sequence and peak velocity in a sample size of 58 showed that the RICC of the peak 
velocity was 0.34 calculated at 10°, and 0.10 when calculating the peak velocity at the  
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amplitude of 5°. This also suggests poor intra individual reliability of the saccadic peak 
velocity. 
      A  few  studies  managed  to  publish  the  normative  data  base  of  human  saccadic  eye 
movement, despite the variability noticed. Bahill (Bahill et al.  1981) recorded over 900 
saccadic eye movements from 13 normal subjects ranging from 20 to 35 years of age. Table 
14.1  shows  the  suggested  normative  data  of  human  saccadic  eye  movements  from  his 
study. Raab (Raab, 1985) reported that the peak velocity of saccades distributed normally 
and ranged from 281 to 541 (mean and SD = 393 +/  50) deg/sec. Wilson (Wilson et al.  
1993) provided another set of normative data (Table 14.2). The normative data suggested 
by Bahill and Wilson are difficult to compared, because they were obtained at different 
amplitude and were presented in different parameters. The exception was the peak saccadic 
velocity acquired at 15°, which showed partial overlap in figures and may be comparable to 
each other. Recently, there have not been studies working on the normative parameters of 
saccades, but comparisons of main sequence using different methods (Träisk et al.  2006). 
 
Table 13.1 Normative data of human saccadic eye movement [Adapted from (Bahill et 
al.  1981) with permission] 
Saccadic magnitude (deg)  Peak velocity and SD 
(deg/sec) 
Duration and S.D (msec) 
5  261 ± 42  42 ± 8 
10  410 ± 67  51 ± 8 
15  499 ± 43  54 ± 7 
20  657 ± 78  64 ± 6 
 
 
Table 13.2 Normative data of human saccadic eye movement, mean± SD [Adapted 
from(Wilson et al.  1993) with permission] 
Saccadic 
magnitude 
(deg) 
peak velocity 
(degree/sec) 
peak 
acceleration 
(deg/sec
2) 
peak 
deceleration 
(deg/sec
2) 
saccades 
accuracy 
(degree) 
saccades 
latency 
(ms) 
15  332 ± 20  51 ± 6   48 ± 7   0.6 ± 1.7  134 ± 46 
25  445 ± 41  59 ± 8   51 ± 9   0.8 ± 0.8  153 ± 41 
35  507 ± 55  63 ± 9   48 ± 9   0.8 ± 1.0  160 ± 38 
male 35  510 ± 59  64 ± 9   49 ± 9   0.9 ± 0.8  161 ± 38 
female 35  504 ± 49  62 ± 8   48 ± 10   0.7 ± 1.1  157 ± 37 
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      More  recently,  Smeets  (Smeets  and  Hooge,  2003)  investigated  the  nature  of  such 
variability by using 2 different recording facilities to record the saccadic eye movements: 
the  video  tracking  method  and  the  scleral  coil  search  method.  They  found  that  the 
variability of main sequence was larger when the saccades were recorded by scleral coil 
search method than the less accurate video tracking method, and suggested that part of the 
variability could be explained by the method used. They also examined the variability on 
three hypotheses: the pulse height noise hypothesis (such motor variability is caused by 
noise in the firing intensity of motoneurons), the localization noise hypothesis (inaccuracy 
of target determination by the experimental subjects), and the independent noise hypothesis 
(measurement inaccuracy). They suggested that the variability in the scleral coil search 
method might come from the pulse height noise, while a combination of localization noise 
and independent noise best described the data obtained by the video system. Another study 
done by van Beers (van Beers, 2007) by analyzing saccades trajectories suggested that the 
uncertainty in the sensory signals and the noise in movement planning as well as execution 
all contributed to the variability in saccade trajectories, and this could be the main resource 
of the natural variability of the main sequence of saccades. However, these two studies used 
hypothetical models to analyze the possible origins of the variability rather than directly 
measuring the signals intensities and relevant noises from neurons, and these theories await 
further validation. 
 
13.2.2. The reliability of quantitative saccadic recording 
      Because of the considerable variability seen in the peak velocity of saccades, some 
researchers have questioned whether the quantitative measurement of the main sequence 
would be reliable, either as neurophysiologic tool in the longitudinal evaluation of disease 
progression,  or  in  the  evaluation  of  therapeutic  effects  of  pharmacologic  treatments. 
Version and colleagues (Versino et al.  1993) recorded saccadic eye movements from 20 
healthy subjects in a time interval of 1 week. They took into account the normal range of 
variability  of  saccades  in  a  normal  population  and  modified  the  ICC  accordingly.  In 
contrast to our study, they concluded that the quantitative measurement of saccades and 
pursuits were reliable, but our interpretation of their data is that the considerable variability 
demonstrates unreliability.  
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      Another  study  (Roy Byrne  et  al.    1995)  has  investigated  the  diurnal  variation  in 
saccades. Parameters for comparison included peak velocity of saccades and mean latency 
of saccades. Types of saccades used for testing included visually guided saccades, memory 
guided saccades, anti saccades and saccades to moving target. Infrared reflecting device 
was  used  for  recording,  and  standard  ICC  was  used  for  all  reliability  calculation.  The 
recordings were done twice in the morning and again twice in the afternoon in a random 
time interval of one week to two months. Roy Byrne and colleagues found good AM to 
AM and PM to PM reliability (RICC within 0.67 to o.78) in the mean latency of all saccades 
types, and RICC was within 0.62 to 0.82 in the comparison of AM to PM. All comparisons 
of peak saccadic velocity showed moderate to excellent reliability, that the RICC was within 
0.70 to 0.95. Our RICC was smaller than theirs, and we did not test the different types of 
saccades in our investigation. 
      More  recently,  Klein  et  al  (Klein  and  Fischer,  2005)  investigated  the  reliability  of 
saccadic measurements over time. He tested 446 patients in an average time interval of 19 
months, aged from 6 to 88 years old. The saccades types used for recording were anti 
saccades  and  pro saccades.  Parameters  used  for  comparison  however,  was  not  typical 
parameters  of  saccades,  but  reaction  time  for  pro saccades;  error  reaction  time,  and 
direction  error  for  anti saccades  mainly.  Both  instrumental  reliability  and  test   retest 
reliability  were  calculated  using  Pearson  correlation  coefficient  or  Intraclass correlation 
coefficient.  He  found  that  in  his  sample  population  there  was  excellent  instrumental 
reliability (using infrared reflecting device, IRIS, Skalar; Delft, Netherlands, r was within 
0.67  –  0.97).    The  RICC  was  within  0.69  –  0.77  in  the  test retest  reliability  test  in  all 
saccades parameter tested. While calculating the reliability, he also took into account the 
normal range of variability. Klein’s study might suggest that some unique parameters in 
specific types of saccades might have better reliability than the dynamic parameters such as 
peak  velocity  of  voluntary  saccades  which  we  used  in  our  study  (we  chose  our 
measurements on the advice of Professor Linda Luxon, who is in charge of the Neuro 
otology Unit of the National Hospital for Neurology and Neurosurgery). The variability of 
the measurements is in fact striking, and this may  also be the reason, for the fact that 
reliable normative data is absent from the literature.  
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       In summary, the reported reliability of saccades has varied in different research studies. 
The major differences between our study and some of the studies described above were 
types of saccades tested and parameters measured. Only visual guided voluntary saccades 
was  tested  in  our  study,  while  anti saccades,  memory  guided  saccades  or  saccades  to 
moving target which involve more sophisticated psychomotor function were tested in the 
studies and showed better reliability. In these studies, different parameters were chosen for 
comparison according to different types of saccades tested, which might also be another 
factor leading to different results of the reliability. It could be concluded that the unique 
parameters of these saccades which involve more complicated psychomotor performance 
had higher reliability for intra individual comparison.  
 
13.2.3. Peak saccadic velocity alone might not be sensitive enough to detect changes of 
serum drug level.  
      Our study design aimed to compare main sequence (the peak velocity of saccades) 
when  subjects  were  in  different  serum  drug levels, and to  correlate  the  results  to  their 
treatment outcome.  If the magnitude of change in the peak velocity of saccades caused by 
the change of serum drug level was not great enough to show above the natural variability 
of saccades, such difference will not be detected. Despite of negative results, it may be true 
that the majority of patients taking carbamazepine or phenytoin have a slightly slower peak 
velocity of saccades compared to the control group. 
      From our study, we can conclude, that the peak velocity of saccades was not sensitive 
enough to be reliably used to detect the changes and the effect of serum drug level. Even in 
one subject whose phenytoin serum drug level decreased significantly from toxic level to 
normal therapeutic level, the Paired T test did not suggest of a significant change in the 
peak  velocity  measured.  It  is  clear  from  our  own  findings  and  also  our  review  of  the 
literature, that the detail of the fact of changing blood levels on saccadic velocity, including 
the  effect  of  intoxication,  are  not  known  –  although  it  is  clinical  experience  that  eye 
movements  are  indeed  affected  by  anti epileptic  drugs  (for  instance,  drug  induced 
nystagmus). 
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13.2.4. Factors which affect saccadic measurements 
Nicotine, Caffein, Alcohol 
      Besides drugs, other substances in common daily use such as nicotine, alcohol and 
caffeine also influence saccades. Some studies found that nicotine improve anti saccades 
performance without affecting pro saccades and might improve the psychomotor function 
in schizophrenic patients (Larrison et al.  2004; Larrison Faucher et al.  2004).  Alcohol 
impaired the velocity and initiation of saccadic eye movement, and increases the latencies 
in anti saccades (Khan  et al.  2003; Nyberg  et al.  2004). Caffeine increases the peak 
velocity of saccades and may reduce the reaction time in finding the targets (Smith et al.  
2003).  In our study, all cases in the control group and the subject group were tested when 
they had not had cigarette, coffee or any alcoholic drinks for at least 12 hours before their 
recording. Thus effects from these substances should have been much minimized in our 
recording.  
 
Fatigue 
      Fatigue has marked effects on saccades (Crevits et al.  2003). The latency of saccades 
was prolonged in Crevits’ study when fatigue was induced by sleep deprivation, but this 
prolongation did not reach a statistical significant level. Schleicher (Schleicher et al.  2008) 
used  the  duration  of  saccades  as  the  parameter  for  comparison,  and  showed  that  the 
duration was only moderately increased, but the blink rate after sleep deprivation were 
significantly increased and appeared to be a good index of fatigue. However, De Gennaro 
(De  Gennaro  et  al.    2000)  found  that  both  latency  and  velocity  of  saccades  were 
significantly affected in addition to blink rates. Porcu (Porcu et al.  1998)  found that in the 
saccadic  eye  movement,  the  accuracy  (gain)  was  sensitive  to  the  severity  of  sleep 
deprivation and decreased significantly in sleep deprivation.  In our studies, although we 
made all reasonable attempts to minimize the effects of fatigue, it was possible, that many 
of the subjects were experiencing fatigue during the second recording and this may have 
contributed to the variability of main sequence, especially those who were tested in the 
same day.  
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Leaning effect (adaptation) 
      Adaptation or learning effect has been shown in several studies (Kojima et al.  2005; 
Watanabe  et  al.    2003).  Most  of  these  studies  examined  modification  in  continuous 
saccades, or saccades occurred consecutively within a very short time interval. It has been 
shown,  for  instance,  that  when  saccades  consistently  overshoot  their  targets,  saccade 
amplitudes gradually decrease to maintain the accuracy. (Herman et al.  2009a). In another 
study, it was found that the amplitude and peak deceleration of saccades were significantly 
decreased during the process of adaptation, while the other dynamic parameters such as 
duration,  latency  and  average  velocity  did  not  show  significant  change  (Collins  et  al.  
2008). In our eye movements recording, most of the cases repeat the whole battery at least 
twice in a time interval which ranged from half an hour to 1 week apart. It is possible that a 
degree of adaptation occurred in some individuals, 
 
Age 
      Finally, the performance of saccades varies with age. A negative linear correlation was 
found  between  the  saccadic  eye  movement  parameters and  age  (peak  saccade  velocity, 
latency and amplitude) in a study population aged from 15 to 75 (Tedeschi et al.  1989). 
Irving’s investigation and survey (Irving et al.  2006) showed that the latency of saccades 
gradually decreased from the age of around/before 5 until before the third decades of life, 
remain more or less the same until the fifth decades, and then gradually increased in older 
age. The peak velocity of saccades gradually increases from the age of 3 until 14, and 
gradually deceases thereafter. The accuracy of saccades (gain) also differs with a larger 
variation according to the magnitude of saccades made. In general, the gain increases after 
the age of 10 until 19, slightly decreases (or increased, depending on the amplitude) during 
the  20s  until  the  age  of  30,  remains  relatively  stable  until  late  forties,  then  gradually 
decreases thereafter. A similar tendency for the parameters in saccades to change with age 
was also reported in Klein study on pro  and anti  saccades (Klein et al.  2005). In our 
control  group,  the  age  range  was  wide  (from  24  to  64  years).  Averaging  their  main 
sequence measurements did not account for this when making comparisons between the 
subject group and the control group. An age matched comparison might have been more 
appropriate.   
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13.2.5. Recording facility and analytic programs 
      Although generally minor in its influence on the results of this study, there were several 
issues related in the recording process and the programs designed for analysis:   
 
Head gear 
      The saccadic eye recording was conducted by using an infrared reflection device, with 
head gear used to place and fix the infrared reflection device in front of the eyes during the 
recording. It was noticed that because of sweating sometimes the position of the head gear 
changed slightly during recording. This would change the angle of infrared reflection and 
might bias the data collected. Such a bias could be observed when converting the data by 
the program designed with Mathematica. Visually and manually adjustment of such data 
might have further biased the analysis.   
 
Eye lashes and blinking 
      Long eye lashes often cause unnecessary noise during recording, especially when the 
infrared reflector could not be moved further away from the cornea. Blinking was another 
source of noise during recording. Such effects could be partially overcome by the noise 
filter but not all. The noise caused by eye lushes and blinking could be further eradicated by 
manually  eliminating  them  after  the  data  was  converted  graphically.  However,  such 
trimming of data trades off the amount of data collected against the accuracy of recording. 
 
13.3 Limitations  
      Small sample size was the major limitation of this study. The sample number in both 
the control group and subject group were less than 15. Although statistics were carried out, 
it was obvious that the power of this study was not good enough to reach any definite 
conclusion. We did not increase the number, because it was our opinion that because of the 
wide  intra subject  variation  in  the  control  group,  it  is  unlikely  that  small  but  genuine 
changes in the subject group would be detectable. Furthermore, our experience from case 2, 
the patient intoxicated with phenytoin, who showed no real differences at intoxicating and 
normal  levels  of  phenytoin,  raised  doubt  about  the  chances  of  detecting  drug induced  
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pharmacodynamic changes. Similarly there was no significant change in eye movement 
measurements in case 3 in spite of changing drug levels. 
      Another limitation of this study was that we did not test different types of saccades 
other than voluntary visual guided saccades. Other types of saccades or saccades task such 
as  anti saccades,  memory  guided  saccades,  or  reflexive  saccades  which  involve  more 
sophisticated psychomotor performance and the parameters unique to these saccades might 
be more reliable and sensitive in terms of the intra individual comparison. Anti saccades is 
a good choice as error rate can be easily calculated and this parameter has been used in the 
analysis  of  psychomotor  performance  under  many  circumstances  (Khan  et  al.    2003; 
Larrison Faucher et al.  2004). The parameters used in reflex saccades and memory guided 
saccades are often not traditionally dynamic saccadic parameters such as latency or peak 
velocity, but reaction time or error rates. Other parameters, such as duration, acceleration, 
and deceleration of saccades are also worth measuring at the same time, as combinations of 
these measurements often help in interpretation when a single parameter measurement fail 
to  provide  conclusive  results.  Alternatively,  the  mathematical  relationship  between 
parameters can also be applied for comparison. The Q value is the ratio between peak 
velocity and average velocity and is often used to evaluate the skewness of saccades waves. 
The Q value is quite consistent (typically about 1.6), even for slow saccades made by tired 
subjects and some patients with neurological disorders (Leigh and Zee, 2006; Liao et al.  
2005). If fatigue or neurological disorders are thought to be confounding factors, the use of 
the Q value might be a good choice.  
 
13.4 Suggestions for future work 
      This  preliminary  study  results  suggested  that  modifications  should  be  made  on  the 
study design, also that new hypothesis could be addressed. 
 
13.4.1 Modifications to the study design 
      Several modifications of the study design can be considered. 
1.  In  the  speculation  that  parameters  of  saccades  which  involve  more  sophisticated 
psychomotor performance are likely to be more reliable and sensitive, and should be tested 
on the recording battery adjusted.  A careful designed regime to include different types of  
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saccades, such as anti saccades, memory guided saccades is likely to be more suitable. The 
length of the time needed for testing should also be considered to avoid fatigue. The effects 
of  learning  and  adaptation  should  be  minimized  as  much  as  possible.  To  eliminate 
adaptation, it would be worthwhile having the subjects make a saccade to a 10° target that 
remained on and not to step back before the second recording. This procedure was used to 
complete the extinction of any residual adaptation from previous recordings (Herman et al.  
2009). It would be better if three recordings were carried out on the subject group, so that 
the peak and trough are less likely to be missed. 
2.  An  age  matched  control subject  group  is  necessary,  and  a  larger  sample  size  is 
mandatory to improve the power of this study. 
3. Well defined criteria for alcohol and caffeine intake as well as cigarette use before eye 
movement recording are necessary, both in the control and subject group. 
4. The analysis program must be modified so that simultaneous measurement of different 
parameters from the output data is possible.  
 
13.4.2 New hypotheses  
      The findings of our preliminary studies pose other questions worth pursuing: 
(1) It would be valuable to test patients who are experiencing carbamazepine or phenytoin 
intoxication. The saccadic eye movement can be recorded at the time of intoxication and 
then again when the intoxication has subsided.  
(2)  The  psychomotor  performance  of  these  patients  should  be  correlated  to  saccades 
parameters, and this might further provide valuable information for epilepsy phenotyping. 
It  is  often  noticed  that  patients  taking  AEDs  have  relatively  worse  psychomotor 
performance, even if they have achieved adequate seizure control or have been seizure free 
for a period of time, and withdrawing AEDs often improves the performance. It is therefore 
worth  investigating  whether  there  are  unanticipated  or  unknown  confounding  factors 
affecting saccadic parameters that are related to psychomotor performance.  
(3) The effects of novel AEDs on saccades should be studied. Many new generation AEDs 
have been introduced into clinical treatment, such as levetiracetam, zonisamide, topiramate, 
and recently lacosamide. The effects of these novel AEDs on saccades are not yet available. 
These AEDs often have excellent effects on some epilepsy syndromes that respond poorly  
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to conventional AEDs in some individuals, which may suggesting that such individuals 
have specific phenotypes. It may be worth seeing whether saccadic eye movements would 
be a useful biomarker of treatment outcome of these novel AEDs. 
       
13.5 Conclusion 
      Our pilot study looking at the effects of AEDs on saccadic eye movements did not 
enable  us  to  draw  any  definite  conclusions.  However,  the  preliminary  analysis  results 
permit us to speculate on the possible problems arising from original study design, and to 
modify the study design. Our findings also allow us to refine the hypothesis and to tender 
suggestions for further work.   
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Appendix 2 Questionnaire for interview 
 
 
 
 
 
 
PATIENT INFORMATION:  
NAME:  
ADDRESS:  
DATE OF BIRTH:                                                                                    
PHONE NUMBERS: 
  Home:__________________________________________________________ 
  Work:__________________________________________________________ 
  Mobile:_________________________________________________________ 
               EMAIL ADDRESS: ______________________________________________ 
1.  BIRTH HISTORY:    
Do you know if there were any problems during your mother’s pregnancy with you, 
during your birth, or during the period immediately following your birth? 
 
2.  PAST MEDICAL PROBLEMS: 
As a child, did you suffer from febrile convulsions, meningitis or a head injury, and 
have you had any other serious illness requiring medical, surgical, psychological or 
psychiatric treatment? 
 
3.  EDUCATION LEVEL: 
 
4.  Déjà vu 
Please describe if there has been any repeated, similar, nice and dreamy like feeling 
in your life, or other similar states. 
 
5.  PAIN SYNDROME: 
Please describe if you have any unusual intermittent, periodic pain, such as 
migraine, facial pain, etc. 
 
a. Pain: (character, location, duration, triggering factors, response to medicine)  
 
b. Migraine: (character, location, duration, triggering factors, response to 
medicine)  
 
c. Others, please describe (low back pain, neuralgia, etc) 
 
 
6.  HISTORY OF BLACKOUTS OR SEIZURES: 
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At what age did your attacks start?  What were they like at the beginning?  How 
often did they occur at the beginning and how often do you get them now?  Do you 
know what caused them? 
 
7.  DESCRIPTION OF YOUR BLACKOUTS OR SEIZURES: 
 
It is common to have one type of attack.  However, two or three different types of 
attacks may occur.  Please try and describe one of the most typical episodes and 
mention other types if they different from the typical one.  In particular, remember 
your feelings when you very first realise an attack is coming on.  It is also very 
useful to have the account of a witness who has seen your attacks. 
 
a. Body and limb position 
 
b. Usually in what circumstances does it happen?  
 
c. Pattern:  Diurnal?  in the morning, at night, during sleep, on awakening, or during 
menstruation period? Any cluster seizure? 
 
d. Prodromal symptoms: symptoms that happens before seizure (not aura) 
 
e. Onset: any aura? Focal motor features? Affective symptoms, such as fear, panic? 
please describe them as detail as you can if there is any. 
 
f. Features: lost of consciousness and the duration, 
 
g. Motor characteristics: spasm? Jerky? Stiffness? Tongue biting? Incontinence? 
Fall or injuries?  
 
 
h. Somatosensory or special sensory manifestations: tingling, numbness, electrical 
shock like feeling, burning, pain or heat, stomach rising sensation? 
 
i. Autonomic manifestation: change in skin colour, elevated blood pressure, heart 
rate, stomach raising sensation, pale looking, sweating… 
 
j. Psychiatric manifestation: dysphasic, amnestic, cognitive, speech arrest or 
disturbance? 
 
k. Automatism: (orofacial, laughter, cry, meaningless sound, fiddeling movements, 
complex action, walking, circling,violent behaviour.) 
 
l: visual or auditory hallucination? Circular or ball shape, multiple colours, 
location?  
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m. Post ictal symptoms: fatigue, sore tongue or lip, limbs?  Affective symptoms? 
Confusions? Giddiness? 
 
 
8.  TRIGGER FACTORS: 
Do your episodes occur by day, by night or both?  Do they occur during any 
particular activity, such as watching television?  Do they occur in relation to any 
other event such as your menstrual period? 
 
 Tiredness?  Alcohol? Sleep deprivation? Flickering or bright light? TV?   
  
9.  MEDICATION: 
Please write down what medications you have taken, roughly when you have been 
on them, and if possible, the does and effect of the medications: 
 
a.  In the past: 
 
b.  At present: 
 
10. WHICH HOSPITALS AND SPECIALISTS HAVE YOU PREVIOUSLY 
CONSULTED AND WHEN? 
 
11. IS THERE ANY OTHER INFORMATION YOU WOULD LIKE US TO 
KNOW? 
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Appendix 3 
 
Burst cell function recovery 
Read in data 
 data = ReadList["C:\\Documents and Settings\\chiening LO\\My 
Documents\\Saccades\\control\\Luis\\text\\Luis left.txt"]; 
data = 15( data)+4; 
data= Take[data,{1,150000}]; 
Plot data 
 ListPlot[( data), PlotJoined -> True, PlotRange->  
{{1,160000},Automatic}]; 
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Reconstruct trajectory with discrete Legendre 
polynomials 
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Find starting points of saccades 
 
 (*Identify the start of each saccade, using a velocity criterion of 30 
degrees per second*) 
temp = Table[{Abs[y[[i]]],i},{i,Length[y]}]; 
temp = Select[temp,#[[1]]>30 &]; 
(*Form a separate list for the data points of each saccade*) 
temp = Split[temp, #2[[2]]==#1[[2]] + 1  &]; 
(*Remove any saccades lasting less than 30 milliseconds which might be 
noise*) 
temp = Select[temp,Length[#]> 10 &]; 
(*Form arrays of the data point index of the start and finish of each 
saccade*) 
starts = Table[temp[[i,1,2]],{i,Length[temp]}]; 
ends = Table[temp[[i,Length[temp[[i]]],2]],{i,Length[temp]}]; 
 mainseq= Table[{x[[ends[[i]]]]-
x[[starts[[i]]]],Max[Abs[Take[y,{starts[[i]],ends[[i]]}]]]},{i,Length[sta
rts]}]; 
  
List all figures 
 Do[ 
    Print[i]; 
    ListPlot[Take[x,{starts[[i]]-50,ends[[i]]+50}], PlotJoined → → → → True, 
PlotRange → → → → All];ListPlot[Take[y,{starts[[i]]-50,ends[[i]]+50}], 
PlotRange → → → → All],{i,Length[mainseq]}]; 
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ListPlot[mainseq,PlotRange ->{{-20,20},{0,500}}]; 
 
 
Selection of desirable data 
  
goodones={}; 
goodones=Drop[goodones,{}]; 
const=Length[goodones]; 
goodones=Drop[goodones,{const}]; 
Show[temp1 = Table[ListPlot[Take[x,{starts[[goodones[[i]]]]-
50,ends[[goodones[[i]]]]+50}], PlotJoined -> True, PlotRange -> 
All],{i,Length[goodones]}]]; 
Show[temp1 = Table[ListPlot[Take[y,{starts[[goodones[[i]]]]-
50,ends[[goodones[[i]]]]+50}],  PlotRange -> All],{i,Length[goodones]}]]; 
(*Do[ 
      Print[i]; 
      ListPlot[Take[x,{starts[[goodones[[i]]]]-
50,ends[[goodones[[i]]]]+50}], PlotJoined -> True, PlotRange -> 
All];ListPlot[Take[y,{starts[[goodones[[i]]]]-
50,ends[[goodones[[i]]]]+50}], PlotRange -> All],{i,Length[goodones]}];*) 
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Further modification 
  
<<Graphics`Graphics`; 
goodones={}; 
goodones=Drop[goodones,{}]; 
const = Length[goodones]; 
goodones = Drop[goodones,{const}]; 
mainseq= Table[{x[[ends[[goodones[[i]]]]]]-
x[[starts[[goodones[[i]]]]]],Max[Abs[Take[y,{starts[[goodones[[i]]]],ends
[[goodones[[i]]]]}]]]},{i,Length[goodones]}];ListPlot[mainseq,PlotRange -
>{{-10,10},{0,600}}]; 
LabeledListPlot[mainseq,PlotRange ->{{-12,12},{0,600}}] 
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Examination 
 i = 49; 
ListPlot[Take[data,{starts[[i]]-50,ends[[i]]+50}]]; 
i = 96; 
ListPlot[Take[data,{starts[[i]]-50,ends[[i]]+50}]]; 
i = 105; 
ListPlot[Take[data,{starts[[i]]-50,ends[[i]]+50}]]; 
i = 103; 
ListPlot[Take[data,{starts[[i]]-50,ends[[i]]+50}]]; 
i = 152; 
ListPlot[Take[data,{starts[[i]]-50,ends[[i]]+50}]]; 
 
 
 
 
 
 
 
 
 
 
 
 
Find data points on nullcline   
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97.0284 q  
121.503 q  
101.249 q    
 Show[ 
    ListPlot[mainseq1, PlotRange -> {{-20,20},Automatic}], 
    ListPlot[mplot1, PlotStyle -> RGBColor[1,0,0],PlotJoined -> 
True,PlotRange -> {{-20,20},Automatic}], 
    ListPlot[mainseq2, PlotRange -> {{-20,20},Automatic}], 
    ListPlot[mplot2,PlotStyle -> RGBColor[1,0,0],PlotJoined -> True, 
PlotRange -> {{-20,20},Automatic}]]; 
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